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Human Papillomavirus
The central aetiological role of the Human Papillomavirus (HPV) in the development of 
cervical cancer was discovered in the beginning of the 1980s.1;2 Ever since, clinical, 
biological and epidemiologic studies have supported the causal role of infection with 
high-risk HPV (hr-HPV) in both cervical cancer and its high-grade non-invasive 
precursors.1;3-6 However, it was not until 2005 that the World Health Organization 
indicated HPV as the primary cause of cervical cancer.7
HPVs are small non-enveloped, double-stranded DNA viruses of approximately 8.000 
base pairs. The viral DNA consists of an early region, a late region, and a non-coding long 
control region. The non-coding control region contains regulatory elements. The early 
region open reading frames (ORFs), E1, E2, E4-E7, encode proteins that are expressed 
early in the viral life cycle. The E1 and E2 regulatory proteins modulate viral replication 
and transcription in the basal layers.8 E2 negatively influences E6 and E7 expression. 
Three of the early ORFs are the oncogenes E5, E6, and E7, which are expressed in more 
distal layers. These ORFs encode multifunctional proteins that may control proliferation 
and transformation of the host cell. E4 encodes proteins affecting the mechanical 
stability of the keratin network which may facilitate viral particle release.8 The two late 
region ORFs L1 and L2 encode the major and minor capsid proteins, respectively.
HPV can infect the epithelium when a micro-abrasion is present. Following infection, the 
early HPV ORFs E1, E2, E5, E6 and E7 are expressed and the viral DNA replicates. In the 
upper layers of the epithelium the viral genome is replicated further,  E4 and the late ORFs 
L1 and L2 are expressed. The L1 and L2 proteins encapsidate the viral genome to form 
progeny virions in the nucleus. The shed virus can then initiate a new infection (Figure 1).9 
The viral life cycle is tightly linked to the epithelial differentiation programme. 
The L1 ORF is the most conserved gene within the genome, and together with the E6 
and E7 ORFs, it has been used to identify new papillomavirus types, subtypes and 
variants.11 For the identification of a new type the L1, E6, and E7 ORFs should differ at 
least 10% from the closest type known. For the detection of a new subtype, a difference 
of 2-10% needs to be present, whereas a dissimilarity of maximally 2% indicates an 
intra-type variant.
Over 120 different HPV genotypes have been identified.12-15 Approximately 40 HPV types 
are able to infect the genital epithelium.16 These genotypes have been classified high 
risk or low risk according to their oncogenic potential.3;14 Genotypes like HPV 6 and 11 are 
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frequently detected in benign lesions like anogenital warts. These types are not related 
to cervical cancer development and are therefore termed low-risk (lr-HPV).17 Whereas 
fourteen HPV genotypes are associated with cervical cancer development and are 
therefore called high-risk (hr-HPV). Of these hr-HPV genotypes, HPV 16 and HPV 18 
account for approximately 70% of all cervical cancers worldwide.14;18;19 Additionally, HPV 
16 is one of the most common types found among women without a cervical 
abnormality.14;20;21 
Fortunately, most HPV infections are transient and the majority of the women with a 
hr-HPV infection do not develop cervical cancer or premalignant lesions. In fact it is a 
relatively rare complication since 90 to 95% of the HPV infections are cleared by the 
immune-system and a large part of the premalignant lesions regress. However, women 
with persistent HPV infections have an increased risk of developing high-grade cervical 
intraepithelial neoplasia (CIN). If not treated, one third to 50% of these CIN lesions will 
progress to cervical cancer over a period of 10-15 years.22
HPV mediated carcinogenesis
The molecular pathogenesis of cancer caused by hr-HPV infections is not fully understood. 
Cervical carcinogenesis is a multi-step  process requiring other events in addition to a 
persistent hr-HPV infection.1;14 It is assumed that one of the key events of HPV–induced 
oncogenesis is the integration of viral DNA into the host genome.8 It is a general 
assumption that this integration into the host genome leads to disruption of the E2 ORF 
of the virus, inducing over-expression of viral E6 and E7 proteins. Subsequently, the E6 
and E7 oncoproteins interfere with two crucial mitosis regulating pathways of the host 
cell. The E6  protein targets the p53 protein, which normally induces growth arrest or 
apoptosis. The binding of E7 causes inactivation of the retinoblastoma protein (pRb) and 
subsequent release of host transcriptional factor E2F, which eventually disrupts cell cycle 
regulation. Inactivation of these two tumour suppressor pathways induces genomic 
instability and subsequent neoplastic transformation of the cell.23 This may lead to an 
invasive tumour which ruptures the basement membrane and will invade the 
sub-epidermal tissue.10
HPV epidemiology
Genital HPV is mainly but not only transmitted through sexual intercourse. HPV is well 
adapted to be transmitted by skin-to-skin contact and therefore transmissibility is several 
times higher than for other (viral) sexually transmitted diseases (STDs).17;24;25 HPV is 
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Figure 1.  
The biology of HPV infection. a) HPV virions infect basal cells of stratified mucosal 
epithelium at the transformation zone. In the basal layers, viral replication is 
accompanied by the expression of early ORFs E1 and E2. In the more distal layers, E6 
and E7 are expressed promoting cell proliferation and delaying differentiation. When 
infected cells differentiate into squamous cells, the E4 protein, and late L1 and L2 
proteins (which form the capsid) are expressed. Progeny virus is shed into the genital 
tract as cargo within desquamated epithelial cells. b) Rarely, the DNA of oncogenic 
HPVs linearises and integrates into the host cell genome leading to disruption of the 
viral E2 ORF. This induces over-expression of E6 and E7 proteins which in turn leads to 
host cell transformation (dysplasia). c) Invasive tumour ruptures the basement 
membrane and invades the sub-epidermal tissue. ORF: open reading frame. Adapted 
from R.T. Tindle (with permission).10
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infection” has often been defined loosely and in general has been described as a positive 
test on more than 2 occasions with  intervals ranging  from 2 months to 7 years, with a 
median of 6 months.4;6;9;21 Definitions of HPV persistence are further complicated by 
differences in HPV detection methods, non-type-specific versus type-specific HPV 
persistence, and restriction to carcinogenic type persistence. Additionally, it is unknown 
whether persistent infections are characterized by the continuing detection of HPV or 
by a state of viral latency during which the virus remains undetectable so it can reappear 
later. A clear understanding of these issues is important for instance in order to effectively 
implement screening strategies that include HPV testing.9
Despite the various definitions of persistence, a persistent infection with a hr-HPV type 
is a major risk factor for the development of cervical abnormalities. As hr-HPV genotypes 
16 and 18 together account for almost 70% of all cervical carcinomas and 55% of the 
high-grade cervical intraepithelial lesions, prophylactic vaccines against these two 
hr-HPV types have been developed.19;39-47 
Worldwide mass vaccination with HPV vaccines will most certainly change HPV 
 epidemiology. Monitoring these changes on a population level may prove crucial in 
 assessing the effect of mass vaccination and overall HPV vaccine efficacy.
HPV vaccination
Currently, two prophylactic vaccines are registered and available in Europe; Gardasil 
(Merck, USA) and Cervarix (GlaxoSmithKline, Belgium). Gardasil is a quadrivalent vaccine 
containing L1 virus-like particles (VLPs) of the hr-HPV types 16 and 18, and VLPs of the 
lr-HPV types 6 and 11 and the classical aluminium hydroxyphosphate adjuvant (Table 
1).47 Cervarix is a bivalent HPV vaccine containing only the VLPs of HPV 16 and 18 as well 
as the new ASO4 adjuvant which consists of 3-deacylated monophosphoryl lipid A and 
aluminium hydroxide (Table 1).40;41
The prophylactic vaccines have shown to be highly effective in preventing persistent 
infections as well as related premalignant lesions.39-44;47 However, it must be emphasized 
that these HPV vaccines are prophylactic, not therapeutic, and therefore, have no efficacy 
against existing HPV 16 or 18 infection or disease.48;49
The primary target group for vaccination consists of preadolescent girls as most of them 
(>95%) are not sexually active yet, and therefore have not been genitally infected with 
HPV. Presently, vaccination programs have started in many countries around the world, 
commonly acquired shortly after onset of sexual activity and new genital infections are 
strongly associated with new and the total number of sexual partners.26;27 As a result, 
genital HPV infection is one of the most common STDs among young sexually active 
women (Figure 2).24 
Up to 80% of sexually active women have been genitally infected by one or more HPV 
types at some point in their life.27;28 Estimates of single point prevalence of genital HPV 
infection among women worldwide vary from  2% up to 44%.17;21;25;27-36 This wide variation 
may largely be explained by the sensitivity of the DNA assay used for the detection of 
HPV as well as by differences in age, geography or differences in other characteristics of 
the populations studied. The mean duration of a cervical infection in a healthy population 
is thought to vary between 8-13 months.21 Most newly acquired infections are considered 
to be transient, at least when their duration is measured by how long the virus can be 
detected in cervical cytological samples.37;38 Describing the average duration of an 
infection, in other words time till clearance, will  be of great importance in establishing a 
clinically relevant definition of a persistent infection. Until now, the term “persistent 
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Figure 2. 
Estimated annual new cases of sexually transmitted diseases in the US in 2007 
(sources: Centers for Disease Control and Prevention, www.cdc.gov, American Social 
health association, www.ashast.org).
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aged 13 to 16 years reached only 50%. The reasons for refusal of vaccination were mainly 
based on negative media attention, and, equally important, a lack of appropriate 
information to compensate the ghost stories about the vaccine and its long term effects. 
This underlines the need of educational campaigns along with vaccine introduction.
Mass vaccination of this young population will most certainly change HPV epidemiology. 
To correlate risk factors associated with HPV infection in the pre- and the post-vaccina-
tion era, baseline data are needed.
Risk factors for HPV
In order to get full insight in risk factors for acquiring genital HPV, results of HPV detection 
must be correlated to demographic characteristics and especially to past and present 
sexual behaviour. Until now, this has only been performed in a limited number of 
studies.33;60-62  
Some studies mentioned sexual activity as the principle risk factor itself, whereas other 
studies discriminated between different aspects of sexual behaviour. Frequently-men-
tioned risk factors are total number of sexual partners, mixing sex with alcohol, being 
single, drug use, oral contraceptive use, current smoking, and age. The contribution of a 
history of STDs to HPV positivity has been challenged. It can be questioned whether 
having an STD other than HPV makes the cervix vulnerable for HPV infection or whether 
it is the other way around. Additionally, it is difficult to distinguish between the influence 
of an STD and the influence of the sexual risky behaviour itself.
Studying sexual behaviour may inform us about the risk of exposure to HPV. In order to 
correlate sexual behaviour to the present or future HPV status it is important to study the 
HPV status prospectively by performing HPV detection on a regular basis.
HPV detection
HPV cannot be grown in conventional cell cultures and serological assays are of limited 
value since they cannot distinguish between current and past infection, and not all 
infections induce measurable antibody levels. Therefore, accurate diagnosis of HPV 
infection relies on the detection of viral nucleic acid.63;64 In the past decades new 
techniques have been developed and advances in existing techniques have been made, 
permitting large scale HPV testing.
primarily targeting 9 to 18 year old girls.50-52 In the Netherlands, the HPV vaccine has been 
assimilated into the national vaccination programmes and catch-up vaccination of girls 
aged 13 to 16 years started in 2009 and vaccination of girls aged 12 years will start in 
2010.
As women age they are more likely to have engaged in sexual activity resulting in 
exposure to HPV in general as well as vaccine specific types. Therefore, the clinical 
benefit of HPV vaccination afforded to older sexually active women is likely to be less 
than that of younger sexually naïve women. Nevertheless, extended vaccination of 
already sexually active women is  under consideration in many countries in order to 
decrease cervical cancer incidence without a 15-20 years lag time.
Acceptability of the HPV vaccine may differ from other vaccines, as it could be seen as a 
vaccine against an STD. Most studies exploring HPV vaccine acceptability among young 
adults and students have been performed in the United States and the United 
Kingdom.53-59 In these reports knowledge, number of sexual partners, educational level, 
and effectiveness of the vaccine were factors associated with vaccine acceptability. 
As vaccine acquisition costs are high, this may also be of influence. Hence, the decision 
to get vaccinated will be based on knowledge and balanced between personal benefit 
and costs. When the vaccine was implemented into the funded Dutch national 
vaccination programme early 2009, the coverage of catch-up vaccination among girls 
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Table 1. HPV vaccines
HPV 6/11/16/18 HPV 16/18
Manufacturer Merck GlaxoSmithKline
Volume Per dose 0.5 mL Per dose 0.5 mL
Adjuvant Aluminium salt 225 μg ASO4:
Al(OH)3 500 μg
MPL® 50 μg
Antigens L1 HPV 6 20 μg
L1 HPV 11 40 μg
L1 HPV 16 40 μg L1 HPV 16 20 μg
L1 HPV 18 20 μg L1 HPV 18 20 μg
Expression 
system
Yeast Hi-5 Baculovirus
Schedule Intramuscular 0,2,6 months Intramuscular 0,1,6 months
18 19
In contrast to the clinical application, highly sensitive and reproducible assays are 
required in vaccination trials, epidemiological and natural history studies, as the aim of 
these studies is to obtain a maximum of information about HPV status in populations 
and to monitor the course of infections in detail.64;72 
Self-sampling
Regarding (hr-) HPV testing, material from vaginal lavages or self-sampling brushes has 
proven to be highly representative for the cervical (hr-) HPV status and have repetitively 
been proven to be as reliable as physician-taken samples.73-78 However, it has been 
shown that self-sampling methods are not suitable for cytological analysis.75;79 Several 
studies have shown that self-sampling for HPV testing was highly acceptable to and 
even favoured by the majority of women.74;80 Self-sampling may be a less costly, a less 
invasive, and a timesaving alternative for the physician-based collection of cervico-vaginal 
material. Additionally, it is easy accessible as self-sampled material could be sent by mail, 
facilitating attempts to contact women who are not reached through present screening 
programmes or women living in rural settings, or with limited resources, i.e. health 
facilities. Several studies have shown that non-responders do actually take part in 
self-sampling studies.73;75;79 Therefore, hr-HPV testing on self-sampled materials might be 
a promising opportunity to increase the efficiency of existing screening programmes as 
well as for establishing cervical cancer screening programs in developing countries.
In general, the HPV assays which are currently used widely are based on one of the two 
following principles.
The first is based on hybridisation of the target HPV DNA to labelled RNA probes in situ.64 
An example of this technique is the non-radioactive signal-amplification method Hybrid 
Capture II (hc2, Digene Corp., Gaithsburg, Maryland, USA). The hc2  is a commercially 
available test and is commonly used in screening. The hc2 test is the only FDA-approved 
screening assay. Unfortunately, as it only differentiates between an hr-HPV infection 
being present or not, it does not have the ability to identify individual genotypes nor 
infections harbouring multiple genotypes. This may be of importance in risk profiling 
and individual patient management.
The second is based on the principle of the consensus polymerase chain reaction (PCR). In 
order to detect HPV DNA in a single sample consensus primers should be used. The most 
widely used assays are the GP5+/6+ PCR system, the Roche Amplicor HPV Test (Roche 
Molecular Systems, Inc., Branchburg, NJ, USA), the PGMY primer set, and the SPF10 primer 
set. Several reports have assessed and compared different assays. Generally, the reports 
compare the ability to rapidly assess and/or genotype HPVs present in genital samples 
with high sensitivity and specificity.64-71 The PCR assay is based on PCR amplification of the 
target HPV DNA directed by consensus or general primers that targets the highly conserved 
region of  the L1 ORF.64;68 Subsequent to the amplification of HPV DNA, reverse hybridisation 
of the amplicon to multiple oligonucleotides provides the possibility to simultaneously 
type up to 37 different HPV genotypes. The oligonucleotide probes which recognize the 
different genotypes are frequently tailed with poly(dT) and immobilised as parallel lines to 
membrane strips. The assay called line blot assay (LBA), line probe assay (LiPA), or linear 
array (LA) require only a little amount of PCR product. 
As previously mentioned, the observed variations in HPV prevalence can be partly 
attributed to the properties of the HPV test used, i.e. its sensitivity and specificity. The 
risk-estimation for high-grade lesions following the outcome of the test is therefore also 
related to the assay used. The first application, the hc2, is aimed at identifying women at 
risk of developing cervical cancer, either in community-based screening programmes or 
in the clinical setting. The PCR based techniques, like the SPF10Lipa, are highly sensitive in 
comparison to hybridization tests like the hc2. As a result, the terms “analytical” and 
“clinical” sensitivity have been introduced.72 Clinically relevant hr-HPV infections can be 
distinguished from clinically irrelevant infections. Clinicians should be aware of these 
differences and should be able to translate the results into appropriate clinical treatment. 
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Aim and outline of this thesis
Worldwide mass vaccination with HPV vaccines will most certainly change HPV 
epidemiology. Monitoring these changes on a population level may prove crucial in 
assessing overall HPV vaccine efficacy. To provide a basis for understanding possible 
future shifts in genotypes, as well as to provide insight in the HPV epidemiology of a 
target group for vaccination now and in the future, the prevalence, incidence and 
clearance rates of specific HPV types must be determined before vaccination takes place. 
Chapter 2 describes the Dutch situation of HPV prevalence and related risk factors 
among young adult women prior to mass vaccination. Furthermore, little is known about 
risk factors for acquiring new HPV infections as well as factors associated with clearance 
of HPV infections. These issues will be addressed in chapter 3.
As women age, they are more likely to have engaged in sexual activity resulting in 
exposure to HPV. Therefore, their clinical benefit of HPV vaccination is likely to be less 
than that of younger sexually naïve women. This may affect their acceptability of the 
HPV vaccine. Additionally, their vaccine acceptability may differ from other vaccines, as 
it could be seen as a vaccine against an STD. This view may also influence vaccine 
acceptability of parents of children in the target group for vaccination. Which in turn is 
very important, as these children are under age and parental consent for vaccination will 
be required. Assessing predictors of intention to receive the vaccine as well as assessing 
knowledge about HPV will be important to create effective vaccination campaigns and 
reach a high vaccine coverage. These issues are addressed in chapter 4 and 5.
To enhance vaccine acceptability, anticipation on factors influencing individual 
decision-making is needed. As vaccine acquisition costs are high, the decision to get 
vaccinated will be balanced between personal benefit and costs. Advising women on 
their personal benefit from vaccination will result in estimating ones individual risk of 
already being HPV 16 and 18 positive. To provide a guideline to estimate ones individual 
risk, a decision-aid based on young women’s behavioural risk factors  and prevalent HPV 
infections is designed and discussed in Chapter 6.
To meet the new post-vaccination screening requirements, the CSP may need 
transformation. Cervico-vaginal self-sampling may be an easy accessible, user-friendly, 
and timesaving alternative for the physician-based collection of cervico-vaginal material. 
Furthermore, it may be used to monitor women after the implementation of HPV 
vaccination. Chapter 7 reports the efficiency of HPV detection using a new method of 
sample storage, transportation and processing.
The results presented in the following chapters as well as future directions are generally 
discussed in Chapter 8 and summarised in Chapter 9.
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Abstract
Infection with Human Papillomavirus (HPV) is a necessary event in the multi-step process 
of cervical carcinogenesis. Little is known about the natural history of HPV infection 
among unscreened young adults. As prophylactic vaccines are being developed to 
prevent specifically HPV 16 and 18 infections, shifts in prevalence in the post-vaccine era 
may be expected. This study provides a unique opportunity to gather baseline data 
before changes by nationwide vaccination occur. This cross-sectional study is part of a 
large prospective epidemiologic study performed among 2065 unscreened women 
aged 18 to 29 years. Women returned a self-collected cervico-vaginal specimen and 
filled out a questionnaire. All HPV DNA-positive samples (by SPF10 DEIA) were genotyped 
using the INNO-LiPA HPV genotyping assay. HPV point prevalence in this sample was 
19%. Low and high risk HPV prevalence was 9.1% and 11.8%, respectively. A single HPV 
type was detected in 14.9% of all women, while multiple types were found in 4.1%. HPV 
types 16 (2.8%) and 18 (1.4%) were found concomitantly in only 3 women (0.1%). There 
was an increase in HPV prevalence till 22 years. Multivariate analysis showed that number 
of lifetime sexual partners was the most powerful predictor of HPV positivity, followed 
by type of relationship, frequency of sexual contact, age, and number of sexual partners 
over the past 6 months. This study shows that factors independently associated with 
HPV prevalence are mainly related to sexual behaviour. Combination of these results 
with the relative low prevalence of HPV 16 and/or 18 may be promising for expanding 
the future target group for catch-up vaccination. Furthermore, these results provide a 
basis for research on possible future shifts in HPV genotype prevalence, and enable a 
better estimate of the effect of HPV 16-18 vaccination on cervical cancer incidence.
Upcoming mass vaccination with Human Papillomavirus (HPV) vaccines will most certainly 
change HPV epidemiology. Monitoring these changes on population level may prove 
crucial in assessing the effect of mass vaccination and overall HPV vaccine efficacy. In the 
Netherlands, girls aged 12 years will be vaccinated as of September 2009, and the catch-up 
vaccination (girls aged 13 to 16 years) will probably start in the first part of 2009.
Introduction
Until now, only a limited number of large studies have investigated HPV epidemiology in 
female adolescents and young female adults. Even fewer studies have investigated HPV 
epidemiology in relation to past en present sexual behaviour.
Genital infection with HPV is the most common sexually transmitted disease (STD) 
among young sexually active women.1 Most sexually active women (>50%) have been 
genitally infected by one or more HPV types at some point in their life.2 Fourteen HPV 
genotypes are associated with cervical cancer development and are therefore called 
high-risk (hr-HPV). Of these hr-HPV genotypes, hr-HPV 16 and 18 are related to 70% of all 
cervical cancers. Therefore, prophylactic vaccines against these two HPV types have 
been developed. It has been estimated that the best results of prophylactic vaccination 
will be achieved by vaccinating women before they become genitally infected i.e. 
sexually active. Presently, vaccination programmes are being started in many countries 
around the world, targeting 9 to 16 year old girls.3;4 Additionally, catch-up vaccination of 
already sexually active women is  under consideration in many countries in order to get 
a faster decrease in cervical cancer incidence.
Estimates of HPV infections among asymptomatic women around the world range from 
2% to 44%.5-8 The wide variation in prevalence is largely explained by differences in 
sensitivity of the HPV-DNA assay used, differences in age, or differences in other 
characteristics of the populations studied.2;7 
Additionally, little is known about risk factors for acquiring genital HPV in young female 
adults. Therefore, further assessment of risk factors like sexual behaviour is important. 
Knowledge of baseline, i.e. pre-vaccination, epidemiology of type specific HPV infections 
in relation to sexual behaviour is important in order to decide whether catch-up 
vaccination may be beneficial. After nationwide implementation of the prophylactic 
HPV vaccine, HPV epidemiology will most likely change due to expected  decreases in 
HPV 16-18 prevalence and incidence, as well as possible changes in other types occurring 
due to cross-protection of the vaccine. Due to these shifts, prevalence and incidence of 
other HPV types may increase and therefore may change the oncogenicity of these 
types.
Therefore, this study, conducted before the nationwide introduction of HPV vaccines, 
provides a unique opportunity to determine baseline data on HPV prevalence in 18 to 29 
year old women in the Netherlands. Additionally, no regular cervical cancer screening is 
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tube was closed, and enclosed in the seal bag. Finally, the collection tube was placed in 
the return envelope, together with the questionnaire, and sent to the Department of 
Obstetrics and Gynaecology for further processing and HPV assessment. The samples 
were stored at room temperature.
Questionnaire
In this study we used a questionnaire consisting of two parts. The first part was composed 
of questions regarding socio-demographic variables like educational level, religion, 
smoking, medication use, contraceptive use, and ethnicity. Race and ethnicity were 
self-reported into different categories. The second part consisted of questions regarding 
sexual behaviour to gain insight in risk factors for acquiring genital HPV. Results of HPV 
detection were correlated to past and present sexual behaviour. Sex was defined as 
vaginal, oral, and/or anal sex. For women who had at least 1 lifetime sex partner, 
additional questions were asked on age at first sexual contact, age of first sex partner, 
number of sex partners before the age of sixteen, lifetime number of sex partners, 
number of sex partners in the past 6 months, gender of sex partners, frequency of sexual 
contact, condom use, and history of STDs.
HPV DNA Detection and Genotyping
Broad-spectrum HPV DNA amplification was performed using a short PCR fragment 
assay (SPF10-LiPA HPV detection/genotyping assay, SPF10 system version 1, manufactured 
by Labo Biomedical Products BV, Rijswijk, the Netherlands). This assay amplifies a 65-bp 
fragment of the L1 open reading frame and allows detection of at least 43 different HPV 
types.9-12 The SPF10 PCR was performed with a final reaction volume of 50 μl containing 
10 μl of the isolated DNA sample, 10 mmol/liter Tris-HCl (pH 9.0), 50 mmol/liter KCl, 2.0 
mmol/liter MgCl2, 0.1% Triton X-100, 0.01% gelatin, 200 μmol/liter of each deoxynucleoside 
triphosphate, 15 pmol each of the forward and reverse primers tagged with biotin at the 
5'end, and 1.5 U of AmpliTaq Gold (Perkin-Elmer). The mixture was incubated for 9 
minutes at 94°C, 40 cycles of 45 s at 45°C, and 40 cycles of 45 s at 72°C, with a final 
extension of 5 minutes at 72°C. Each experiment was performed with a separate positive 
and negative PCR control. The presence of HPV DNA was determined by hybridization of 
SPF10 amplimers to a mixture of general HPV probes recognizing a broad range of HPV 
genotypes, in a microtiter plate format, as described previously.9-12 
 All HPV DNA-positive samples (by SPF10 DEIA) were genotyped using the INNO-LiPA HPV 
genotyping assays. 
performed in this age group, as the Dutch Cervical Screening Programme starts at the 
age of 30 years. This study is part of a large prospective epidemiologic study conducted 
to study the dynamics of HPV infections, in particular HPV 16/18, and to get more insight 
in specific risk factors for acquiring genital HPV, like past and present sexual behaviour. 
These results provide a basis for understanding possible future shifts in genotypes, and 
presumably enable a better estimate of the effect of HPV 16/18 vaccination on cervical 
cancer incidence.
Methods
Study population and study design
This cross-sectional study is part of a large prospective epidemiologic study performed 
among 2065 unscreened women aged 18 to 29 years. Women were recruited between 
June and September 2007, using different advertisements, as well as active recruitment 
sites, and posters at general practices in the city regions of Arnhem, Nijmegen, and Den 
Bosch, the Netherlands. Furthermore, advertisement on the internet were used, which 
were accessible in the whole of the Netherlands. Of the 2297 women who responded to 
the advertisements, 2065 (89.9%) consented with the study, returned the cervico-vaginal 
swab specimens, and filled out the questionnaire. Written informed consent was obtained 
from all participants. This study was approved by the local Medical Ethics Committee.
Specimen Collection and Processing
All women were asked to fill out a questionnaire and to self-collect a cervico-vaginal 
sample in the privacy of their own home. Women received an explanatory letter, an 
informed consent form, a questionnaire, and a self-sample kit by mail. The self-sample kit 
contained a collection device (a small brush packaged in an individual sterile cover, 
Rovers® Viba-brush, Rovers Medical Devices B.V., Oss, the Netherlands), a collection tube 
containing medium (SurePathtm, Tripath Imaging®, Inc., Burlington NC, USA), instructions 
how to perform the cervico-vaginal self-sample (written and in cartoon), and a return 
package consisting of a leak-proof seal bag, absorption sheet, and a reclosable plastic 
return envelope (Easyslider, Transposafe Systems Holland BV, Sassenheim, the 
Netherlands). In brief, participants were instructed to wash their hands before opening 
the brush cover, to hold the brush by the end of the handle, to insert the brush 
approximately 7 cm into the vagina (similar to inserting a tampon), to gently turn the 
brush 5 times, and to place the top of the brush in the collection tube. The collection 
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Results
Socio-demographic characteristics
The age distribution and socio-demographic characteristics of the 2065 participants are 
summarised in table 1. Many women attended higher vocational training or University in 
past or presence (n=1545, 75.6%). Of all women, 622 (30.3%) were single and 1431 (69.7%) 
were involved in a relationship. Only 69 women (3.4%) reported an ethnicity other than 
Dutch, including “other European” 1.1% (n=23), Caribbean 0.7% (n=15), Turkish 0.2% (n=4), 
Asian 0.6% (n=12), African 0.2% (n=3), and “other” 0.6% (n=12). Because of these small 
numbers, they were divided into two groups: Dutch (96.6%, n= 1981), and “other” (3.4%, 
n=69).
Additionally, the mean age at first sexual contact was 16.7 years, and the mean sexual 
age (i.e. years of being sexually active) was 6.8 years. Women who were not sexually 
active yet were significantly more often living with their parents (11.5%, n=41 versus 
4.4%, n=75, p=<0.001, data not shown).
Prevalence of HPV infection
Of the 2065 adequate specimens, 19% (n=393) tested positive for one or more HPV 
genotypes.  Age-specific prevalence is shown in table 1. There was an overall increase in 
HPV prevalence with age till 22 years, afterwards a plateau phase was reached. Prevalence 
of HPV infection showed a decrease at 23 years and a peak among women aged 27 years 
(13%, n=24, and 31%, n=52, respectively). However, as the 95% confidence interval was 
overlapping with adjacent age groups, the differences were considered accidental 
findings (Figure 1).
The overall prevalence of hr-HPV types was 11.8% and of lr-HPV types 9.1%, including 
co-infections. Prevalence of both hr- and lr-HPV types showed an almost similar age-
distribution (Figure 2A).
Prevalence of specific HPV genotypes
A single HPV-type was detected in 14.9% of all women, while multiple types were found 
in 4.1% (21.6% of all HPV-positive women). We identified 25 different genotypes, most 
common types detected were HPV type 16 (2.8%, n=57), HPV type 51 (2.5%, n=51), and 
HPV type 52 (2.5%, n=52). HPV types 18, 6, and 11, were detected in 1.4% (n=28), 0.6% 
The 28 oligonucleotide probes that recognize 25 different types were tailed with 
poly(dT) and immobilized as parallel lines to membrane strips (Labo Bio-Medical 
Products B.V., Rijswijk, the Netherlands). The HPV genotyping assay was performed as 
described previously.9 Samples that tested positive using the DNA enzyme immunoassay 
but that showed no results on the LiPA strip were considered to be HPV X type, i.e. 
genotypes not available on the LiPA strip. Low-risk HPV (lr-HPV) types were defined as 
HPV type 6,11, 34, 40, 42, 43, 44, 53, 54, 55, 58, 66, 70, 74, and “X”; and hr-HPV types as HPV 
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 59, 68, 73, and 82.
Statistical Analysis
All women who completed the questionnaire and submitted a swab for HPV evaluation 
were included in the final analysis (n= 2065). 
The Chi-Square test was used to test associations between demographic variables or 
behavioural characteristics and HPV. Differences of medians of continuous variables 
between the groups were analysed using non-parametric tests (Mann-Whitney).
In univariate and multivariate analysis, data of some variables were grouped due to small 
numbers and/or to gain a better overview. We grouped ethnicity into two groups: Dutch 
and not Dutch. Lifetime number of partners and number of partners in the past six 
months were divided into four categories, and frequency of sexual contact was grouped 
into five categories. Years of being sexually active (i.e. sexual age) ranged from 0 to 23 
years, the category  “0” years consisted of women who became sexually active in the 
past year. Because of the small numbers, 0 and 1 year were combined as well as 13 to 23 
years. Chlamydia, genital warts, Syphilis, Gonorrhoea, Genital Herpes, and HIV were 
defined as STD. In further statistical analysis previous STDs were defined as yes or no.
Variables found to be significantly related to HPV infection by univariate analyses were 
entered into a multiple logistic regression model with forward selection procedures to 
identify variables that contributed independently to the probability of HPV prevalence.
Participants with missing data on variables included in the multivariate analysis were 
excluded. In all tests, p values < 0.05 were regarded statistically significant. 
Statistical analyses were performed using SAS 8.0 (SAS Institute Inc., Cary, NC, USA) and 
SPSS 14.1 (Chicago, Illinois, USA).
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Table 1.  HPV prevalence by demographic variables among all women
Sample 
size (n)
HPV
Prevalence (n)
               p
Overall 2065 393 (19.0%)              -
Age (in years) <0.001*
 18 142 12     (8.5%)
 19 173 19   (11.0%)
 20 190 24   (12.6%)
 21 185 30   (16.2%)
 22 187 41   (21.9%)
 23 185 24   (13.0%)
 24 186 43   (23.1%)
 25 182 44   (24.2%)
 26 186 41   (22.0%)
 27 168 52   (31.0%)
 28 172 37   (21.5%)
 29 109 26   (23.9%)
Ethnicity** 2050 0.73*
Dutch 1981 378   (19.1%)
Other 69 12   (17.4%)
Education*** 2044 0.424*
Lower secondary / Lower vocational training 71 13   (18.3%)
Higher Secondary / Vocational training 428 72   (16.8%)
Higher vocational training / University 1545 303   (19.6%)
Current smoking 2054 <0.001*
Yes 406 114  (28.1%)
No 1648 277  (16.8%)
Using OCC 2061  0.758*
Yes 1459 275  (18.8%)
No 602 117  (19.4%)
Living with parents 2052 0.008*
Yes 357 59   (14.0%)
No 1695 340   (20.1%)
Relationship 2053 <0.001*
Married 125 7     (5.6%)
Living together 483 73   (15.1%)
LAT 823 177   (21.5%)
Single 622 134   (21.5%)
Sexual activity ever <0.001*
Yes 1947 389 (20%)
No 116 4     (3.4%)
HPV+: HPV positive if one or more genotypes (high-risk as well as low-risk) are detected simultaneously.
Sample sizes change because of missing values of the questionnaire.
n: number
p: p-value
-: not applicable
*by Chi-square test
**ethnicity was self-reported
***type of education: group of lower secondary education includes 2 women who reported only primary/ 
no education
LAT: living apart together
OCC: oral contraceptives
Figure 1. 
95% Confidence interval of HPV prevalence by age (n=2065).
There was an overall increase in HPV prevalence with age till 22 years, afterwards a plateau phase was 
reached. A decrease is shown at 23 years and a peak among women aged 27 years, however, as the 95% 
confidence interval (95% C.I.) is overlapping with adjacent age groups, the differences were considered 
accidental findings.
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(n=12), and 0.2% (n=4), respectively (Figure 3A and 3B). In 3.5% of the women the HPV 
type could not be specified and was named Lipa X (n=72). A simultaneous presence of 
HPV 16 and 18 only occurred in 3 women (0.1%). HPV DNA was detected in 4 women who 
reported never having had sex. It concerned single infections with HPV type 33, two 
times HPV type 16, and a co-infection with HPV type 66 and 52. 
Sexually active women
When univariate analysis was restricted to sexually active women, factors significantly 
associated with HPV prevalence were increasing age, current smoking, number of partners 
in the past 6 months, and years of being sexually active (i.e. sexual age) (Table 2 and Figure 
2B). Sexual age was defined as time interval in years between age at first sexual contact 
and current age. Furthermore, a higher number of lifetime sexual partners, was significantly 
associated with overall HPV prevalence as well as hr-HPV prevalence (Table 2 and Figure 4). 
Women without an HPV infection tended to be married or living together with their 
partner. Age at first sexual contact did not show a significant relationship with current HPV 
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Figure 2A. 
Prevalence of low-risk and high-risk types by age (n=2065).
Prevalence of overall and both high-risk (hr-) and low-risk (lr-) HPV types showed an almost similar 
age-distribution. In some women both hr- and lr-types were detected.
Figure 3A. 
Prevalence of high-risk HPV types.
Most common types detected were HPV type 16 (2.8%, n=57), HPV type 51 (2.5%, n=51), and HPV type 52 
(2.5%, n=52). In some women both low-risk and high-risk types were detected.
Figure 2B. 
Prevalence of low-risk and high-risk types by sexual age (n=1943).
Only sexually active women were selected (n=1943). Overall HPV prevalence, as well as high-risk (hr-) and 
low-risk (lr-) HPV prevalence, showed an increase with rising sexual age. However, hr-HPV prevalence 
decreased from a sexual age of 10 years. In some women both hr- and lr-types were detected.
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prevalence (Table 2). HPV prevalence, as well as hr- and lr-HPV prevalence, showed an 
increase with rising sexual age (Table 2 and Figure 2B). However, hr-HPV prevalence 
decreased from a sexual age of 10 years (Figure 2B). Oral contraceptive (OCC) use could 
not be defined as a risk factor for HPV positivity.
After logistic regression, age, smoking, number of sexual partners (lifetime and in past 
6 months), type of relationship, living with parents, and sexual age were significantly 
associated with HPV prevalence. Additionally, HPV prevalence was lower among women 
without a previous STD (Odds Ratio (OR)  0.355, p<0.001, Table 2), but there was no 
significant difference between the type of STDs. Women who reported to be non-smokers 
tested significantly less often positive for HPV than women who reported to be current 
smokers (17.8% versus 28.3%, OR 0.551, p <0.001, Table 2). Women not living with their 
parents tested significantly more often positive for HPV than women who were living 
with their parents (20.9% versus 15.2% , OR 1.468, 95% C.I. 1.055;2.041, p=0.02). 
Age at first sexual intercourse was not significantly related to HPV prevalence, whereas 
sexual age was (p= 0.053, and p< 0.001, respectively).
The analysis was concluded by completing a multivariate regression analysis on all 
factors that showed a significant relation with HPV in the univariate analysis. The factors 
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Figure 3B. 
Prevalence of low-risk HPV types.
In some women both low-risk and high-risk types were detected. HPV genotype 53 and 66 may also be 
considered as possible high-risk types.
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Table 2.   HPV prevalence and Odds Ratio’s for HPV prevalence among sexually 
active women using univariate analysis and logistic regression.
n
HPV+
n (%) / 
Median (range)
p OR (95% C.I.)   p
Age (years) 1947 25    (18-29) <0.001^ 1.097 (1.059;1.136) <0.001
Current smoking 1936 <0.001*
No 1536 274   (17.8%) 0.551 (0.428;0.711) <0.001
Yes 400 113   (28.3%) 1 (ref )
Using OCC 1944  0.272*
No 528 114   (21.6%) 1.148 (0.898;1.467) 0.272
Yes 1416 274   (19.4%) 1 (ref )
Living 
with parents
1934  0.022*
No 1619 398   (20.9%) 1.468 (1.055;2.041) 0.023
Yes 315 48   (15.2%) 1 (ref )
Relationship 1935 <0.001*
Married 125 7     (5.6%) 0.216 (0.099;0.471) <0.001
Living together 483 73   (15.1%) 0.647 (0.480;0.874) 0.004
Single 511 131   (25.6%) 1.254 (0.967;1.625) 0.088
LAT¤ 816 176   (21.6%) 1 (ref )
Age at first 
intercourse** 
(years)
1944   0.053*
≤ 13 45 13   (28.8%) 1.517 (0.719;3.204) 0.274
14-16 935 203   (21.7%) 1.036 (0.688;1.560) 0.866
17-19 803 139   (17.3%) 0.782 (0.514;1.190) 0.251
≥ 20 161 34   (21.1%) 1 (ref )
Lifetime 
sex partners 
(number)
1938 <0.001*
1 403 17    (4.2%) 0.044 (0.025;0.077) <0.001
2-5 924 136  (14.7%) 0.173 (0.125;0.239) <0.001
6-10 397 127     (32%) 0.470 (0.334;0.662) <0.001
>10 214 107     (50%) 1 (ref )
Gender of sex 
partner(s)
1939 <0.001*
Male 1829 349     (19.1) 0.393 (0.260;0.594) <0.001
Female 6 0       (0%) 0.000 (0.000; .) 0.999
Both 104 39  (37.5%) 1 (ref )
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living together and having a relationship but living apart. This was followed by frequency 
of sexual contact (p=0.001), age (p<0.001), and number of sexual partners in past 
6 months (p=0.018), with a protective effect of having a single partner. Sexual age 
(p=0.022) was also independently associated with HPV prevalence. Additionally, condom 
use was not defined as an independent risk factor as it was dependent on age, type of 
relationship, frequency of sexual contact, and number of sexual partners in the past six 
months.
independently associated with a risk of being HPV positive were, with an exception for 
age, mainly related to sexual behaviour (Table 3). The number of lifetime sexual partners 
was the most powerful independent predictor of HPV prevalence (p<0.001). Followed by 
type of relationship (p<0.001), with a significant difference between being married / 
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Figure 4. 
Number of lifetime sexual partners by high-risk HPV.
A higher number of lifetime sexual partners was significantly associated with overall HPV prevalence as 
well as hr-HPV prevalence. 
95% C.I.: 95% Confidence Interval.
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Table 2.   Continued
n
HPV+
n (%) / 
Median (range)
p OR (95% C.I.)   p
Sex partners in 
past 6 months 
(number)
1939 <0.001*
0 170 22   (12.9%) 0.140 (0.077;0.254) <0.001
1 1485 249   (16.8%) 0.190 (0.125;0.288) <0.001
2 188 66   (35.1%) 0.509 (0.310;0.835) 0.008
>2 99 51   (51.1%) 1 (ref )
Sexual contact 
in past 6 months 
(frequency)
1886 <0.001*
0 146 19      (13%) 0.461 (0.274;0.775) 0.003
1-6 221 66   (29.9%) 1.312 (0.927;1.857) 0.125
7-24 239 47   (19.7%) 0.754 (0.519;1.096) 0.139
25-54 729 111   (15.2%) 0.553 (0.418;0.732) <0.001
>54 551 135   (25.4%) 1 (ref )
Ever diagnosed 
an STD?
1940 <0.001*
No 1755 315   (17.9%) 0.355 (0.257;0.488) <0.001
Yes 186 71   (38.2%) 1 (ref )
Condom use 1938 <0.001*
Never (0%) 924 142   (15.4%) 1.005 (0655;1.541)  0.983
Sometimes 
(0-50%)
499 134   (26.9%) 2.031 (1.313;3.143) 0.001
Most of times 
(50-100%)
318 82   (25.8%) 1.923 (1.210;3.055) 0.006
Always (100%) 197 30   (15.2%) 1 (ref )
Sexual age 
(years)***
1943 8      (1-13) <0.001^ 1.096 (1.061;1.133) <0.001
n: number
Sample sizes change because of missing values of the questionnaire
HPV+: HPV positive if one or more genotypes are detected simultaneously
p: p-value, OR: Odds Ratio
95% C.I.: 95% Confidence Interval
^Mann Whit ey
*by Chi-square test 
**below the age of 10 years several cases of sexual abuse were reported 
***Sexual age in years with 0 and 1 combi ed as well as sexual age higher than 13
ref: reference, OCC: oral contraceptives, LAT: living apart together, STD, sexually transmitted disease
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(1.4%) were found concomitantly in only 3 women (0.1%). These results are comparable 
with recent studies among young women, although different sampling methods were 
used.8;13-15 In this large study, self-collected cervico-vaginal samples were used. Material 
from self-sampling brushes or vaginal lavages has been proven to be highly representative 
for the cervical HPV status.16 HPV point prevalence was linked to sexual behaviour by 
using questionnaires. As the questionnaires were only provided with a study number, 
they could be considered as fairly anonymous, inducing high credibility. The number of 
sexual partners, as well as the type of current relationship were significantly associated 
with HPV positivity. Several international studies confirm sexual behaviour and a high 
number of sexual partners as the most important risk factors to contract STDs.5;15;17-22 
In this study not only the number of sexual partners in the past six months but also 
number of lifetime sexual partners was independently associated with a higher risk for 
HPV prevalence. An active HPV infection is likely to be dependent on recent sexual 
activity and may therefore be acquired recently, whereas latent or persistent infection 
could be influenced by past sexual behaviour. A higher number of lifetime sexual 
partners increases the risk of getting infected with one or more HPV types in time. Every 
HPV infection has its type dependent clearance which takes 8 to 14 months on average. 
Women, who have not been sexually active recently, i.e. in the past six months, may test 
positive for HPV. Another explanation for the influence of the sexual past is that latent 
infections are detected. Detecting a latent infection is dependent on the sensitivity of 
the technique used. In this study the highly sensitive HPV genotyping test SPF10-LIPA is 
used, which could make it difficult to discriminate between active (i.e. chronic productive 
infections) and latent infections because of its low threshold value. Therefore, results of 
this study, showing point prevalence of HPV infections, may be a mixture of latent and 
active or persistent infections.
Furthermore, multivariate analysis provided insight in the independent risk factors for 
prevalent HPV infection. The independent risk factors were all related to sexual behaviour, 
with the exception for age. We found that HPV prevalence increased with age. Studies 
often show HPV prevalence decreasing towards 30 years. This may be explained by the 
fact that the Dutch Cervical Screening Programme starts at the age of 30 years, and 
therefore these women are unscreened. Furthermore, we did not study women above 
the age of 29, and we did not combine different age groups, which may provide another 
perspective by levelling the differences. Other explanations could be the techniques 
used or differences in the population studied. The use of contraceptive methods like 
condoms was influenced by type of relationship. Results of several studies on condom 
use have been inconsistent partly owing to the fact that different populations have been 
studied.7;15;22;23 Furthermore, our multivariate analysis showed no significant relation 
Discussion
This is the first Dutch HPV epidemiological study conducted among unscreened women 
aged 18 to 29 years. The point prevalence of HPV DNA in this sample was 19%. Lr- and 
hr-HPV prevalence were 9.1% and 11.8%, respectively. Hr-HPV types 16 (2.8%) and 18 
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Table 3.   Adjusted Odds Ratio’s for HPV prevalence among sexually active women 
using multivariate logistic regression (n=1820).
Adj. OR (95% C.I.) p
Age (years) 1.160 (1.081;1.246) <0.001
Relationship <0.001
Married 0.227 (0.098;0.525)   0.001
Living together 0.565 (0.397;0.801)   0.001
Single 1.037 (0.685-1.570)   0.864
LAT 1 (ref )
Lifetime sex partners (number) <0.001
1 0.061 (0.031;0.117) <0.001
2-5 0.208 (0.139;0.313) <0.001
6-10 0.512 (0.350;0.748) <0.001
>10 1 (ref )
Sex partners in past 6 months (number)   0.018
0 0.153 (0.009;2.723)   0.201
1 0.467 (0.278;0.784)   0.004
2 0.674 (0.389;1.169)   0.160
>2 1 (ref )
Sexual contact in past 6 months (frequency)   0.001
0 1.218 (0.073;20.232)   0.886
1-6 0.701 (0.431;1.142)   0.160
7-24 0.541 (0.345;0.848)   0.008
25-54 0.513 (0.375;0.703) <0.001
>54 1 (ref )
Sexual age (years)* 0.917 (0.851;0.988)   0.022
n: number
Adj. OR: Adjusted Odds Ratio
95% C.I.: 95% Confidence Interval
p: p-value
LAT: living apart together
ref: reference
*Sexual age in years with 0 and 1 combined as well as sexual age higher than 13 years
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between HPV positivity and smoking. Results of studies regarding the effect of smoking 
and HPV have also been inconsistent.8;21;24
No correlation of educational level with HPV prevalence was seen. However, the over-
representation of women attending university college possibly limits generalisation of 
these findings, and may be influenced by the method of recruitment. Nevertheless, this 
study provides a unique sample with an equal distribution of women over the age 
groups of 18 to 29 years, using one of the last opportunities to gather baseline i.e. 
pre-vaccine data. These baseline data enable future study on HPV dynamics. HPV 
epidemiology will most likely change after vaccination due to expected decreases in 
HPV 16-18 prevalence and incidence, as well as decreases in other types due to cross-
protection of the vaccine. These decreases in type specific prevalence and incidence 
may be substituted by increases in other HPV genotypes. The relative low point 
prevalence of HPV 16 and 18, and co-infection with both types in only 0.1%, combined 
with independent predictors of prevalent HPV infection, may be promising for future 
catch-up vaccination. These results suggest that it may be possible to expand the future 
target group for catch-up vaccination by including women with a higher age or by 
targeting women with a low risk profile.
This study shows that sexual behaviour, especially the number of sexual partners as well 
as type of current relationship, remain the dominant and individual risk factors for HPV 
positivity i.e. HPV point prevalence. These unique baseline epidemiological data on HPV 
prevalence in combination with knowledge of sexual behaviour provide a basis for 
research on possible future shifts in HPV genotype prevalence, and enable a better 
estimate of the effect of nationwide HPV 16-18 vaccination on cervical cancer 
incidence.
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Abstract
Infection with Human Papillomavirus (HPV) is a necessary event in the multi-step 
process of cervical carcinogenesis. Most sexually active women have been genitally 
infected by HPV at some point in their life. The natural dynamics of HPV acquisition, 
clearance, and persistence, may be influenced by viral, host, and environmental factors. 
Only a few studies investigated the natural course of HPV in healthy unscreened young 
women. The aim of this study is to obtain more insight into the dynamics of high-risk (hr) 
HPV infections and specific risk factors of incidence and clearance of genital HPV among 
young unscreened women.
This prospective epidemiologic study analyses the results of HPV detection in 1812 
women aged 18 to 29 years. Women provided three consecutive cervico-vaginal 
self-samples with a 6 month interval and filled out accompanying questionnaires. 
Hr-HPV prevalence at study entry was 11.8% (n= 213). During the follow up hr-HPV 
incidence in sexually active women was 6.3% (n=218). The most commonly acquired 
hr-HPV type was HPV 16 (2.3%, n=80). The risk of hr-HPV acquisition increased with being 
single, change in current type of relationship, as well as change in number of sexual 
partners 3 months prior to sampling, and sexual age at study entry. Hr-HPV clearance 
was significantly associated with current type of relationship as well as total number of 
sexual partners (lifetime). This study showed that hr-HPV incidence as well as clearance 
were related to past and present sexual behaviour. These results suggest that some 
infections were newly acquired whereas others were acquired in the past and remained 
latent below detection level and could be considered as accidental pick-ups. As HPV 
infections are very common, it is difficult to discriminate separate risk factors for HPV 
dynamics. Our results indicate that sexual behaviour itself, i.e. being sexually active, is 
the most important determinant, and that certain aspects of sexual behaviour may be of 
particular interest when looking at genotypes separately.
Introduction
Genital infection with Human Papillomavirus (HPV) is the most common sexually 
transmitted disease (STD) among young sexually active women.1 Most sexually active 
women have been genitally infected by one or more HPV types at some point in their 
life.2 Infection with HPV is a necessary event in the multi-step process of cervical 
carcinogenesis.3-6 Fortunately, HPV infections are usually transient without causing any 
symptoms or abnormalities. Estimates of HPV point prevalence among asymptomatic 
women around the world range from 2% to 44%.7-9 The wide variation in prevalence is 
largely explained by differences in age, geography or differences in other characteristics 
of the populations studied, as well as by differences in sensitivity of the HPV-DNA assay 
used.2;9 
The natural dynamics of HPV acquisition, clearance and persistence, may be influenced 
by viral, host, and environmental factors.10;11 Still, little is known about these factors, and 
until recently, only a few large studies investigated the natural course of HPV in female 
adolescents and young women. Even fewer studies have prospectively investigated the 
natural course in relation to past and present sexual behaviour in a young and unscreened 
population.
This study presents the descriptive epidemiological results on the dynamics of high- risk 
(hr) HPV infections in general as well as hr-HPV type specific infections. It provides an 
unique insight into specific risk factors for acquisition and clearance of genital HPV 
infections among young unscreened women before mass vaccination affects the natural 
history of HPV.
Materials and Methods
Study population and study design
This prospective epidemiologic study was performed among 2065 unscreened women 
aged 18 to 29 years. Women were recruited between June and September 2007, using 
different advertisements, as well as active recruitment sites, and posters at general 
practices in the city regions of Arnhem, Nijmegen, and Den Bosch, the Netherlands. 
Furthermore, advertisements on the internet were used, which were accessible 
throughout the Netherlands. Of the 2297 women who responded to the advertisements, 
2065 (89.9%) consented with the study, returned the cervico-vaginal swab specimens, 
and filled out the questionnaire at baseline (time point 0 months, i.e. T0). 
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ethnicity were self-reported into different categories. The second part consisted of 
questions regarding sexual behaviour. Results of HPV detection were correlated to past 
and present sexual behaviour. Sex was defined as vaginal, oral, and/or anal sex. For 
women who had at least 1 lifetime sex partner, additional questions were asked on age 
at first sexual contact, age of first sex partner, number of sex partners before the age of 
sixteen, lifetime number of sex partners, number of sex partners in the three months 
prior to sampling, gender of sex partners, frequency of sexual contact, condom use, and 
history of STDs.
HPV DNA Detection and Genotyping
As the aim of this study was to obtain a maximum of information about the HPV status 
in the study population and to monitor the course of infections in detail, the highly 
sensitive broad-spectrum HPV DNA amplification was performed using a short PCR 
fragment assay (SPF10-LiPA HPV detection/genotyping assay, SPF10 system version 1, 
manufactured by Labo Biomedical Products BV, Rijswijk, the Netherlands). This assay 
amplifies a 65-bp fragment of the L1 open reading frame and allows detection of at least 
43 different HPV types.13-15 The SPF10 PCR was performed with a final reaction volume of 
50 μl containing 10 μl of the isolated DNA sample, 10 mmol/liter Tris-HCl (pH 9.0), 50 
mmol/liter KCl, 2.0 mmol/liter MgCl2, 0.1% Triton X-100, 0.01% gelatin, 200 μmol/liter of 
each deoxynucleoside triphosphate, 15 pmol each of the forward and reverse primers 
tagged with biotin at the 5′end, and 1.5 U of AmpliTaq Gold (Perkin-Elmer). The mixture 
was incubated for 9 minutes at 94°C, 40 cycles of 45 s at 45°C, and 40 cycles of 45 s at 
72°C, with a final extension of 5 minutes at 72°C. Each experiment was performed with a 
separate positive and negative PCR control. The presence of HPV DNA was determined 
by hybridization of SPF10 amplimers to a mixture of general HPV probes recognizing a 
broad range of HPV genotypes, in a microtiter plate format, as described previously.13-15 
 All HPV DNA-positive samples (by SPF10 DEIA) were genotyped using the LiPA HPV 
genotyping assay. 
The 28 oligonucleotide probes that recognize 25 different types were tailed with 
poly(dT) and immobilized as parallel lines to membrane strips (Labo Bio Medical Products 
BV, Rijswijk, the Netherlands). The HPV genotyping assay was performed as described 
previously.13  Samples that tested positive using the DNA enzyme immunoassay but that 
showed no results on the LiPA strip were considered to be HPV X type, i.e. genotypes not 
available on the LiPA strip. Low-risk HPV (lr-HPV) types were defined as HPV type 6,11, 34, 
40, 42, 43, 44, 53, 54, 55, 58, 66, 70, 74, and “X”; and hr-HPV types as HPV 16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 59, 68, 73, and 82.
The study consisted of 3 sequential test-moments with a 6 month interval (mean 5.8 
months, SD 0.63 months). From the 2065 participants at study entry, a total of 253 (12.3%) 
women were excluded from further analyses. These women became pregnant (n=63, 
3.0%), got vaccinated against HPV (n=9, 0.4%), or were lost to follow-up (n=181, 8.8%). 
This resulted in a final number of 1812 (87.7%) participating women, of whom 1703 
reported to be sexually active at study entry. An additional 26 women became sexually 
active during the follow up, i.e. 13 every 6 months. Results of these women were used for 
further analyses.
Written informed consent was obtained from all participants. This study was approved 
by the Local Medical Ethics Committee.
Specimen Collection and Processing
All women were asked to fill out a questionnaire and to self-collect a cervico-vaginal 
sample in the privacy of their own home at 0, 6, and 12 months. Women received an 
explanatory letter, an informed consent form, a questionnaire, and a self-sample kit by 
mail. The self-sample kit contained a collection device (a small brush packaged in an 
individual sterile cover, Rovers® Viba-brush, Rovers Medical Devices B.V., Oss, the 
Netherlands), a collection tube containing medium (SurePathtm, Tripath Imaging®, Inc., 
Burlington, NC, USA), instructions how to perform the cervico-vaginal self-sample 
(written and in cartoon), and a return package consisting of a leak-proof seal bag, 
absorption sheet, and a reclosable plastic return envelope (easyslider, Transposafe 
Systems Holland B.V., Sassenheim, the Netherlands). 
The self sample was taken and processed as described earlier.12 In brief, participants were 
instructed to wash their hands before opening the brush cover, to hold the brush by the 
end of the handle, to insert the brush approximately 7 cm into the vagina (similar to 
inserting a tampon), to gently turn the brush 5 times, and to place the top of the brush 
in the collection tube. The collection tube was closed, and enclosed in the seal-bag. 
Finally, the collection tube was placed in the return envelope, together with the 
questionnaire, and sent to the Department of Obstetrics and Gynaecology for further 
processing and HPV assessment. The samples were stored at room temperature.
Questionnaire
In this study, a questionnaire consisting of two parts was used. The first part was 
composed of questions regarding socio-demographic variables like educational level, 
religion, smoking, medication use, oral contraceptive use (OCC), and ethnicity. Race and 
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Results
Baseline Characteristics
Of the 2065 participants at study entry, 253 women (12.3%) were excluded because of 
pregnancy, vaccination against HPV, or because they did not return all three samples. In 
general, the demographic characteristics and sexual behaviour at study entry were 
similar for the excluded women (n= 253, 12.3%) and the included women (n=1812, 87.7%). 
However, smoking, OCC use and type of relationship differed between the included and 
excluded women. Analysis showed that the excluded group consisted of significantly 
more smokers ( 28.3% versus 18.6%, p=<0.01), less OCC users (57.4% versus 72.7%, 
p=<0.01), and more women who were married or cohabiting. However, type of 
relationship as well as OCC use was confounded by women who were pregnant and 
therefore excluded (data not shown). Most important, the HPV prevalence at study entry 
was not significantly different between included and excluded women.
The results of the remaining 1812 women were used for further analyses. Their mean age 
at baseline was 23.2 years (SD 3.3). Age distribution and socio-demographic characteristics 
are summarised in Table 1. Many women attended higher vocational training or University 
in past or presence (n=1384, 76.7%). Of all women, 557 (30.8%) were single and 1249 
(69.2%) were involved in a relationship. Only 53 women (2.9%) reported an ethnicity 
other than Dutch. Because of these small numbers, they were divided into two groups: 
Dutch (97.1%, n= 1750), and “other” (2.9%, n=53).
At study entry the mean age at first sexual contact was 16.7 years, and the mean sexual 
age (i.e. years of being sexually active) was 6.4 years. Furthermore, 107 (5.9%) women 
reported not to be sexually active in past or presence. Of these women, 26 became 
sexually active during follow up.
Prevalence of HPV infection
Of the 1812 women included in this analysis, 343 women (18.9%) were positive for one or 
more HPV infections at study entry, of whom 3 women reported not to be sexually active 
in past or presence. Lr- and hr-HPV prevalence were 8.9% (n=161) and 11.8% (n=213), 
respectively. Five most frequent hr-HPV types were HPV 16 (2.8%, n=51), HPV 18 (1.4%, 
n=25),  HPV 31 (1.4%, n=25), HPV 51 (2.5%, n=45), and HPV 52 (2.3%, n=41). During this year 
of follow up, 1218 (67.2%) of the 1812 women remained HPV negative at all time points.
Statistical Analysis
Results were used for further analyses when women completed the questionnaires and 
submitted the swab for HPV evaluation at all three time points (T0-T6-T12 ) and when they 
were not pregnant or vaccinated against HPV during the follow up (n= 1812).
Acquisition was defined as transition from an HPV-negative state to an HPV-positive state, i.e. 
HPV positive for a genotype that had not been detected in the previous self-sample. Clearance 
of infection was defined as the absence of one or multiple HPV types that had been present in 
the previous self-sample. This introduces two possible moments of acquisition and clearance, 
namely, between T0 and T6 and between T6 and T12.  For statistical analysis of clearance, the 
results of clearance were compared to women not clearing their HPV infection in that transition 
moment. For HPV acquisition and clearance only sexually active women were included. This 
resulted in 3445 transition moments (T0 →T6 1703 + 13 newly sexually actives= 1716 + T6→T12 
1716 + 13 newly sexually actives = 1716 + 1716 + 13 = 3445 transition moments).
The Chi-Square test was used to test associations between demographic variables or 
behavioural characteristics and HPV incidence. In univariate and multivariate analysis, data 
of some variables were grouped due to small numbers and/or to gain a better overview. 
We grouped ethnicity into two groups: Dutch and not Dutch. Lifetime number of partners 
and number of partners in the past months were divided into four and three categories, 
respectively. Frequency of sexual contact was grouped into four categories. Years of being 
sexually active at study entry (i.e. sexual age) ranged from 0 to 23 years, the category  “0” 
years consisted of women who became sexually active in the year prior to the start of the 
study. Because of the small numbers, 0 and 1 year were combined as well as 13 to 23 years. 
For the same reason, having both female and male sex partners were grouped together 
with having male sex partners only. Chlamydia, genital warts, Syphilis, Gonorrhoea, Genital 
Herpes, and HIV were defined as STD. In further statistical analysis previous STDs were 
defined as yes or no.
Some questions like age, smoking, age at first intercourse, and lifetime number of sex 
partners, were only asked at study entry. Other questions were asked at all time points. At 
each transition moment we measured if there was a change in the existing answer i.e. 
variable. For example, stop or start OCC use or change in type of relationship. This way a 
new variable was created consisting of “change yes/no”. Variables significantly related to 
HPV incidence or clearance by univariate analyses were entered into a multiple logistic 
regression model with forward selection procedures to identify variables that contributed 
independently to the probability of HPV incidence or clearance. Participants with missing 
data on variables included in the multivariate analysis were excluded. 
In all tests, p values < 0.05 were regarded statistically significant. Statistical analyses were 
performed using SPSS 16.0 (Chicago, Illinois, USA).
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Incidence of HPV infections among sexually active women
Transition from an HPV-negative state to an HPV-positive state, i.e. HPV incidence, could 
occur between T0 and T6 and between T6 and T12. Among sexually active women this 
resulted in 3445 transition moments. Hr-HPV incidence was 6.3% (n=218) (Table 2).
For hr-HPV types 16 and 18 the acquisition rate were 2.3% (n=80) for HPV 16 and 1.2% 
(n=40) for HPV 18 (Table 2).
Risk factors for acquiring hr-HPV infections in sexually active women
The risk factors for hr-HPV incidence are presented in Table 3. Factors significantly 
associated with hr-HPV incidence in univariate analysis were increasing age, smoking, 
type of current relationship, change in type of relationship, change in having a new 
relationship, increasing sexual age, total number of sex partners (lifetime), having had 
two or more partners in the 3 months prior to testing, and a change in number of 
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Table 1.  Baseline characteristics of all 1812 women (including non-sexually active 
women)
n (%)
Age (in years) 1812
 18 126 (7.0)
 19 159 (8.8)
 20 180 (9.9)
 21 170 (9.4)
 22 168 (9.3)
 23 156 (8.6)
 24 164 (9.1)
 25 160 (8.8)
 26 157 (8.7)
 27 149 (8.2)
 28 134 (7.4)
 29 89 (4.9)
Ethnicity* 1803
Dutch 1750 (97.1)
Other 53 (2.9)
Education 1804
Lower secondary / Lower vocational training 56 (3.1)
Higher Secondary / Vocational training 356 (19.7)
Higher vocational training / University 1384 (76.7)
Other 8 (0.4)
Current smoking 1803
Yes 335 (18.6)
No 1468 (81.4)
Using OCC 1810
Yes 1315 (72.7)
No 495 (27.3)
Living with parents 1802
Yes 317 (17.6)
No 1485 (82.4)
Relationship 1806
Married 78 (4.3)
Living together 417 (23.1)
LAT 754 (41.7)
Single 557 (30.8)
Table 2.  Incidence and clearance of HPV infections among sexually active women
Incidence (n) Clearance (n)*
Hr-HPV 6.3% (218/3445) 40.9% (187/457)
HPV 16 2.3% (80/3445) 56.3% (67/119)
HPV 18 1.2% (40/3445) 62.7% (37/59)
n: number
* for clearance, only the women were included who were positive for the specific HPV genotype or group, 
the results of clearance were compared to women not clearing their HPV infection
Hr-HPV: high-risk HPV
Sexual activity at study entry 1810
Yes 1703 (94.1)
No 107 (5.9)
Sample sizes change because of missing values of the questionnaire
n: number
* ethnicity was self-reported
LAT: living apart together
OCC: oral contraceptives
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Table 3.   Odds Ratio’s for high-risk HPV, HPV 16  and HPV 18 incidence among 
 sexually active women using univariate logistic regression (n=3445)
Hr-HPV HPV 16 HPV 18
n Events*   OR (95% CI)                                           p
        (n)
Events*   OR (95% CI)                                       p
          (n)
   Events*   OR (95% CI)                                      p
            (n)
Age (years)** 3445 218 1.06 (1.02;1.11) <0.01 80 1.04 (0.97;1.11) 0.33 40 1.04 (0.95;1.15) 0.39
Smoking** 3427
No 2766 161 0.66 (0.48;0.90) <0.01 65 1.04 (0.59;1.83) 0.90 29 0.63 (0.31;1.26) 0.19
Yes 661 57 1.00 (ref ) 15 1.00 (ref ) 11 1.00 (ref )
Current OCC use 3429
No 1000 68 1.13 (0.84;1.53) 0.41 23 0.98 (0.60;1.60) 0.93 12 1.08 (0.55;2.14) 0.82
Yes 2429 147 1.00 (ref ) 57 1.00 (ref ) 27 1.00 (ref )
Change No 3247 197 0.61 (0.36;1.03) 0.06 77 2.14 (0.52;8.77) 0.29 36 0.65 (0.20;2.15) 0.50
Change Yes 178 17 1.00 (ref ) 2 1.00 (ref ) 3 1.00 (ref )
Living with 
parents**
3425
No 2861 182 1.00 (0.69;1.44) 0.99 69 1.37 (0.70;2.67) 0.36 35 1.39 (0.54;3.55) 0.50
Yes 564 36 1.00 (ref ) 10 1.00 (ref ) 5 1.00 (ref )
Relationship 3439
Married 201 9 0.44 (0.22;0.90) 0.02 1 0.15 (0.02;1.08) 0.06 1 0.32 (0.04;2.46) 0.27
Living together 998 41 0.41 (0.28;0.60) <0.01 23 0.69 (0.39;1.21) 0.19 10 0.65 (0.28;1.49) 0.31
LAT 1394 87 0.63 (0.46;0.86) <0.01 28 0.60 (0.35;1.02) 0.06 16 0.74 (0.36;1.56) 0.43
Single 846 81 1.00 (ref ) 28 1.00 (ref ) 13 1.00 (ref )
Change No 2759 155 0.58 (0.43;0.79) <0.01 59 0.71 (0.42;1.19) 0.19 28 0.56 (0.28;1.11) 0.10
Change Yes 669 62 1.00 (ref ) 20 1.00 (ref ) 12 1.00 (ref )
New relationship 3426
No 3247 201 0.63 (0.37;1.06) 0.08 76 1.41 (0.44;4.50) 0.57 38 1.05 (0.25;4.38) 0.95
Yes 179 17 1.00 (ref ) 3 1.00 (ref ) 2 1.00 (ref )
Change No 3247 201 0.52 (0.27;1.00) 0.05 76 1.15 (0.28;4.75) 0.85 38 1.15 (0.16;8.45) 0.90
Change Yes 98 11 1.00 (ref ) 2 1.00 (ref ) 1 1.00 (ref )
Age at first 
intercourse 
(years)**
3402
≤ 13 72 4 1.32 (0.41;4.23) 0.64 2 1.31 (0.26;6,65) 0.74 0 1.00 (-;-) 1.00
14-16 1654 118 1.73 (0.94;3.17) 0.08 35 0.99 (0.41;2.39) 0.99 26 2.58 (-;-) 0.99
17-19 1394 84 1.44 (0.78;2.68) 0.25 37 1.25 (0.52;3.00) 0.61 14 1.64 (-;-) 0.99
≥ 20 282 12 1.00 (ref ) 6 1.00 (ref ) 0 1.00 (ref )
Sexual Age 
(years)**, ***
3400 218 1.07 (1.03;1.11) <0.01 80 1.03 (0.96;1.10) 0.40 40 1.09 (0.10;1.20) 0.06
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Lifetime sex 
partners 
(number)**
3390
1 712 25 0.26 (0.16;0.43) <0.01 6 0.20 (0.08;0.52) <0.01 2 0.13 (0.03;0.60) <0.01
2-5 1618 95 0.45 (0.31;0.65) <0.01 39 0.58 (0.32;1.06) 0.08 16 0.45 (0.19;1.05) 0.07
6-10 694 49 0.54 (0.35;0.83) <0.01 19 0.66 (0.33;1.31) 0.24 13 0.85 (0.35;2.08) 0.73
≥ 11 366 45 1.00 (ref ) 15 1.00 (ref ) 8 1.00 (ref )
Gender of sex 
partner(s)
2965
Male, both 2920 188 3.03 (0.42;22.10) 0.28 71 4.03 (-;-) 1.00 34 1.90 (-;-) 1.00
Female 45 1 1.00 (ref ) 0 1.00 (ref ) 0 1.00 (ref )
Change No 2912 177 2.07 (0.28;15.24) 0.48 67 3.80 (0.00-;-) 1.00 35 1.97 (0.00;-) 1.00
Change Yes 33 1 1.00 (ref ) 0 1.00 (ref ) 0 1.00 (ref )
Sex partners in 
past 3 months 
(number)
3431
0 429 22 0.46 (0.26;0.82) <0.01 8 0.37 (0.15;0.90) 0.03 4 0.82 (0.18;3.69) 0.80
1 2738 168 0.55 (0.36;0.84) <0.01 59 0.43 (0.23;0.79) <0.01 33 1.06 (0.32;3.48) 0.92
≥ 2 264 28 1.00 (ref ) 13 1.00 (ref ) 3 1.00 (ref )
Change No 2686 132 0.39 (0.29;0.52) <0.01 44 0.33 (0.21;0.52) <0.01 25 0.45 (0.23;0.85) 0.01
Change Yes 728 85 1.00 (ref ) 35 1.00 (ref ) 15 1.00 (ref )
Sexual contact 
in past 3 months 
(frequency)
3426
0 431 22 0.88 (0.55;1.40) 0.59 8 0.83 (0.39;1.76) 0.62 4 0.80 (0.28;2.30) 0.68
1-3 338 41 2.26 (1.56;3.28) <0.01 17 2.32 (1.32;4.07) <0.01 7 1.80 (0.78;4.18) 0.17
4-12 417 26 1.09 (0.70;1.68) 0.70 5 0.53 (0.21;1.34) 0.18 3 0.62 (0.19;2.05) 0.43
≥ 13 2240 129 1.00 (ref ) 50 1.00 (ref ) 26 1.00 (ref )
Change No 2339 113 0.49 (0.37;0.65) <0.01 51 0.83 (0.52;1.32) 0.43 24 0.66 (0.35;1.24) 0.19
Change Yes 1027 97 1.00 (ref ) 27 1.00 (ref ) 16 1.00 (ref )
STD**** 3422
No 3397 216 1.63 (0.22;12.10) 0.63 79 0.57 (0.8;4.28) 0.59 39 0.28 (0.04;2.11) 0.22
Yes 25 1 1.00 (ref ) 1 1.00 (ref ) 1 1.00 (ref )
Change No 3352 212 1.45 (0.35;6.03) 0.61 74 0.32 (0.10;1.04) 0.06 38 0.51 (0.07;3.76) 0.50
Change Yes 45 2 1.00 (ref ) 3 1.00 (ref ) 1 1.00 (ref )
Table 3.   continued
Hr-HPV HPV 16 HPV 18
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        (n)
Events*   OR (95% CI)                                      p
          (n)
   Events*   OR (95% CI)                                      p
            (n)
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Risk factors for acquiring an HPV 16 or HPV 18 infection in sexually active women
Risk factors for acquiring an HPV 16 or HPV 18 infection are presented in Table 3 and 
Table 4.
Univariate analysis for HPV 16 incidence showed that having had a total of 11 or more sex 
partners (lifetime) compared to having had 1 partner, having had 2 or more sex partners 
in the past 3 months, change in number of sex partners in past 3 months, as well as 
frequency of sexual contact in the past 3 months were significantly increasing the risk of 
acquiring an HPV 16 infection. After multivariate analysis, change of number of sex 
partners in the past 3 months and frequency sexual contact in the past 3 months 
remained as independent risk factors for HPV 16 incidence.
In univariate analysis, having had a total of 11 or more sex partners (lifetime), change in 
number of sex partners in the past 3 months, as well as change in condom use were 
partners in 3 months prior to testing. Furthermore, frequency of sexual contact in 3 
months prior to testing, change in frequency of sexual contact in 3 months prior to 
testing, frequency of condom use, and a change in condom use were associated with 
hr-HPV incidence. 
The analysis was concluded by completing a multivariate regression analysis on all 
factors that showed a significant relationship with hr-HPV incidence in the univariate 
analysis. The factors independently associated with a risk of acquiring a hr-HPV infection 
were type of relationship, change in type of relationship, increasing sexual age, and 
change in number of sex partners in the past 3 months (Table 4). 
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Condom use 3001
Never 1866 101 0.99 (0.57;1.73) 0.98 35 1.03 (0.40;2.66) 0.95 19 1.40 (0.33;6.06) 0.65
Sometimes 511 43 1.59 (0.87;2.92) 0.13 21 2.31 (0.86;6.21) 0.10 5 1.35 (0.26;7.00) 0.72
Most of times 349 36 1.99 (1.07;3.72) 0.03 10 1.59 (0.54;4.72) 0.40 10 4.03 (0.88;18.53) 0.07
Always 275 15 1.00 (ref ) 5 1.00 (ref ) 2 1.00 (ref )
Change No 1956 104 0.70 (0.51;0.94) 0.02 40 0.87 (0.51;1.47) 0.59 17 0.47 (0.24;0.93) 0.03
Change Yes 934 70 1.00 (ref ) 22 1.00 (ref ) 17 1.00 (ref )
n: number
Sample sizes change because of missing values of the questionnaire
Hr-HPV: high-risk HPV
* number of HPV infections acquired during follow up
OR: Odds Ratio
95% CI: 95% Confidence Interval
p: p-value
** data retrieved at study entry
ref: reference
OCC: oral contraceptives
Change: change in variable in 3 months prior to sample
LAT: living apart together
*** Sexual age in years at baseline with 0 and 1 years combined as well as sexual age higher than 13 years
**** STD, sexually transmitted disease in 3 months prior to sample
Table 3.   continued
Hr-HPV HPV 16 HPV 18
         n Events*   OR (95% CI)                                           p
        (n)
Events*   OR (95% CI)                                      p
          (n)
   Events*   OR (95% CI)                                      p
            (n)
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associated with a higher risk of acquiring an HPV 18 infection. After completing the 
multivariate analysis for HPV 18 incidence, risk factors that were independently related to 
the risk of acquiring HPV 18 were number of lifetime partners and a change in number 
of partners in the past 3 months.
Clearance of hr-HPV infections in sexually active women
For analysis of clearance, the results of clearance were compared to women not clearing 
their HPV infection. Among the transition moments of the sexually active women who 
were hr-HPV positive (n= 457), the hr-HPV clearance was 40.9% (n=187). For HPV 16 and 
HPV 18 the clearance rate during follow up was 56.3% (n=67) and 62.7% (n=37), 
respectively (Table 2).
To compare factors associated with hr-HPV clearance, univariate analysis followed by 
multivariate analysis was used. Univariate analysis showed that total number of partners 
(lifetime), number of partners in three months prior to sampling, as well as type of 
relationship were associated with HPV clearance. Multivariate analysis showed  type of 
relationship and total number of partners (lifetime) to be independently associated with 
hr-HPV clearance (Table 5).  
Factors influencing HPV 16 and HPV 18 clearance in sexually active women
In univariate analyses only the total number of partners (lifetime) showed  a significant 
association with HPV 16 clearance (data not shown).
Univariate analysis for HPV 18 clearance showed type of relationship and never or 
sometimes using a condom compared to always using condoms as factors positively 
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Table 4.  Adjusted Odds Ratio’s for hr-HPV, HPV 16  and HPV 18 incidence among 
sexually active women using multivariate logistic regression
Hr-HPV
(n=2686)
HPV 16
(n=3346)
HPV 18
(n=2820)
Adj. OR 
(95% CI)
p
Adj. OR 
(95% CI)
p
Adj. OR 
(95% CI)
p
Relationship
Married 0.29 (0.13;0.69) <0.01 - - - -
Living together 0.35 (0.22;0.56) <0.01 - - - -
LAT 0.58 (0.38;0.86) <0.01 - - - -
Single 1.00 (ref ) - - - -
Change - -
No 0.61 (0,43;0.89) <0.01 - - - -
Yes 1.00 (ref ) - - - -
Sexual Age 
(years)*,**
1.09 (1.04;1.15) <0.01 - - - -
Lifetime 
sex partners 
(number)*
1 - - - - 0.17 (0.04;0.83) 0.03
2-5 - - - - 0.42 (0.17;1.05) 0.06
6-10 - - - - 0.79 (0.31;1.99) 0.61
≥ 11 - - - - 1.00 (ref )
Sex partners 
in past 3 
months 
(number)
0 - - - - - -
1 - - - - - -
≥ 2 - - - - - -
Change
No 0.59 (0.39;0.88) <0.01 0.31 (0.20;0.49) <0.01 0.49 (0.23;1.05) 0.07
Yes 1.00 (ref ) 1.00 (ref ) 1.00 (ref )
Sexual 
contact in 
past 3 months 
(frequency)
0 - - 0.52 (0.24;1.14) 0.10 - -
1-3 - - 1.69 (0.94;3.03) 0.08 - -
4-12 - - 0.30 (0.09;0.98) 0.05 - -
≥ 13 - - 1.00 (ref ) - -
Hr-HPV: high-risk HPV
n: number
Adj. OR: Adjusted Odds Ratio
95% CI: 95% Confidence Interval
p: p-value
ref: reference
LAT: living apart together
Change: change in variable in 3 months prior to sample
* data retrieved at study entry
** Sexual age in years at baseline with 0 and 1 years combined as well as sexual age higher than 13 years
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Table 5.   Hr-HPV clearance, Odds Ratio’s and Adjusted Odds Ratio’s for hr-HPV 
clearance among sexually active women using univariate logistic 
regression (n=457) and multivariate logistic regression (n=446)
n
Events*
(n)
     OR 
(95% CI)
p
Adj. OR 
(95% CI)
p
Age (years)** 457 187 1.00 (0.94;1.06) 0.91 - -
Smoking** 457
No 321 137 1.28 (0.85;1.94) 0.24 - -
Yes 136 50 1.00 (ref ) - -
Current OCC 
use
453
No 144 59 1.01 (0.67;1.51) 0.97 - -
Yes 309 126 1.00 (ref ) - -
Change No 434 179 1.52 (0.57;4.08) 0.41 - -
Change Yes 19 6 1.00 (ref ) - -
Living with 
parents**
455
No 390 157 0.79 (0.46;1.33) 0.37 - -
Yes 65 30 1.00 (ref ) - -
Relationship 455
Married 10 8 9.19 (1.88;44.93) <0.01 7.48 (1.47;38.17) 0.02
Living together 107 52 2.17 (1.30;3.62) <0.01 1.97 (1.17;3.32) 0.01
LAT 183 78 1.70 (1.09;2.68) 0.02 1.75 (1.10;2.78) 0.02
Single 155 47 1.00 (ref ) 1.00 (ref )
Change No 338 134 0.85 (0.56;1.30) 0.45 - -
Change Yes 117 51 1.00 (ref ) - -
New 
relationship
452
No 426 175 1.12 (0.50;2.52) 0.79 - -
Yes 26 10 1.00 (ref ) - -
Change No 426 175 1.05 (0.37;3.00) 0.93 - -
Change Yes 15 6 1.00 (ref ) - -
Age at first 
intercourse 
(years)**
455
≤ 13 12 4 0.60 (0.15;2.39) 0.47 - -
14-16 235 101 0.90 (0.44;1.88) 0.79 - -
17-19 175 67 0.74 (0.35;1.58) 0.44 - -
≥ 20 33 15 1.00 (ref ) - -
Sexual Age 
(years)**, ***
455 187 0.99 (0.93;1.05) 0.71 - -
Lifetime sex 
partners 
(number)**
449
1 27 15 1.54 (0.66;3.61) 0.32 1.22 (0.50;2.94) 0.67
2-5 168 76 1.02 (0.62;1.66) 0.94 0.93 (0.56;1.53) 0.78
6-10 149 46 0.55 (0.33;0.93) 0.02 0.54 (0.32;0.92) 0.02
≥ 11 105 47 1.00 (ref ) 1.00 (ref )
Gender of sex 
partner(s)
390
Male, both 389 158 1.11 (0.00;-) 1.00 - -
Female 1 0 1.00 (ref ) - -
Change No 400 164 - - - -
Change Yes 0 0 - - - -
Sex partners in 
past 3 months 
(number)
455
0 59 24 1.83 (0.83;4.02) 0.13 - -
1 341 146 2.00 (1.06;3.75) 0.03 - -
≥ 2 55 15 1.00 (ref ) - -
Change No 313 136 1.46 (0.97;2.20) 0.07 - -
Change Yes 142 49 1.00 (ref )
Sexual 
contact in 
past 3 months 
(frequency)
455
0 59 24 0.95 (0.54;1.67) 0.85 - -
1-3 59 18 0.61 (0.33;1.10) 0.10 - -
4-12 42 20 1.25 (0.66;2.40) 0.49 - -
≥ 13 295 124 1.00 (ref )
Change No 308 128 1.03 (0.69;1.54) 0.89 - -
Change Yes 142 58 1.00 (ref ) - -
STD**** 455
No 446 182 0.86 (0.23;3.25) 0.83 - -
Yes 9 4 1.00 (ref ) - -
Change No 440 182 1.41 (0.42;4.76) 0.58 - -
Change Yes 12 4 1.00 (ref )
Condom use 396
Never 245 109 1.74 (0.84;3.60) 0.14 - -
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In this study not only change in the number of sexual partners in the past three months 
but also number of lifetime sexual partners was associated with a transition from hr-HPV 
negative status to a hr-HPV positive status. A higher number of lifetime sexual partners 
increases the risk of getting infected with one or more HPV types in time. Several studies 
associated past sexual behaviour with HPV incidence.2;16-18 A possible explanation for the 
influence of past sexual behaviour on present detection of HPV after a former negative 
sample could be that the infection was acquired in the past and remained present with 
levels of shed virus below the threshold of detection as if it were cleared. These infections 
may be considered as an accidental pick-up. 
Detecting an infection is dependent on the sensitivity of the technique used. In this 
study the highly sensitive SPF10 LiPA HPV genotyping assay was used, which could make 
it difficult to discriminate between truly newly acquired infections and  accidental 
pick-ups because of its low threshold value. For this reason we can only claim to have 
measured the “presumed” incidence rate of a new type for those negative at the previous 
test moment.27
Change in number of partners in past 3 months was significantly related to acquiring a 
hr-HPV, an HPV 16 as well as an HPV 18 infection. However, some other specific risk 
factors differed. For hr-HPV, type of relationship as well as change in current type of 
relationship, and sexual age were risk factors. For HPV 16, frequency of sexual contact 
influenced transition, and for HPV 18, lifetime number of partners was associated with 
HPV incidence. Looking at the transition moments of the separate genotypes, a remark 
must be made that the numbers are small making the results difficult to interpret. 
Nevertheless, all factors associated with HPV transition were related to sexual behaviour 
and therefore influencing the risk of acquiring an HPV infection. 
Furthermore, type of relationship was associated with both the risk of acquiring a hr-HPV 
infection as well as clearance of the previous detected infection. Women being single 
were most at risk for acquiring an infection, whereas women who were in a relationship, 
no matter which form, had a better chance of clearing the previously detected infection. 
This may be explained by the fact that women in a relationship may have more accidental 
pick-ups which may not be detected during the next measurement. Additionally, singles 
may have a higher chance of acquiring a true new infection during follow up. These 
infections may need a longer time to transit to an HPV negative status again than this 
study provided. 
Every HPV infection has its type dependent clearance which takes 8 to 14 months on 
average.2;7;9;10;19;27;28 The difference in estimations of time to clearance may be attributed to 
the interval between test moments. Additionally, the meaning of an intermediate negative 
test has been inconsistently defined 7;16;29-33, resulting in various definitions of incidence, 
persistence, and clearance. We did not measure exact time to clearance. Many infections 
associated with clearance. However, multivariate analysis showed that condom use was 
confounded by type of relationship and reversely. Therefore, no independent influencing 
factors were identified (data not shown).
Discussion
At study entry the point prevalence of hr-HPV was 11.8%. During follow up hr-HPV 6 months 
incidence was 6.3%. Factors significantly associated with hr-HPV incidence were related 
to present sexual behaviour like currently being in a relationship and change in number of 
sexual  partners 3 months prior to sampling. These findings are consistent with results from 
studies describing factors associated with HPV infection.2;16 However, some studies describe 
sexual behaviour itself as a risk factor whereas others indicate specific aspects of sexual 
behaviour.2;17-19 Several international studies confirm sexual behaviour and a high number of 
sexual partners as the most prominent risk factors to contract STDs.7;17;18;20-26
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Sometimes 67 26 1.37 (0.59;3.19) 0.46 - -
Most of times 46 15 1.05 (0.42;2.63) 0.92 - -
Always 38 12 1.00 (ref )
Change No 244 109 1.50 (0.97;2.31) 0.07 - -
Change Yes 137 48 1.00 (ref ) - -
n: number
Sample sizes change because of missing values of the questionnaire
* number of HPV infections cleared during follow up
OR: Odds Ratio
95% CI: 95% Confidence Interval
p: p-value
Adj. OR: Adjusted Odds Ratio
** data retrieved at study entry
ref: reference
-: not applicable
OCC: oral contraceptives
Change: change in variable in 3 months prior to sample
LAT: living apart together
*** Sexual age in years at baseline with 0 and 1 years combined as well as sexual age higher than 13 years
**** STD, sexually transmitted disease in 3 months prior to sample
Table 5.   continued
n
Events*
(n)
     OR 
(95% CI)
p
Adj. OR 
(95% CI)
p
72 73
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Chapter 4
Parental acceptance of 
Human Papillomavirus vaccines
80 81
Abstract
This study was conducted to determine whether parents would accept Human 
Papillomavirus (HPV) vaccination for their children and which variables may influence 
their decision, including knowledge about cervical cancer and HPV. Three-hundred- 
fifty-six parents of children aged 10 to 12 years were interviewed regarding the 
acceptance of an HPV vaccine for their children and their knowledge of HPV and cervical 
cancer. All data were recorded anonymously. Results were compared using the χ2 - and 
the Mann-Whitney test. HPV vaccination would be accepted by 88% of the parents, 
preferably when the child is aged 10 to 12 years. Parents of children who received all the 
vaccinations of the National Vaccination Programme accepted HPV vaccination 
significantly more. Less than a third of all parents had heard of HPV, and 14% were aware 
of the causal relationship of HPV and cervical cancer. Knowledge of HPV and cervical 
cancer, religion, age, education, and marital status did not show any significant relation 
with HPV vaccine acceptance. A majority of the parents would accept HPV vaccination. 
HPV vaccine acceptance seems to be dependent on vaccine acceptance in general, even 
more than on knowledge of HPV and its causal relation with cervical cancer. However, 
parents requested more information about cervical cancer, HPV, and HPV vaccination, 
before the HPV vaccine is introduced.
Introduction
Several studies have shown that a persistent infection with high-risk Human 
Papillomavirus (hr-HPV) is the most important risk factor for developing cervical cancer 
and its precursor lesions. Cervical cancer is the second most common cancer in women 
worldwide and hr-HPV genotypes can be detected in over 99% of all cases.1-3 In the 
Netherlands approximately 600 women are diagnosed with invasive cervical cancer 
annually. The annual mortality rate is approximately 3.0 per 100,000 women.
HPV is primarily transmitted sexually. Sexually active young adults stand a greater risk of 
being infected with HPV due to the high prevalence of HPV among these age groups.4 
The lifetime risk of acquiring a genital HPV infection is estimated to be at least 80% for 
sexually active women.5 In order to prevent HPV infections and reduce the risk of cervical 
abnormalities and cervical cancer, prophylactic HPV vaccines are being developed.6-10 
In June 2006 the United States Food and Drug Administration (FDA) and in September 
2006 the European Medicines Agency (EMEA) announced the approval of a first vaccine 
developed to prevent cervical cancer and precancerous genital lesions due to hr-HPV 
genotypes 16 and 18, and genital warts due to low-risk HPV genotypes 6 and 11.
Since 70% of all cervical carcinomas harbour hr-HPV genotypes 16 and 18, the developed 
vaccines are predominantly targeted against these genotypes. HPV 16 and 18 vaccines 
seem safe, well tolerated and effective.(7-10) It has been estimated that HPV vaccination 
will reduce the risk of cervical cancer for 12-year-old girls by 61.8%.11 To achieve the 
greatest public health benefit girls and/or boys should be vaccinated prior to the onset 
of sexual activity. Therefore, the proposed target population for future HPV vaccination 
consists of pre-teenage children (aged 10-12). Since the pre-teenage children are under 
age, parental consent will be required. Most studies addressing parental vaccine 
acceptability have been carried out in the United States and the United Kingdom.12-14 
This study was conducted to assess whether Dutch parents agree to vaccinate their 
children against HPV infections, which factors influence their decision, and to study their 
knowledge about HPV, cervical cancer, and HPV vaccination.
Materials and Methods
In order to interview parents of children in the age of 10 to 12 years, the study proposal 
was discussed with the principals of primary schools in the urban area of Nijmegen, the 
Netherlands. Forty-five schools were approached, of which 26 reacted and 17 schools 
participated in this study. Some schools with many pupils from immigrant parents did 
not participate because of the supposed language barrier of these parents.
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All parents of children aged 10 to 12 years received a letter containing a section describing 
the aims of the study together with some basic information regarding cervical cancer, 
HPV and HPV vaccination developments, and an informed consent form. Parents who 
returned a signed informed consent form were interviewed.
Of the 1150 parents approached, 426 parents (37%) responded, and 356 parents (31%) 
were willing to cooperate of whom, 95.5% were born in the Netherlands.
All interviews lasted 5 to 10 minutes and were conducted by phone by one of the 
researchers (M.G.) using a survey specifically developed for this study. Most questions 
were close-ended. Questions were subdivided into socio-demographic items and items 
regarding knowledge of the risk factors for cervical cancer, the transmission route of 
HPV, its relationship with cervical cancer, the development of a vaccine against HPV, and 
the acceptance of this vaccine as prevention of cervical cancer.
In order to avoid influence by the information given in the covering letter of this study, 
the parents were asked to respond to the knowledge questions disregarding the letter. 
All data were recorded anonymously. The χ2 - and Mann-Whitney tests were used to 
analyse the results. This questionnaire study did not need approval of the Ethics 
Committee, as it was a fairly non-invasive form of data collection.
Results
All participating parents had sufficient knowledge of the Dutch language and were 
taking care of at least one child between the age of 10 and 12 years. The parents, of 
whom 324 (91%) were women and 32 (9%) men, were interviewed by phone. 
The demography of the population is displayed in Table 1. The mean age of the parents 
was 42.2 years. Of the 356 parents interviewed 92% were either married or had a partner, 
51% had additional education after high school, 16% worked in the medical field, 93% 
had more than one child, and 60% had both boys and girls.
Of the parents interviewed, 29.5% had ever heard of HPV, and 14.3% of the parents knew 
HPV is related to cervical cancer (Table 2). Median knowledge scores of HPV, cervical 
cancer and HPV vaccination were calculated (0-7). The two groups of parents with higher 
education or working in the medical field had significantly more knowledge about HPV 
and cervical carcinoma (respectively p<0.001; p<0.001, Mann-Whitney test). Among the 
parents working in the medical sector, parents with a university degree had a significantly 
higher score on the knowledge part than parents who did not have a university degree 
(p=0.005, Mann-Whitney Test). The median knowledge score was also calculated for the 
sexes and women had a significantly higher score than men (2 versus 1, p=0.019, 
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Table 1.  Population characteristics willing or unwilling to vaccinate
     Willingness to vaccinate
Total 
   (n=356) (%)
Yes
   (n=313) (%)
No
   (n=43) (%)
p
Gender
Female (324) 324 91.0 282 90.1 42 97.7 n.s.
Male     (32) 32 9.0 31 9.9 1 2.3 n.s.
Average age (±SD)* 42.2 (±4.4) 42.1 (±4.4) 43.0 (±3.7) n.s.
Marital status
Married/ partner 327 91.9 287 91.7 40 93.0 n.s.
Single/divorced/widow 29 8.1 26 8.3 3 7.0 n.s.
Education
< High school 174 48.9 156 49.8 18 41.9 n.s.
≥ High school 182 51.1 157 50.2 25 58.1 n.s.
Occupation
(Para) medic 57 16.0 48 15.3 9 20.9 n.s.
Non (para) medic 299 84.0 244 78.0 31 72.1 n.s.
(Para) medics
College degree 18 31.6 16 33.3 2 22.2 n.s.
No college degree 39 68.4 32 66.7 7 77.8 n.s.
Country of birth
The Netherlands 340 95.5 300 95.9 40 93.0 n.s.
Other 16 4.5 13 4.1 3 7.0 n.s.
Religion 202 56.7 180 57.5 22 51.5
n.s.
Practising religion 57 16.0 49 15.7 8 18.6 n.s.
Someone with cervical cancer 
close to interviewed parent
137 38.5 118 37.7 19 44.2 n.s.
Interviewed parent/ partner  
has had a Pap smear
342 96.1 300 95.9 42 97.7 n.s.
Interviewed parent/partner 
treated for abnormal Pap smear
21 5.9 20 6.4 1 2.3 n.s.
Gender children
Boy(s) 68 19.1 58 18.5 10 23.3 n.s.
Girl(s) 76 21.3 65 20.8 11 25.6 n.s.
Boy(s) and girl(s) 212 59.6 190 60.7 22 51.2 n.s.
Age other children
<12 years old 177 49.7 156 49.8 21 48.8 n.s.
>12 years old 124 34.8 105 33.6 19 44.2 n.s.
<12 and >12 years old 29 8.2 28 8.9 1 2.3 n.s.
No other children 26 7.3 24 7.7 2 4.7 n.s.
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Of the parents interviewed, 313 (87.9%) would accept vaccination of their children against 
HPV if the Dutch government approves an HPV vaccine. Parents opposed to HPV 
vaccination thought that the vaccine should first be used for several years before they 
would agree to vaccinate their children. They were mainly afraid of late side effects. One 
of the parents was concerned that this vaccination might lead to promiscuity and sexual 
intercourse at an earlier age. Of all children studied 98.3% received the recommended 
vaccinations of the National Vaccination Programme. The vaccination level in the group 
opposed to HPV vaccination was significantly lower, 93.0% versus 99% of the children of 
parents that accept HPV vaccination (p=0.004, χ2 test). Many parents, whether they 
accepted vaccination or not, desired more information regarding HPV, cervical cancer, 
and HPV vaccination. Based on prior knowledge and the information provided during 
the interview, 313 parents (87.9%) thought both girls and boys should be vaccinated 
(Table 3). Parents who accept HPV vaccination were significantly more willing to vaccinate 
both girls and boys compared to parents opposed to HPV vaccination (91.1% versus 
65.1%, respectively, p<0.001, χ2 test). Almost 19% of the parents indicated that the HPV 
vaccination should be combined with other vaccinations in the National Vaccination 
Programme, 13% preferred the age of 9, together with the last vaccinations that are 
given at that age, like Measles, Rubella, Tetanus, Polio and Diphtheria. The age of 10 to 12 
years was preferred by 58.6% of the parents. Of all parents, 23% thought that the child 
Mann-Whitney test). Nevertheless, knowledge did not show a significant relation with 
acceptance of HPV vaccination of their children. Neither did religion, age, education, and 
marital status (Multivariate analysis, χ2 test).
Parental acceptance of Human Papillomavirus vaccines Chapter 4
4
Grade primary school
6th grade 1 0.3 1 0.3 0 0.0 n.s.
7th grade 183 51.4 158 50.5 25 58.1 n.s.
8th grade 172 48.3 154 49.2 18 41.9 n.s.
Children received all the 
recommended vaccinations
Yes 350 98.3 310 99.0 40 93.0 0.004
No 6 1.7 3 1.0 3 7.0
n: number
p: p-value
n.s.: not significant
* SD: Standard deviation, in years
Table 1.  continued
     Willingness to vaccinate
Total 
   (n=356) (%)
Yes
   (n=313) (%)
No
   (n=43) (%)
p
Table 2. Knowledge of parents regarding HPV, cervical cancer, and the HPV vaccine
Knowledge questions
   Total
      (n=356)   (%)
Had heard of HPV 105 29.5
Knew genital warts can be transmitted sexually 157 44.1
Knew about the causal relation of HPV and cervical cancer 51 14.3
Thinks there is a relationship between smoking and cervical cancer 129 36.2
Thinks there is a relationship between age at first intercourse and cervical 
cancer 69 19.4
Thinks there is a relationship between number of sexual partners and 
cervical cancer 226 63.5
Had heard of the HPV vaccine 22 6.2
n: number
Table 3.  Opinions of parents on HPV vaccination willing or unwilling to vaccinate
Willingness to vaccinate
   Total 
    (n=356) (%)
   Yes 
    (n=313) (%)
   No
    (n=43) (%)
p
Both boys and girls should 
be vaccinated 313 87.9 285 91.1 28 65.1 <0.001
Opinion child important 82 23.0 65 20.8 17 39.5 0.006
Age at vaccination (years) *
0-3       21 5.9 19 6.1 2 4.8 n.s.
9         46 13.0 41 13.1 5 11.9 n.s.
10-12  208 58.6 187 59.7 21 50.0 n.s.
13-18  80 22.5 66 21.1 14 33.3 n.s.
n: number
p: p-value
* one parent, against all vaccinations, did not answer the question
n.s.: not significant
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puberty (9 to 12 years of age). If the HPV vaccination were to be implemented in the 
National Vaccination Programme for children under 13 years of age, it would be advisable 
to offer the HPV vaccine to unvaccinated children later on in their lives as well, as the mean 
titre for vaccine induced antibodies to HPV were over 80 times higher than those seen in 
natural infections.7
Despite the fact that the participants were predominantly female and had experience 
with the cervical screening programme, only about one third of the parents had ever 
heard of HPV, and less than 15% knew about the causal relation of HPV and cervical 
cancer. Similar results and even lower awareness are shown in British studies.14;20;21 An 
American study showed that a brief educational intervention of the parents opposed to 
or undecided about the HPV vaccine significantly improved the acceptance of an HPV 
vaccine from 55 to 75%.13 This was contradicted by a study by Dempsey et al. In this 
study a random half of the study participants received an “information sheet” together 
with the survey. There was no significant difference between the 2 groups with respect 
to the mean parental vaccine acceptability scale score, suggesting that receipt of the 
HPV information sheet did not substantially alter parental acceptability of HPV vaccines.22 
An already high level of acceptance at the onset of this study could explain the difference. 
However, it may have been due to the different methodologies employed, and the fact 
that they did not specifically report on undecided or opposed parents.
Most parents in our study indicated that they would like to receive more information on 
HPV, cervical cancer, and HPV vaccination. However, as in the Dempsey study, knowledge 
was not a significant predicting factor for HPV vaccination acceptance. This indicates that 
an educational campaign should cover not only knowledge of HPV and cervical carcinoma, 
but also beliefs and behaviours associated with the acceptance of vaccination.
In conclusion, despite the fact that our study had several limitations like less participation 
of immigrant parents, a participation rate of 31%, 91% female participants, and a relatively 
high educational level, it has shown a remarkable correspondence with results of other 
studies.12;14;22;23 The only population characteristic that significantly influenced parental 
HPV vaccination acceptance was whether parents had given their children all the 
recommended vaccinations or not. HPV vaccine acceptance seems to be dependent on 
vaccine acceptance in general, i.e. trust in the recommending body. In this study 
population vaccine acceptance in general was already high. Despite a lack of knowledge 
of HPV infections, cervical cancer, and HPV vaccination, most parents accept vaccination 
of their 10 to 12 year-old children against HPV infections once recommended by the 
government.
should be involved in deciding whether to be vaccinated against HPV or not. This was 
significantly higher among the parents who would not accept HPV vaccination for their 
child (39.5%, p=0.006, χ2 test).
Discussion
The main target group for vaccination against HPV will consist of pre-teenage children. 
Therefore, parental consent is needed in order to successfully implement an HPV 
vaccination programme in the near future. Most studies addressing parental HPV vaccine 
acceptability have been carried out in the United States and the United Kingdom.12-14 This 
study focused on the Dutch parents. In this study the participation rate of 31% was lower 
than the 35% achieved in a comparable Dutch study of future childhood vaccines.15  The 
low response rate can be explained by the fact that parents were approached through 
their children by letter instead of directly by the researcher. This study by Hak et al. showed 
11% of the parents had no intention to accept any new vaccine.15 This is consistent with 
findings in our study, if the Dutch authorities approve the HPV vaccine 88% of the parents 
interviewed accept HPV vaccination of their child. An English study showed that an HPV 
vaccine uptake rate of 80% would be achievable, yet only 38% were definite in their 
approval and 15% were opposed to vaccination.12 In an American study 24% of the parents 
opposed to vaccination perceived that after HPV vaccination their children would be more 
likely to initiate sexual intercourse at a younger age.13 In our study only one parent expressed 
her concerns. In the American study this question was specifically asked which might have 
led to the higher outcome, as well as the fact that abstinence until marriage is still a focus 
in American sexual education.16;17 The suggestion that widespread vaccination will alter 
sexual practices is disputed by two other recent American studies.17;18 Epidemiological 
studies show that 50% of women contract a genital HPV infection within 2 years after 
becoming sexually active.9;19 To be the most effective HPV vaccine should be given before 
becoming sexually active. According to non-published data from another study in the 
urban area of Nijmegen among 18 to 25 year-old students, the median age of first sexual 
intercourse was 16 years. Further analysis showed that at the age of 13.4 years and 11.8 
years, less than, respectively 2.0% and 0.5% have had their first sexual encounter. Providing 
the vaccine to 10 to 12 years olds seems right in order to protect a large majority. 
Additionally, anti-body-titres in response to vaccination are higher at a younger age. In this 
study parents opposed to HPV vaccination were significantly more likely to think that it is 
of great value that their children should express their opinion about the vaccination. 
Therefore, they selected more often adolescents in the age 13 to 18 as the target group for 
vaccination. However, the majority of all parents would agree with vaccination in early 
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Abstract
To determine whether young Dutch adults had ever heard of human papillomavirus 
(HPV) and whether they would accept vaccination, a cross-sectional survey was 
performed. Additionally, factors influencing their decision were assessed. Six hundred 
participants aged 18 to 25 years were recruited from two university departments and 
one non-university technical college. One hundred and six (17.7%) participants had 
heard of HPV and 536 (94%) had heard of cervical carcinoma. Women had significantly 
more knowledge of cervical carcinoma than men. A medical education, knowledge of 
HPV, knowledge of cervical cancer and knowledge of the cervical screening programme 
were not significantly associated with acceptance of HPV vaccination, whereas gender 
and age did show a significant relationship. In total, 61% of the female participants and 
48% of the male participants were willing to accept a catch-up HPV vaccination. This 
study found that average knowledge levels of HPV and cervical cancer were low. Despite 
this lack of knowledge, a small majority of the study population would accept a catch-up 
HPV vaccination. Women and younger participants were significantly more willing to 
accept HPV vaccination. However, in these subgroups, acceptance of HPV vaccination 
seems to be affected by other, still unidentified, factors. These factors could be evaluated 
in a more qualitative orientated study. An educational campaign is needed to cover 
knowledge about HPV and cervical carcinoma, and beliefs and behaviours associated 
with the acceptance of vaccination.
Introduction
Infection with Human Papillomavirus (HPV) is a necessary event in the multi-step process 
of cervical carcinogenesis. HPV has been detected in almost 100% of cervical cancers.1 
More than 35 HPV genotypes can infect the genital tract, of which at least 13 are 
considered high-risk (hr). HPV genotypes 16 and 18 account for almost 70% of all cervical 
carcinomas.2 Prophylactic vaccines have been developed to prevent HPV 16 and 18 
infections specifically. Randomised double-blind placebo-controlled studies show a 
decrease of > 90% in the incidence and up to a complete decrease in the persistence of 
HPV 16 and 18 infections and associated cytological abnormalities and lesions.3-6 It has 
been estimated that the best results of a prophylactic vaccine will be achieved by 
vaccinating women before they become sexually active.6 This means that the main 
target group for vaccination consists of pre-teenagers. In order to decrease cervical 
cancer without a 15 to 20 year lag time, catch-up vaccination is necessary. The main 
target group for catch-up vaccination consists of women aged 15 to 26 years.
Before introduction of an HPV vaccine, it is important to consider whether the public is 
aware of the causal relationship between HPV infection and cervical cancer.7 Studies in 
the United States (US) and the United Kingdom (UK) have found low awareness among 
women in health care and university settings.8-11
In June and September 2006, respectively, the US Food and Drug Administration and the 
European Medicines Agency announced their approval of a vaccine developed to 
prevent cervical cancer and precancerous genital lesions due to hr-HPV genotypes 16 
and 18, and genital warts due to low-risk HPV genotypes 6 and 11.
It is also very important to consider whether society accepts the vaccination of 
adolescents/young adults against a sexually transmitted disease (STD).7 A British study 
investigated attitudes and behaviour regarding vaccination against (sexually transmitted) 
hepatitis B. The study showed that there was low awareness, but that nearly all 
participants were in favour of vaccination.12 Most studies exploring HPV vaccine 
acceptability among young adults and students have been performed in the US and the 
UK.13-19 In order to enhance vaccine acceptability, factors influencing individual 
decision-making need to be studied. In earlier reports knowledge, number of sexual 
partners, educational level, and effectiveness of the vaccine have been associated with 
vaccine acceptability.13-15;17 In this Dutch study, information on attitudes about HPV 
vaccination and predictors of intention to receive a vaccine were assessed, as well as 
knowledge of HPV and other risk factors of cervical cancer.
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Multivariate logistic regression with forward selection procedures was used to identify 
variables that contributed independently to probability of acceptance of HPV. Again, the 
dependent variable was acceptance of HPV vaccination. In the selection procedure, all 
the variables with a p-value < 0.10 in the univariate regression were used, as these were 
potentially related to acceptance of HPV vaccination. P-values for entry into the model 
were considered in the forward selection procedures in order to identify other potentially 
important variables. The adjusted odds ratios with 95% CI of the final model are 
presented.
Results
Of the 600 participants, 377 (62.8%) were women and 223 (37.2%) were men. This 
participation rate reflects the male-female distribution of students in this region. The 
average age was 19.8 years, and 91% (n=547) were born in the Netherlands. At the time 
of study, 440 participants (73.3%) considered themselves to be sexually active in the 
present or past. The average age of first sexual intercourse was 16.6 years (standard 
deviation (SD) 1.6). The mean number of sexual partners was 2.1 (SD 3.6), and 0.8% (n=5) 
had ever had an STD.
Knowledge of HPV and cervical carcinoma
Table 1 and 2 present the knowledge of HPV, risk factors for cervical carcinoma, and Pap 
smears. Of the 600 participants, 106 (17.7%) had heard of HPV, of whom 84% (n=89) knew 
that HPV was transmitted sexually. Of these 106 participants, 16% (n=17) knew that using 
a condom is not fully protective, and 29 participants (27.4%) knew that the lifetime risk of 
acquiring a genital HPV infection was >50%. The causal relationship with cervical 
carcinoma was known by 86 participants (81%).
Of the 600 participants, 565 (94.2%) had heard of cervical carcinoma. The mean 
knowledge of risk factors was low (3.1 out of 8). The risk factors ‘promiscuity ‘ and 
‘smoking’ were mentioned by 22.3% (n=126) and 42.8% (n=242) of the students, 
respectively. The misconception that a hereditary cause was a risk factor for developing 
cervical carcinoma was reported by 72% (n=407) of the students, and urinary tract 
infection and age were mentioned as risk factors by 27.3% (n=154) and 49.7% (n=281) of 
the students, respectively.
Materials and Methods
For this cross-sectional survey, 659 young adults in Nijmegen, the Netherlands were 
recruited during August and September 2005, before reports about the HPV vaccine 
appeared in newspapers in early October 2005. Participants were approached at random 
at two university departments and one non-university technical college during their 
lunch break. The inclusion criteria were: age between 18 and 25 years; sufficient 
knowledge of the Dutch language to answer the questionnaire; and studying at one of 
the three institutions at which the study was conducted. Six hundred (91.0%) students 
took part in the study; 150 were medical students, 250 were attending the language 
department of the university, and 200 students were attending the non-university 
technical college. The most common reason for refusing to participate was time 
related.  A self-administered questionnaire was used for this study, which students were 
asked to fill out individually under the supervision of the researcher (CS). The questionnaire 
data were processed anonymously. The questionnaire contained questions about 
demography, sexual activity, knowledge of HPV in general, cervical carcinoma, Pap 
smears, and acceptance of HPV 16 and 18 vaccination. The questions about knowledge 
were multiple-choice questions and were not preceded by any extra information besides 
the questionnaire itself. If the participants had heard of cervical carcinoma, they were 
given a list of potential risk factors and then asked to indicate if they thought each was a 
risk factor; the question contained a “don’t know” option. For the statistical analysis of 
knowledge, a score was computed which was corrected for guessing. The multiple-choice 
question on HPV vaccine acceptability also contained a ‘don’t know’ option. Participants 
who had never heard of HPV were not excluded from the statistical analysis on vaccine 
acceptance, as a recent study showed that HPV vaccine acceptance seems to be 
dependent on vaccine acceptance in general, more than on knowledge of HPV and its 
causal relationship with cervical cancer.12;20 
Fisher’s exact test was used to test differences between men and women for statistical 
significance for two proportions, and the t-test was used for continuous variables. 
Chi-square test was used to test differences between the education groups for statistical 
significance for categorical variables, and one-way analysis of variance was used for 
continuous variables.
 Univariate logistic regression was used to study the ability of the variables to discriminate 
between participants who accept HPV vaccination and those who do not, separately for 
each variable. The dependent variable was acceptance of HPV vaccination (yes, no), as 
present in the questionnaire. Due to the small numbers, sexual activity, sexarche, and 
number of partners were grouped. The crude odds ratios with 95% confidence interval 
(CI) are presented.
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Table 1.  Knowledge of HPV, risk factors for cervical carcinoma, and Pap smears  
by gender
Total
n=600
  Men
  n=223
    Women
   n=377
p
Had heard of HPV 106 (17.7%)   27 (12.1%)      79 (21%) <0.01
Had heard of cervical 
carcinoma
565 (94.2%) 192 (86.1%) 373 (98.9%) <0.01
If heard of cervical 
carcinoma, named risk 
factors* 
 
    Early sexarche 61 (10.8%) 17 (8.8%)     44 (11.9%) 0.32
    Promiscuity 126 (22.3%) 42 (21.9%)     84 (22.5%) 0.91
    No condom use 110 (19.5%) 39 (20.3%)     71 (19.0%) 0.74
    Urinary tract infections 154 (27.3%) 60 (31.3%)     94 (25.2%) 0.14
    Oral contraconceptive 93 (16.5%) 25 (13.0%)     67 (18.0%) 0.15
    Smoking 242 (42.8%) 87 (45.3%)
    
155
(41.6%) 0.42
    Heredity 407 (72.0%) 134 (69.8%)
    
273
(73.2%) 0.43
    Age 281 (49.7%) 79 (41.1%)    202 (54.2%) <0.01
Knowledge of cervical 
carcinoma (score 0-8)
(mean) (SD)
3.1 (1.3) 2.8 (1.6)     3.2 (1.2) <0.01**
Knew that from the age 
of 30 years, Dutch women 
get a Pap smear
195 (32.5%) 67 (30.2%) 128 (34.0%) 0.78
Knew Pap smears 
diagnose cervical 
carcinoma and
pre-malignancies
352 (62.3%) 114 (51.4%) 238 (63.1%) <0.01
Knew an abnormal Pap 
smear is not always due to 
cervical carcinoma
326 (54.3%) 87 (39.2%) 239 (63.4%) <0.01
Will get a Pap smear in the 
future***
   -     -     -     - 314 (83.3%) -
n: number
p: p-value for difference between men and women using the Fisher exact test
* more answers possible
SD: Standard Deviation
** using t-test
 -: not applicable
*** women only
Table 2.  Knowledge of HPV, risk factors for cervical carcinoma, and Pap smears  
by education
Medical faculty
n=150
Non-medical 
faculty
n=250
Technical 
college
n=200
p
Had heard of HPV 93 (62.0%) 3 (1.2%) 10 (5.0%) <0.01
Had heard of cervical 
carcinoma
148 (98.7%) 240 (96%) 177 (88.5%) <0.01
If heard of cervical 
carcinoma, named risk 
factors*
    Early sexarche 43 (29.1%) 9 (3.8%)      9 (5.1%) <0.01
    Promiscuity 71 (48.0%) 30 (12.5%) 25 (14.1%) <0.01
    No condom use 53 (35.8%) 38 (15.8%) 19 (10.7%) <0.01
    Urinary tract infections 38 (25.7%) 67 (27.9%) 49 (27.7%) 0.86
    Oral contra conceptive 24 (16.2%) 42 (17.5%) 26 (14.7%) 0.78
    Smoking 60 (40.5%) 101 (42.1%) 81 (45.8%) 0.42
    Heredity 109 (73.6%) 186 (77.5%) 112 (63.3%) <0.01
    Age 102 (68.9%) 118 (49.2%) 61 (34.5%) <0.01
Knowledge of cervical 
carcinoma (score 0-8)
(mean) (S.D.)
3.3 (1.3) 2.9 (1.2) 3.0 (1.5) 0.07**
Knew that from the 
age of 30 years, Dutch 
women get a Pap smear
52 (34.7%) 73 (29.2%) 59 (29.5%) 0.47
Knew Pap smears 
diagnose a cervical 
carcinoma and  
pre-malignancies
98 (65.3%) 145 (58.0%) 108 (54.0%) <0.01
Knew an abnormal Pap 
smear is not always due 
to cervical carcinoma
121 (80.7%) 126 (50.4%) 78 (39.0%) <0.01
Will get a Pap smear in 
the future***
96 (85.0%) 141 (89.8%) 78 (75.0%) <0.01
n: number
p: p-value for differences between groups of education using the Chi-Square test
* more answers possible
** one-way analysis of variance (ANOVA)
*** women only
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Only a lower age and female gender were associated with vaccine acceptance. This is in 
accordance with the results of Gudmundsdottir et al.21 As expected, only 48% of the 
men in this study would accept HPV vaccination. If male participants were told explicitly 
about genital warts and the minor risk of penile carcinoma, their acceptance of 
Men versus women
Table 1 presents the knowledge of HPV, risk factors for cervical carcinoma, and Pap 
smears by gender. Significantly more women had heard of HPV than men. Women were 
also significantly more likely to have heard of cervical carcinoma than men (98.9% (n=373) 
versus 86.1% (n=192)).
Of the 600 participants, 58.9% (n=352) knew that a Pap smear could detect cervical 
carcinoma and pre-malignant lesions. Significantly more women were aware of this fact 
than men. Additionally, 326 (54.5%) students were aware that an abnormal Pap smear is 
not always due to cervical carcinoma. Significantly more women knew about this. Of all 
377 women, 314 (83.3%) intended to have a Pap smear in the future.
Type of education
Table 2 presents knowledge of HPV, risk factors for cervical carcinoma, and Pap smears 
by education. Of the 106 participants who had heard of HPV, 93 (87.7%) were medical 
students. Students at the technical college had heard of cervical cancer significantly less 
often. As expected, the risk factors ‘promiscuity’ and ‘early sexarche’ were mentioned 
significantly more often by medical students than by non-medical students. Medical 
students were significantly more aware of the fact that an abnormal Pap smear is not 
always due to cervical carcinoma. Women at the technical college were significantly less 
likely to report their intention to have a Pap smear in the future.
Acceptance of HPV vaccination
Of the 600 participants, 336 (56.0%) were willing to accept HPV vaccination. A medical 
education, knowledge of HPV, knowledge of cervical cancer and knowledge of the 
cervical screening programme were not significantly associated with acceptance of HPV 
vaccination (Table 3). In addition, no association was found with sexual activity, sexarche 
and number of sexual partners. Men and older participants were less likely to accept HPV 
vaccination in both univariate and multivariate logistic regression analysis (Table 3).
Discussion
In general, knowledge of HPV and cervical cancer in this study population of young 
adults aged 18 to 25 years was low. However, multivariate analysis showed that 
acceptance of HPV vaccination is not influenced by knowledge or a medical education. 
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Table 3.   Odds Ratios and adjusted Odds Ratios for the acceptance of HPV 
vaccination using logistic regression
n OR (95% C.I.) p Adj. OR (95% C.I.) 
(n=346)
p
Gender
Male
Female
373 0.31 (0.16;0.63)
1.00 (ref )
<0.01 0.32 (0.16;0.63) <0.01
Education
Medical
Non-medical-university
Non-university technical
373
0.65 (0.28;1.49)
1.01 (0.44;2.33)
1.00 (ref )
0.31
0.99
            - -
Age (year) 371 0.84 (0.71;0.99) 0.04 0.84 (0.71;0.99) 0.04
Had heard of HPV
Yes
No
373
1.93 (0.92;4.03)
1.00 (ref )
0.08             - -
Knowledge of HPV 373 0.82 (0.64;1.06) 0.10             - -
Knowledge of cervical 
cancer 
373 0.79 (0.59;1.06) 0.12             - -
Knowledge of national 
cervical screening 
programme
348 1.28 (0.87;1.89) 0.21             - -
Sexual activity
Yes
No
373 2.00 (0.99;4.10)
1.00 (ref )
0.05             - -
Sexarche 373 1.21 (0.96;1.52) 0.11             - -
Number of sexual 
partners
352 1.21 (0.82;1.78) 0.34             - -
n: number
OR: Odds Ratio
95% C.I.: 95% Confidence Interval
Adj. OR: Adjusted Odds Ratio, adjusted for the other variable in the model
ref: reference
-: not selected using multivariable logistic regression model with selection procedures
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based on students aged 18 to 25 years with a relatively high education. Additionally, 
participants had to have sufficient knowledge of the Dutch language to answer the 
questionnaire. Only 73 % considered themselves to be sexually active, and less than 1% 
ever had an STD. This indicates that knowledge levels could be even lower in the general 
population. No bias was expected between the participants and the non-participants, 
as the students were approached ad random and the major reason for refusal was time 
related.
In conclusion, this study found that almost all participants had heard of cervical 
carcinoma, but knowledge of risk factors was low. Only a few students had heard of HPV 
and its relationship with cervical carcinoma. Despite this general lack of knowledge, a 
small majority of young adult women aged 18 to 25 years would accept HPV vaccination. 
Multivariate analysis showed that acceptance of HPV vaccination is influenced by 
younger age and female gender but not by knowledge or educational level. This study 
found that the exact factors which influence vaccine acceptance in this age group, in 
both men and women, remain to be elucidated. These factors could be evaluated in a 
future, more qualitative orientated, explorative study. The fact that “knowledge“ did not 
reach significance shows that an intervention is needed that covers knowledge of HPV 
and cervical cancer, and beliefs and behaviours associated with the acceptance of HPV 
vaccination. 
Ethical Approval
The local Medical Ethics Committee advised that formal approval was not required for 
this non-invasive anonymised study.
vaccination may increase. This indicates that in order to increase herd immunity by 
including males in the “catch-up” vaccination campaign, strategies to improve their 
motivation to accept vaccination are needed. Otherwise, their vaccine acceptability is of 
less value. 
An American study investigated the predictors of intention to receive a vaccine among 
52 women aged between 18 and 30 years. Knowledge and higher number of sexual 
partners were associated with acceptance of an HPV vaccine.15 These associations were 
not confirmed in this present much larger study. 
Only a minority of the study participants had heard of HPV and even fewer were aware 
of its causal relationship with cervical carcinoma. This low level of knowledge of HPV is 
comparable with results from a study performed in Canada in 2000, where 13% of high 
school students (aged 15 to 20 years) had heard of HPV.8 The awareness of HPV was also 
limited among students attending a public university in Florida; HPV was the STD about 
which they knew the least.11 This resemblance is notable, as it was expected that the 
awareness of HPV would have changed substantially since 2000 due to new developments. 
However, the present study was conducted before the front-page news about the HPV 
vaccine was reported in the newspapers.
Although most students in this study (93.8%) had heard of cervical carcinoma, only a 
minority could identify the risk factors correctly. These findings are in good agreement 
with earlier reports. Waller et al. also concluded that the level of knowledge of risk factors 
was low. Only 14% of males and females aged 16 to 75 years were aware that there was 
a link between sexual activity and cervical carcinoma. It also appeared that young 
adolescents (16 to 24 years) had the least knowledge of risk factors. Educational level was 
an important predictor of the level of knowledge.22 In the present study, educational 
level did not reach significance; this may be explained by the fact that all participants 
were relatively highly educated. As expected, medical students had the best knowledge, 
and non-university technical college students had the poorest knowledge, but this 
difference was not reflected in vaccine acceptance.
This study found that there are many misconceptions about cervical cancer. A majority 
of students identified heredity as a cause of cervical cancer. It may well be that 
misconceptions have a negative influence on vaccine acceptance. This shows that it is 
important to provide information about the true risk factors of HPV infection and the 
possible clinical sequelae, as well as ensuring that misconceptions are corrected.
A study conducted in Michigan with men and women aged 20 to 46 years showed that 
the preferred time to receive information about HPV was before becoming sexually 
active. In this group the mean age of first sexual intercourse was 18 years.9 In the present 
study, the mean age of first sexual intercourse was 16.6 years (SD 1.6). 
The results of this study cannot be generalised to the whole Dutch population as it was 
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Abstract
Efficacy of Human Papillomavirus (HPV) vaccines has been proven in women who are 
HPV 16 and/or 18 negative at time of vaccination. The benefit of HPV vaccination of 
sexually naïve women is likely to be higher than that of older already sexually active 
women. The individual decision of these women to get vaccinated will be balanced 
between costs and personal benefit. A risk assessment may determine ones personal 
benefit from vaccination and may be helpful in counselling individual women in 
outpatient settings by providing insight in one’s personal situation. This study is based 
on the results of a large prospective epidemiologic study among 2065 unscreened 
women aged 18 to 29 years, and includes mathematic modelling to estimate the 
probability of an HPV 16 and/or HPV 18 infection. Finally, data were used from 1322 
women aged 18-25 years who reported to be sexually active in past or present time. 
Women returned a self-collected cervico-vaginal specimen and filled out a questionnaire. 
The model predicting the optimal probability of being HPV 16 and/or 18 positive was 
based on the combination of age, number and gender of sexual partners, condom use, 
and frequency of sexual contact in past 6 months. A nomogram including significant 
predictors is provided to calculate the probability of  being HPV 16 and/or 18 infected. In 
total 16% of the variance (R-square) in this model could be explained by the selected 
variables, the discriminatory power (AUC) was 79%. After the internal validation using 
bootstrap methods the corrected R-square  and AUC were 10.2% and 75%, respectively. 
The basal risk of being HPV 16 and/or 18 positive was 4%. The cut-off value to estimate 
an HPV 16 and/or 18 infection was 8%. This was based on the point where the sum of the 
sensitivity and twice the specificity was maximal. The sensitivity and specificity at this 
point were 51% and 88%, respectively. This risk assessment tool may be helpful in 
individual counselling. Additionally, women with a high probability of HPV 16 and/or 18 
positivity may benefit from HPV testing prior to vaccination.
Introduction
Widespread application of the HPV vaccine is expected to have a significant impact on the 
incidence of cervical pre-malignant lesions and cervical cancer. Presently, vaccination 
programmes have started in many countries around the world, targeting 11 to 16 year old 
girls.1;2 Additionally, catch-up vaccination of already sexually active women is under consideration 
in many countries in order to get a faster decrease in cervical cancer incidence. Some studies 
question whether comprehensive universal strategies for nationwide catch-up vaccination are 
superior to a “targeted” approach.3-5 An attempt to target a nationwide subpopulation based 
on risk factors does not seem to be a reasonable option as many women eligible for vaccination 
would be excluded based on the high prevalence of risk factors. However, as some of these 
women could potentially benefit from vaccination, identifying women individually with a 
higher probability of being HPV vaccine-type positive may be helpful in counselling.
In the Netherlands, the vaccine is assimilated into the  National Vaccination Programme (NVP) 
and will be free of charge for the target group which consists of 12 year old girls. Single catch-up 
vaccination of girls aged 13 to 16 years will be implemented in the NVP as well. HPV vaccination 
has started recently. 
Older adolescent women and young adult women (i.e. 17 through 25 years) who cannot take 
part in the NVP based on their age, may therefore need to pay for the vaccine. As women age, 
they are more likely to have engaged in sexual activity resulting in exposure to HPV in general 
as well as vaccine specific types. It must be emphasized that HPV vaccines are prophylactic, not 
therapeutic, and have no efficacy against existing HPV infection or disease.6;7 Therefore, the 
clinical benefit afforded to older sexually active women is likely to be less than that of younger 
sexually naïve women. Thereby, the decision to get vaccinated will be balanced between 
personal benefit and costs. It is likely that these women will ask physicians and gynaecologists 
about the health benefit of this vaccine and the level of benefit for their individual situation.
In order to decide whether vaccination on an individual basis may be beneficial, assessment of 
a risk profile may be important. Additionally, it provides the opportunity to test women at risk 
on an individual basis before excluding them from vaccination. To estimate the risk of  currently 
being infected with high-risk (hr) HPV vaccine-type 16 and/or 18, knowledge of epidemiology 
of type specific HPV infections in relation to socio-demographic characteristics like ethnicity 
and education, and sexual behaviour is important. However, little is known about the 
association between behavioural risk factors of young women and past or prevalent HPV 
infection.2;3;5;8 To optimize the individual risk estimation of HPV 16 and/or 18 positivity at time of 
vaccination, we explored the possibility of composing a risk factor assessment tool, i.e. a 
prediction model, that may be helpful in counselling individual women in outpatient settings 
by providing insight in one’s personal situation.
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44, 53, 54, 55, 58, 66, 70, 74, and “X”; and hr-HPV types as HPV 16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 59, 68, 73, and 82.
Questionnaire
We used a questionnaire consisting of two parts. The first part was composed of questions 
regarding smoking, medication use, contraceptive use, and socio-demographic variables 
like educational level, religion, and ethnicity. Race and ethnicity were self-reported into 
different categories. The second part consisted of questions regarding sexual behaviour 
to gain insight in risk factors for acquiring genital HPV. Sex was defined as vaginal, oral, 
and/or anal sex. Questions were asked on age at first sexual contact, age of first sex partner, 
number of sex partners before the age of sixteen, number of sex partners lifetime, number 
of sex partners in the past 6 months, gender of sex partners, frequency of sexual contact, 
condom use, and history of sexually transmitted diseases (STD). 
Statistical analyses
In this study we aimed at identifying sexually active women at risk for hr-HPV vaccine types 
16 and/or 18 from those not at risk. The risk of a present HPV 16 and/or 18 infection was 
chosen over the single risk of a present infection with both HPV 16 and 18 simultaneously, as 
the presence of a single infection with HPV 16 or  a single infection with HPV 18 already 
influences the protective effect of the vaccine and therefore may influence a woman’s 
decision to get vaccinated. 
Categories of specific variables were grouped in case of small numbers or in case of a similar 
risk of being infected. Age higher than 24 years was grouped into one category, as a plateau 
phase was reached in HPV prevalence after the age of 24.8 Lifetime number of partners was 
divided into 3 categories and number of partners in the past six months was divided into 
four categories. Gender of sex partners was divided into 2 categories; category 1 consisting 
of male gender, category 2  consisting of female and both female and male gender. 
Frequency of sexual contact was grouped into five categories. Years of being sexually active 
(i.e. sexual age) ranged from 0 to 23 years, the category  “0” years consisted of women who 
became sexually active in the past year. Because of the small numbers, 0 and 1 year were 
combined as well as 13 to 23 years. Previous infection with at least one of the following was 
defined as having had a previous STD: Chlamydia, genital warts, Syphilis, Gonorrhoea, Genital 
Herpes, or HIV.
Univariate logistic regression was used to study the ability of socio-demographic and sexual 
behaviour  variables to discriminate between women with an HPV 16 and/or 18 infection 
from those without an HPV 16 and/or 18 infection. This was performed for each variable 
Materials and Methods
Study population and study design
This study is based on the results of a large prospective epidemiologic study performed 
among 2065 unscreened women aged 18 to 29 years. Women were recruited between 
June and September 2007, using different advertisements, as well as active recruitment 
sites, and posters at general practices in the city regions of Arnhem, Nijmegen, and Den 
Bosch, the Netherlands. Furthermore, advertisements on the internet were used, which 
were accessible in the whole of the Netherlands. Of the 2297 women who responded to 
the advertisements, 2065 (89.9%) consented with the study. Of the 2065 women, 1430 
were aged 18 to 25 years, i.e. a target group for vaccination as the prophylactic HPV 
vaccines are registered through the age of 25 years. Of these 1430 women 1428 provided 
information on sexual activity of whom 7.4% (n=106) reported not be sexually active. 
Data of these sexually naïve women were not used to compose the prediction model as 
this study assesses the risk of sexually active women of being HPV positive. Therefore, we 
only used data from the 1322 (92.6%) women aged 18 to 25 years who reported to be 
sexually active in past or present time. 
Written informed consent was obtained from all participants. This study was approved 
by the Local Medical Ethics Committee.
Specimen Collection and Processing
All women were asked to fill out a questionnaire and to self-collect a cervico-vaginal 
sample in the privacy of their own home. Women received an explanatory letter, an 
informed consent form, a questionnaire, and a self-sample kit by mail. The self sample kit 
contained a collection device (a small brush packaged in an individual sterile cover, 
Rovers® Viba-brush, Rovers Medical Devices B.V., Oss, the Netherlands), a collection tube 
containing medium (SurePathtm, Tripath Imaging®, Inc., Burlington, NC, USA), instructions 
how to perform the cervico-vaginal self-sample (written and in cartoon), and a return 
package consisting of a leak-proof seal bag, absorption sheet, and a reclosable plastic 
return envelope (Easyslider, Transposafe Systems Holland BV, Sassenheim, the 
Netherlands).  The self-sample was taken and processed as described earlier.8
All HPV DNA-positive samples were genotyped using the SPF10-LiPA HPV genotyping 
assay. The HPV genotyping assay was performed as described previously.9;10
Samples that tested positive using the DNA enzyme immunoassay but that showed no 
results on the LiPA strip were considered to be HPV X type, i.e. genotypes not available 
on the LiPA strip. Low-risk HPV (lr-HPV) types were defined as HPV type 6,11, 34, 40, 42, 43, 
Individual risk factor assessment of sexually active women prior to HPV vaccination;  
how effective is your HPV vaccination? Chapter 6
6
110 111
Simultaneous infection with HPV 16 (2.8%) and 18 (1.3%) occurred in only 2 women (0.2%).
Although HPV DNA was detected in 4 of the 106 sexually naïve women, these data were 
not used for further analyses. It concerned three single infections with a hr-HPV type of 
which two times HPV type 16, and a co-infection with a lr- and a hr-HPV type. Simultaneous 
infection with HPV 16 (n=2, 1.9%) and 18 (n=0) did not occur. 
Prediction Model
Table 1 shows the ORs (OR’s) of the probability of being infected with HPV 16 and/or 18. 
Except for increasing age, all factors significantly associated with HPV 16 and/or 18 
prevalence were related to sexual behaviour.
Multivariate logistic regression with backward variable deletion showed five factors 
contributing  independently  to the risk of being HPV 16 and/or 18 positive. These factors 
were age, the number of lifetime sexual partners, gender of sexual partner(s), condom 
use, and frequency of sexual intercourse in the last 6 months (Table 2).
To calculate the probability of being infected with HPV 16 and/or 18 a prediction model 
was constructed. This model was constructed using this multivariate analysis. In total 
16% of the variance (R-square) in this model could be explained by the selected variables, 
the discriminatory power (AUC) was 79%. After the internal validation using bootstrap 
methods the corrected R-square was 10.2% and the corrected AUC was 75%. In this 
study the basal risk of being HPV 16 and/or 18 positive was 4%. The cut-off value to 
predict the likelihood of having an HPV 16 and/or 18 infection was 8%. This was based 
on the point where the sum of the sensitivity and twice the specificity was maximal. The 
sensitivity and specificity at this point were 51% and 88%, respectively. When having a 
probability of >8% the subject could be defined as having high risk for being  infected 
with HPV 16 and/or 18. Note this test has higher specificity than a test that is based on 
equal “costs” of misclassification of cases and non-cases. 
Figure 1 shows a nomogram to calculate the probability of being infected with HPV 16 
and/or 18 based on the prediction model. This procedure allocated the weight to each 
variable in the model. To read the probability from the prediction model the 
corresponding number of points of each of the 5 variables can be read from the scale 
above. Subsequently, all points are added up into a total score. With use of the total 
score, the corresponding probability of being HPV 16 and/or 18 infected can be read 
from the scale below. This procedure is illustrated using two examples below.
Example 1:
For instance, a 22 year old women (age: 34 points) visits the outpatient gynaecological 
clinic asking for advise on HPV vaccination. She has had a total number of 3 sexual 
separately. The dependent variable was HPV 16 and/or 18 infection. The crude odds ratios 
(OR) with 95% confidence interval (CI) are presented.
Multivariate logistic regression with backward variable deletion was used to estimate  the 
probability of HPV 16 and/or 18 infection. The variables used were selected based on 
previous study.8 Again, the dependent variable was HPV 16 and/or 18 infection. The following 
possible HPV 16 and/or 18 infection related variables were used in the selection procedure: 
age, current smoking, living with parents, type of relationship, sexual age i.e. years of being 
sexually active, number of partners during lifetime, gender of sexual partner(s), number of 
partners in last six months, frequency of sexual intercourse in last six months, ever diagnosed 
with a STD, and condom use. The adjusted odds ratios with 95% confidence interval (CI) of 
the final model are presented. Participants with missing data on variables included in the 
multivariate analysis were excluded. The R-square is presented to indicate the total 
percentage explained variance in the outcome. The area under the curve (AUC) of the 
receiver operating characteristic curve is presented as a measure of predictive discrimination. 
In general, these measures will be to high because the model  is developed solely  using the 
study sample and this model may perform less on a different random sample. Therefore, to 
evaluate the reliability of the created prediction model an internal validation was performed 
using bootstrap methods.11 The corrected R-square and the corrected AUC are presented.
Using the multivariable prognostic model, a boundary value of the risk of HPV 16 and/or 18 
infection, given the values of the prognostic variables only, was constructed under the 
condition of higher ‘costs’ of misclassification of non-cases compared to cases. This resulted 
in a high-specific test. In other words, the cut-off value for the probability to be infected was 
selected so that the sum of the sensitivity and two times the specificity discriminating 
infected subjects from non-infected subjects was maximal.
Finally, a nomogram was constructed using this multivariable prognostic model.
In all tests, p values < 0.05 were regarded statistically significant. Statistical analyses were 
performed using SAS 8.2 (SAS Institute Inc., Cary, NC, USA) and SPSS 16.0 (Chicago, Illinois, 
USA), and R 2.1 (r-project.org).
Results
HPV Prevalence
Of the 1322 sexually active women 17.6% (n=233) tested positive for one or more HPV 
genotypes. A single HPV type was detected in 13.6% (n=180) of all sexually active women, 
while multiple types were found in 4.0% (n=53) of these women. The prevalence of hr-HPV 
types was 11.5% (n=152) and of lr-HPV types 7.7% (n=102), including co-infections. 
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partners (lifetime, 71 points), the gender of her partners was male  (0 points), she never 
uses condoms (32 points), and has had sexual intercourse once a week i.e. 26 times in the 
past six months (0 points). If we sum up the points 34+71+0+32+0 this results in 137 
points. Her corresponding probability of being HPV 16 and/or 18 positive is 1.3%. This is 
below the basal risk of 4% and below the cut-off value of 8%. Therefore, according to this 
“risk assessment tool”, this woman has a low likelihood of vaccine-type hr-HPV infection 
and she may decide for direct HPV vaccination.
Example 2:
However, if she was 22 years (34 points), has had a total number of 6 sexual partners 
(lifetime, 100 points), the gender of her partners were both male and female (50 points), 
she sometimes used condoms (78 points), and has had sexual intercourse 2 times in the 
past six months (72 points), her total of points would raise to 34+100+50+78+72=334 
points, resulting in a corresponding probability of 35%. In this situation she would be 
considered to have a high risk of being infected with HPV 16 and/or 18. This provides the 
woman with insight in her personal situation, and as this does not concern population 
based circumstances, she may choose to test for HPV prior to vaccination.
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Table 1.  Odds Ratio’s for the risk of an infection with  HPV 16 and/or 18 among 
sexually active women using logistic regression
    n OR (95% C.I.)
Age* (years) 1322 1,24 (1.06;1.44)
Current smoking 1316
No 1083 0.90 (0.45;1.82)
Yes 233 1.00 (ref )
Using OCC 1321
No 245 1.49 (0.78;2.84)
Yes 1076 1.00 (ref )
Living with parents 1313
No 1019 0.94 (0.48;1.81)
Yes 294 1.00 (ref )
Relationship 1316
Single 370 1.90 (1.05;3.43)
Married, LT 265 0.66 (0.27;1.65)
LAT 681 1.00 (ref )
Age at first intercourse**
(years)
1319
≤ 13 29 3.15 (0.42;23.43)
14-16 662 1.95 (0.46;8.31)
17-19 541 1.55 (0.35;6.76)
≥ 20 87 1.00 (ref )
Sexual Age*** (years) 1318 1.56 (1.04;1.28)
Lifetime sex partners (number) 1317
1 329 0.07 (0.02;0.28)
2-5 657 0.38 (0.21;0.67)
>5 331 1.00 (ref )
Gender of sex partner(s) 1319
Male 1258 0.24 (0.11;0.54)
Female, both 61 1.00 (ref )
Sex partners in past 6 months (number) 1316
0 124 0.13 (0.03;0.66)
1 997 0.31 (0.13;0.72)
2 131 0.46 (0.15;1.37)
>2 64 1.00 (ref )
Sexual intercourse in past 6 months
(frequency) 1287
0 110 0.28 (0.08;1.02)
1-6 132 1.00 (ref )
7-24 138 0.30 (0.09;0.95)
25-54 492 0.21 (0.09;0.49)
>54 415 0.56 (0.27;1.16)
Ever diagnosed an STD? 1317
No 1231 0.62 (0.24;1.59)
Yes 86 1.00 (ref )
Condom use 1316
Never (0%) 630 0.90 (0.25;3.20)
Sometimes (1-99%) 555 2.96 (0.90;9.76)
Always (100%) 131 1.00 (ref )
n: number
OR: Odds Ratio
95% C.I.: 95% Confidence Interval
* Age, grouped in one category when 24 or higher
ref: reference
OCC: oral contraceptives
LT: Living together
LAT: Living apart together
** below the age of 10 years several cases of sexual abuse were reported
*** Sexual age in years with 0 and 1 combined as well as sexual age higher than 13
STD: Sexually Transmitted Disease
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method to read the probability of currently being infected with hr-HPV vaccine-types 16 
and/or 18. It may be used as a decision-aid in outpatient clinics to provide women with 
insight into their own individual situation. Furthermore, it provides an individual based 
strategy to identify women with a higher probability of being positive, providing the 
opportunity to perform an HPV test before vaccination, as part of these women may still 
benefit from vaccination. 
Population based strategies may consist only of selectively vaccinating women without 
risk factors or with a low risk profile, or vaccinating women with a high risk of future 
acquisition of HPV.3;12 This study shows an opportunity for the use of risk profiling besides 
Discussion
We explored the possibility of composing a risk factor assessment tool, i.e. a prediction 
model, regarding individual HPV vaccine benefit, which may be helpful in counselling 
individual women in outpatient settings. The information needed is easy to obtain 
during an outpatient clinic visit and does not include expensive diagnostic tools or 
invasive pelvic examinations. The prediction model has been constructed using data 
from 1322 sexually active women aged 18 through 25 years who may form the group for 
additional (catch-up) vaccination. This risk factor assessment tool provides a simple 
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Figure 1. 
Nomogram to read the probability of HPV 16 and/or 18 infection.
To read the probability from the prediction model, the corresponding number of points of each of  
the 5 variables can be read from the scale above. All points are added up, and using the total score the 
corresponding probability of being HPV 16 and/or 18 infected can be read from the scale below.  
The maximal probability of HPV 16 and/or 18 is 45%, i.e. 351 points.
Age 24: ≥ 24, i.e. 24+25 (in years)
Partntot: total number of partners (lifetime)
Partner: gender of partner; male=male, female= female or both male and female
Cont6m: frequency of sexual intercourse in past 6 months
Table 2.   Adjusted Odds Ratio’s for the risk of an infection with HPV 16 and/or 18 
among sexually active women using multivariate logistic regression 
(n=1274)
Adj. OR (95% C.I.)
Age* (years) 1.18 (1.01;1.38)
Lifetime sex partners (number)
1 0.14 (0.03;0.64)
2-5 0.57 (0.30;1.07)
>5 1.00 (ref )
Gender of sex partner(s)
Male 0.38 (0.16;0.91)
Female, both 1.00 (ref )
Condom use
Never (0%) 1.87 (0.38;9.27)
Sometimes (1-99%) 4.54 (1.01;20.32)
Always (100%) 1.00 (ref )
Sexual intercourse in past 6 months
(frequency)
0 0.34 (0.09;1.27)
1-6 1.00 (ref )
7-24 0.30 (0.09;0.99)
25-54 0.24 (0.10;0.61)
>54 0.66 (0.30;1.47)
n: number
Adj. OR: Adjusted Odds Ratio
95% C.I.: 95% Confidence Interval
*Age, grouped in one category when 24 or higher
ref: reference
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What is already known on this topic
Infection with HPV is a necessary event in the multi-step process of cervical carcinogenesis. 
Prophylactic vaccines are developed to prevent specifically HPV 16 and 18 infections. 
Efficacy of HPV vaccines has been proven in women who are HPV 16 and/or 18 negative 
at time of vaccination. The benefit of HPV vaccination of sexually naïve women is likely 
to be higher than that of older already sexually active women.
What this study adds
The individual decision of older sexually active women to get vaccinated will be balanced 
between costs and personal benefit. This risk assessment tool may be used in outpatient 
settings to estimate the probability of HPV 16 and/or 18 infection in sexually active 
individuals requesting counselling before HPV vaccination. It provides insight in one’s 
personal situation. Furthermore, it may provide a guideline to discriminate between 
sexually active individuals eligible for direct vaccination and sexually active individuals 
who may benefit from prior HPV testing.
the questionable population-based vaccination eligibility approach. Since vaccination is 
costly, sexually active women may need more insight in their personal situation before 
deciding to get vaccinated. Individually-focused risk profiling may be used to answer 
questions on an individual basis. Moreover, it may be used to predict whether the 
vaccine may be administrated immediately or if HPV-testing before vaccination may be 
indicated. This may be translated into a personal “benefit” i.e. cost savings. The vaccination 
of sexually active women may considerably increase the speed with which results are 
obtained in the fight against cervical cancer.5 Women with previous exposure to HPV or 
a current HPV infection may still benefit to some extent from vaccination, provided that 
they have not been infected with both  vaccine hr-HPV types. In this study only 2 women 
(0.2%) were positive for both hr-HPV vaccine types 16 and 18 simultaneously, resulting in 
no benefit of vaccination. Looking at population based level most women will have the 
potential to benefit from vaccination since the prevalence of HPV vaccine type 16 and/
or 18 is low.5;13 Therefore, a vaccination strategy consisting of testing all sexually active 
women prior to vaccination will be senseless as it will be expensive and excessive. 
However, looking at counselling individual sexually active women with a higher 
probability of being hr-HPV vaccine-type positive, a strategy with HPV testing may be 
useful. Therefore, this model provides insight in personal “risk factors”  and therefore 
may contribute to a woman’s conscious decision regarding direct vaccination or prior 
HPV testing.
A limitation of using cross-sectional data is the identification of current HPV infection 
and partial retrospective analyses of potential risk factors. An additional  disadvantage of 
using cross-sectional data for the prediction model may be that information on previous 
infection is lacking. However, this problem is contradicted by a study performed by 
Schwarz et al. which concluded that  vaccination of women who are serologically 
negative at time of vaccination, without knowledge of previous infections, is effective.14 
Therefore, transient infections, that play a very small role in the overall development of 
clinical disease, are of importance at the moment when a woman is considering 
vaccination.
In conclusion, we composed a risk assessment tool that may be helpful in counselling 
individual women in outpatient settings. It provides an estimation of the probability of 
being infected with HPV 16 and/or 18 and therefore provides insight into the personal 
situation. Furthermore, it may provide a guideline to discriminate between sexually 
active individuals eligible for direct vaccination and sexually active individuals who may 
benefit from prior HPV testing. Furthermore, future research is of specific interest as risk 
profiling may be used to predict hr-HPV persistence and future infections, both affecting 
vaccine efficacy.
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Detection and genotyping of Human 
Papillomavirus in self-obtained cervico-vaginal 
samples by using the FTA cartridge:
New possibilities for cervical cancer screening
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Abstract
This study assesses Human Papillomavirus (HPV) detection and genotyping in 
self-sampled genital smears applied to an indicating FTA elute cartridge (FTA cartridge). 
The study group consisted of 96 women, divided into two sample sets. All samples were 
analysed by the HPV-SPF10 Line Blot 25. Set 1 consisted of 45 women attending the 
gynaecologist; all obtained a self-sampled cervico-vaginal smear, which was applied to 
an FTA cartridge. HPV results were compared to a cervical smear (liquid-based) taken by 
a trained physician. Set 2 consisted of 51 women who obtained a self-sampled 
cervico-vaginal smear at home, which was applied to an FTA cartridge and to a 
liquid-based medium. DNA was obtained from the FTA cartridges by simple elution as 
well as extraction. Of all self-obtained samples of set 1, 62.2% tested HPV-positive. The 
overall agreement between self- and physician-obtained samples was 93.3%, in favour 
of the self-samples. In sample set 2, 25.5% tested HPV-positive. The overall agreement for 
high-risk HPV presence between the FTA cartridge and liquid-based medium and 
between  DNA elution and extraction was 100%.
This study shows that HPV detection and genotyping in self-obtained cervico-vaginal 
samples applied to an FTA cartridge is highly reliable. It shows a high level of overall 
agreement with HPV detection and genotyping in physician-obtained cervical smears 
and liquid-based self-samples. DNA can be obtained by simple elution and is therefore 
easy, cheap, and fast. Furthermore, the FTA cartridge is a convenient medium for 
collection and safe transport at ambient temperatures. Therefore, this method may 
contribute to a new way of cervical cancer screening.
Introduction
Infection with Human Papillomavirus (HPV) is a necessary event in the multi-step process 
of cervical carcinogenesis.1;2 As a result, the clinical value of HPV testing has been well-
established.3-8 In the United States, the Food and Drug Administration (FDA) has 
authorized a high-risk HPV (hr-HPV) assessment for primary screening in women aged 30 
and older. This is in addition to regular cytological screening as well as for the triage of 
smears of atypical cells of undetermined significance. In the Netherlands, additional 
hr-HPV testing has been approved and recommended in all follow-up smears after the 
detection of a first-time borderline or mild dysplasia (BMD) smear. The beneficial effect 
of HPV testing will most likely increase in case hr-HPV assessment replaces cytology as 
primary screening tool.3-5;7
Regarding (hr-)HPV testing, material from vaginal lavages or self-sampling brushes has 
proven to be highly representative for the cervical (hr-)HPV status.9-14 In addition, 
cervico-vaginal self-samples have repetitively been proven to be as reliable as 
physician-taken samples.15;16 Subsequently, several studies have shown that self-sampling 
for HPV testing was highly acceptable to women, although some women were concerned 
about performing the test properly.14;17 Hr-HPV testing on self-sampled materials might 
be a promising opportunity to increase the efficacy of population-based screening 
programmes worldwide.9;10;13;18 Cervico-vaginal self-sampling may be an easy, accessible, 
user-friendly, and timesaving alternative for the physician-based collection of 
cervico-vaginal material.14;17
In the Dutch cervical screening programme approximately 70% of the women who are 
invited actually take part. Tragically, half of the cervical carcinomas are diagnosed in the 
remaining group of non-responders.13;19;20 Cervical cancer incidence would decrease 
significantly if these non-responders could be reached.5;8 Several studies have shown 
that non-responders actually do take part in self-sampling studies.9;13;21 Self-sampling is a 
less costly and a less invasive collection method.16 Self-sampled material could be more 
easily obtained in populations that are difficult to reach and in settings with limited 
resources, facilitating the introduction of organised HPV-based cervical screening 
programmes in developing countries as well.
However, the vast majority of studies assessing self-sampling have used liquid-based 
storage and transport media.9;12;13;21 Since these solutions can be inflammable, hazardous, 
and potentially infectious, careful handling is required and regular mailing may even not 
be allowed. This severely hampers the introduction of cervico-vaginal self-sampling 
methods. Dried fluid spots or solid carriers have already been used for decades in the 
postnatal screening of certain congenital disorders and diseases. Solid carriers have also 
been successfully used in studies detecting and genetically characterizing measles virus 
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Material and Methods
The study group consisted of 96 women, divided into two sample sets (Figure 3). 
Sample set 1
Between September and October 2008, 45 women were recruited at the Department of 
Obstetrics and Gynaecology of the Radboud University Nijmegen Medical Centre, the 
Netherlands. These participants visited the gynaecologist for follow-up after diethyl-
stilbestrol-exposition in utero, treatment of cervical dysplasia, or follow up after two 
BMD smears. The median age was 38 years (standard deviation 6.85 years, range 23 to 51 
years).
All women were asked to self-collect a cervico-vaginal sample after having received 
instructions on how to perform the self-sample (verbally, written, and in cartoon). 
strains, as well as in studies assessing viral load and genotypic-resistance for human 
 immunodeficiency virus (HIV).22-24 As dried material on a solid carrier is neither hazardous 
nor inflammable, applying genital self- samples on these solid carriers (like FTA cartridges) 
can solve storage and transportation problems.
In this study, we have assessed the use of self-sampled cervico-vaginal smears applied to 
a new FTA cartridge, i.e. the Whatman® indicating FTA® elute cartridge (Figure 1 and 2) 
which allows easy storage and transport as the virus is denaturised upon application. 
Additionally, the cartridge overcomes the uncertainty of women about performing the 
procedure properly, as it has an indicating dye which changes from purple to white 
when a (genital) sample is applied. Furthermore, we assessed the novel method of direct 
HPV DNA elution without requiring further purification.
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Figure 1. 
Whatman® indicating FTA® elute 
cartridge.
Figure 3. 
Study design.
Figure 2. 
Whatman® indicating FTA® elute 
cartridge upon application.
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Medical Microbiology. The samples were stored at room temperature. In the original 
study of the 2065 women, a control for sample sufficiency, i.e. detection of human 
beta-globin, was performed and showed less than 1% false negative samples.25
The self-sampling material on the FTA cartridge was compared to the self-sampling 
material stored in the liquid-based medium (Figure 3).
Specimen preparation LBC
For isolation of DNA from cervical scrapes in liquid-based cytology medium, the 
MagNAPure LC Isolation station (Roche Diagnostics GmbH, Roche Applied Science, 
Mannheim, Germany) was used; 500µL of material was isolated using the MagNA Pure LC 
Total Nucleic Acid Isolation Kit (Roche Diagnostics GmbH, Roche Molecular Biochemicals, 
Mannheim, Germany), as described by the manufacturer. With each set of 28 cervical 
scrape samples four negative controls were included. Nucleic acid was resuspended in a 
final volume of 50µL; 10µL was used for PCR analysis.26
Specimen preparation of the indicating FTA elute cartridge
The indicating FTA elute matrix contains an indicating dye that changes from purple to 
white upon application of a colourless sample such as cervico-vaginal swab. The FTA 
cartridges were punched using a sterilised perforator specifically designed for the FTA 
cartridges (3-mm Harris Uni-core device, Whatman). The sample amount varied between 
samples, and to optimize the number of punches to cover this variation, pilots were 
performed using a different number of punches. For this study, only three punches were 
considered to compare DNA elution and extraction, as well as individual genotypes.
The FTA elute matrix is chemically treated with proprietary reagents that lyses cells upon 
contact, causing the release of nucleic acids. DNA was recovered from the FTA elute 
matrix through a simplified elution process using heat and water. Inhibitory components, 
such as haemoglobin, are retained on the FTA elute matrix. 
Elution
The three punches were transferred into a 1.5-mL microfuge tube, 1500µL of sterile 
water was added to the punches and immediately pulse vortexed 3 times, for a total of 
5 seconds. The water was removed with a sterile fine-tip pipette. Fifty microliters of 
sterile water was added to the punches, and the tube was transferred to a heating block 
at 95°C for 30 minutes. At the end of the incubation period the sample was removed 
from the heating block and pulse vortexed approximately 60 times. It was additionally 
In brief, participants were instructed to wash their hands before opening the brush cover 
(Rovers® Viba-Brush, Rovers Medical Devices B.V., Oss, the Netherlands), to hold the brush 
by the end of the handle, to insert the brush approximately 7 cm into the vagina (similar 
to inserting a tampon), and to gently turn the brush 5 times. Subsequently, the brush 
was applied to the FTA cartridge (Whatman® indicating FTA® elute cartridge, catalogue 
number WB 659223, GE Healthcare, United Kingdom) (Figure 1 and 2). The FTA cartridge 
was dried to air. After self-sampling, a vaginal speculum was inserted and a physician 
obtained a regular cervical smear using a Rovers® Cervex-brush® (Rovers Medical Devices 
B.V., Oss, the Netherlands) that was rinsed in a Thinprep® vial (Cytyc corp. Boxborough, 
MA, USA). Regular liquid-based cytological (LBC) examination was performed and 0.5mL 
of LBC homogenised medium was used for HPV assessment.
In order to assess the samples anonymously, all self-obtained samples and cervical LBC 
samples were provided with an unique patient code before they were sent to the 
laboratory. 
Sample set 2
Sample set 2 consisted of 51 healthy participants who were randomly recruited from a 
prospective self-sampling study of HPV prevalence, incidence and clearance among 
2065 unscreened women between 18 and 29 years of age.25 All women were asked to 
self-collect a cervico-vaginal sample in the privacy of their own home. Women received 
an explanatory letter, an informed consent form, and a self-sample kit by mail. The 
self-sample kit was provided with an anonymous code to ensure privacy. The self-sample 
kit contained a collection device (a small brush packaged in an individual sterile cover, 
Rovers® Viba-Brush, Rovers Medical Devices B.V., Oss, the Netherlands), an FTA cartridge 
(Whatman® indicating FTA® elute cartridge, catalogue number WB 659223, GE Healthcare, 
United Kingdom) (Figure 1 and 2), a collection tube containing medium (SurePathtm, 
Tripath Imaging®, Inc., Burlington, NC, USA), instructions how to perform the 
cervico-vaginal self-sample (written and in cartoon), and a return package consisting of 
a leak-proof seal bag, absorption sheet, and a reclosable plastic return envelope 
(Easyslider, Transposafe Systems Holland BV, Sassenheim, the Netherlands). Except for 
the fact that they used an additional liquid based medium, the instructions of how to 
perform the self-sample were similar to the instructions described above. In brief, 
participants were instructed to first apply the self-sample on the FTA cartridge and to 
subsequently place the top of the brush in the collection tube. The collection tube was 
closed and enclosed in the seal bag. Finally, the collection tube was placed in the return 
envelope together with the dried FTA cartridge and sent to the Department of Obstetrics 
and Gynaecology for further processing and HPV assessment at the Department of 
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In the second sample set, the self-sampled material stored in liquid based solution was 
compared to self-sampled material on the FTA cartridge. Again, results of DNA elution 
and extraction from the FTA cartridge were compared (Figure 3). In the original study 
population of sample set 2 (n=2065), detection of beta-globin was used as a control for 
sample sufficiency and showed less than 1% false negatives. 
Comparing the presence of hr-HPV between the two samples, results were termed 
concordant or discordant based on the following definitions. If analyses showed identical 
genotypes in both samples, the results were termed concordant. Genotyping results 
were termed discordant when no similarities in the genotypes existed.
This study was approved by the local Medical Ethics Committee. All participants were 
informed and provided an informed consent.
Statistics
All data were analysed using SPSS version 16.0 for Windows (Chicago, Illinois, USA). 
Agreement was measured by absolute agreement and Cohen’s kappa statistics, a measure 
of the agreement between two methods that is in excess of that due to chance.
Results
The study group consisted of 96 women between 18 and 51 years of age. The results of 
the two sample sets are described separately, since sample set 2 consisted of healthy 
unscreened women and sample set 1 consisted of women with a higher risk of an HPV 
infection than in the general population as they had initially been referred to the 
gynaecologist for cervical follow-up for several reasons.
Sample set 1
The median age of the 45 women in sample set 1 was 38 years (standard deviation 6.85 
years, range 23 to 51 years). 
Cervico-vaginal self-obtained sample versus physician-obtained cervical smear
Of the 45 self-collected cervico-vaginal samples on the FTA cartridges, 62.2% (n=28) 
tested positive for one or more HPV genotypes. This high prevalence was expected due 
to the nature of the follow-up. Of these 28 samples, 25 also tested positive for HPV in the 
cervical smear sample obtained by the physician.
centrifuged for 30 seconds, and the eluted DNA was placed into a new microcetrifuge 
tube with a pipette. The eluted DNA was stored at -80°C.
Finally, 10µL of the eluate was used for PCR analysis.
Isolation
For additional comparison, DNA was extracted from three other punches using the 
QIAGEN® DNeasy Tissue Kit (QIAGEN Inc, Valencia, CA, USA), as described by the 
manufacturer.
Subsequently, HPV DNA assessment was performed identically as for the LBC specimens, as 
described below. All HPV tests were performed by laboratory assistants unaware of the 
cytological status and the results from the comparative HPV detection tests.
HPV detection and genotyping
Broad-spectrum HPV DNA amplification was performed using a short-PCR-fragment 
assay (HPV SPF10 Line Blot 25, Labo Biomedical Products BV, Rijswijk, the Netherlands). 
This assay amplifies a 65-bp fragment of the L1 open reading frame, and allows detection 
of a broad range of hr-, low-risk (lr) and possible hr-HPV genotypes.27
Twenty-eight oligonucleotide probes which recognize 25 different types were tailed with 
poly(dT) and immobilised as parallel lines to membrane strips (Labo Biomedical Products 
BV, Rijswijk, the Netherlands). The HPV genotypes detectable are hr-HPV 16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 59, and 68/73 and two probable hr-HPV types (53 and 66). Samples that 
tested positive using the DNA enzyme immunoassay but that showed no results on the 
LiPA strip were considered to be HPV “X” type, i.e. genotypes not available on the LiPA 
strip. Lr-HPV types were defined as HPV type 6, 11, 34, 40, 42, 43, 44, 54, 55, 58, 70, 74, and 
X. The HPV genotyping assay was performed as described previously.28 The LiPA strips 
were visually inspected, and interpreted using the provided reference guide.
Study design
All samples were assessed for HPV genotyping using the HPV SPF10 Line Blot 25 assay. 
For the first sample set, the self-sampled material on the FTA cartridge was compared to 
a liquid-based cervical smear obtained for diagnostic purposes by a trained physician in 
the outpatient clinic. Additionally, as HPV DNA elution is a novel method to obtain HPV 
DNA from an FTA Elute cartridge, results of DNA elution were compared to results from 
HPV DNA extraction (Figure 3).
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Of the 28 HPV positive samples, 19 samples showed similar types, 5 samples showed an 
additional genotype (sample no. 2,5,9,16, and 25) (Table 1), and 4 samples showed a 
different genotype (sample no. 8,10, 18, and 20) (Table 1). The overall agreement for HPV 
positivity between self-sampling and the cervical smear taken by the physician was 
93.3% (kappa value 0.86, 95% confidence interval (C.I.) 0.713;1.013). 
Concordance and discordance of hr-HPV
Table 1 shows a summary of the genotypes per sample set as well as the concordance 
and discordance for hr-HPV. Taking the samples of all 45 women into account, 42 samples 
(93.3%) were concordant and  3 samples (6.7%) were discordant for hr-HPV presence. In 
these 3 samples, the physician-obtained smear did not contain a hr-HPV type in contrast 
to the self-obtained sample (sample  no. 8, 16, and 18) (Table 1).
Of the 42 concordant samples, 25 showed no hr-HPV DNA in both self- and 
 physician-obtained samples. In 20 of the 45 (44.4%) self-obtained samples, one or more 
hr-HPV types were detected; 17 patients also tested hr-HPV positive in the cervical 
smears obtained by the physician. The overall agreement for hr-HPV positivity was 93.3% 
(kappa value 0.86, 95% C.I. 0.713;1.013).
Concordance and discordance of lr-HPV
In 13 of the 45 (28.9%) self-obtained samples, one or more lr-HPV types were detected, 
10 cases also tested lr-HPV positive in the cervical smears obtained by the physician. The 
overall agreement for lr-HPV positivity was 93.3% (kappa value 0.83, 95% C.I. 0.635;1.016).
Table 1 shows a summary of the genotypes per sample set as well as the concordance 
and discordance for lr-HPV. Taking the samples of all 45 women into account, 42 samples 
(93.3%) were concordant and 3 samples (6.7%) were discordant for lr-HPV presence. In 
these 3 samples the physician-obtained smear did not contain a lr-HPV type in contrast 
to the self-obtained sample (sample no. 2, 5, and 10) (Table 1). Of the 42 concordant 
samples, 32 showed no lr-HPV DNA in both self- and physician-obtained samples.
DNA elution versus DNA extraction
As DNA elution is a novel method of obtaining DNA from an FTA cartridge, HPV DNA 
from the self-sampled material on the FTA cartridge yielded by DNA elution was 
compared to HPV DNA yielded from the cartridge by DNA extraction. The results showed 
a perfect overall agreement of 100% (kappa value 1.0, 95% C.I. 1.0;1.0) indicating the 
reliability of this procedure (Table 1).
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Table 1.  HPV detection by SPF10 Line Blot 25 for corresponding genital self-obtained 
smears and physician-obtained cervical smears (sample set 1)
Sample
HPV detection using 
physician-obtained 
samples (LBC)
HPV detection using self-obtained 
samples 
(FTA cartridge)
HPV 
Accordance 
DNA 
extraction
hr lr
DNA 
extraction
DNA 
elution
hr lr hr lr
1 52 + - 52 52 + - c c
2 51 + - 11, 31, 51 11, 31, 51 + + c d
3 18, 31 + - 18, 31 18, 31 + - c c
4 16 + - 16 16 + - c c
5 53 + - 6, 53 6, 53 + + c d
6 16 + - 16 16 + - c c
7 6 - + 6 6 - + c c
8 N - - 52 52 + - d c
9 16, 66 + - 66 66 + - c c
10 N - - 11 11 - + c d
11 16 + - 16 16 + - c c
12 66 + - 66 66 + - c c
13 X - + X X - + c c
14 59 + - 59 59 + - c c
15 39 + - 39 39 + - c c
16 42 - + 18, 42 18, 42 + + d c
17 16 + - 16 16 + - c c
18 N - - 16 16 + - d c
19 51 + - 51 51 + - c c
20 68, 70 + + 52, 70 52, 70 + + c c
21 51 + - 51 51 + - c c
22 X - + X X - + c c
23 6, 51, 58 + + 6, 51, 58 6, 51, 58 + + c c
24 58 - + 58 58 - + c c
25 31 + - 31, 51 31, 51 + - c c
26 70 - + 70 70 - + c c
27 6 - + 6 6 - + c c
28 X - + X X - + c c
29-45 N N N N N N N c c
LBC: liquid based cytology
hr: hr-HPV types were 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 59, and 68/73, probable hr-HPV: 53 and 66
lr: lr-HPV types were 6, 11, 34, 40, 42, 43, 44, 54, 55, 58, 70, 74, and X
c: concordant
d: discordant
N: HPV negative
-: negative
+: positive
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Discussion
HPV testing in cervical cancer screening has a beneficial effect in patient management 
and can increase the success rate of population-based screening programmes in 
reducing cervical cancer incidence.3-5;7 Regarding hr-HPV testing, cervico-vaginal 
self-obtained samples have repetitively been proven to be as reliable as physician-ob-
tained samples.15;16 This present study underlines the reliability of using cervico-vaginal 
self-samples for hr-HPV testing.
Sample set 2
The median age of the women in sample set 2 was 21 years (range 18 to 29 years). Of the 
51 self-collected cervico-vaginal samples applied to a liquid-based medium, 13 (25.5%) 
tested positive for one or more HPV genotypes. All of these HPV positive samples also 
tested positive for HPV on the FTA cartridge (Table 2). Moreover, the overall agreement 
for HPV positivity between the FTA cartridge and liquid-based medium was 100% (kappa 
value 1.0, 95% C.I. 1.0;1.0).
Of the 13 HPV positive samples, 10 samples showed similar types, 2 samples showed an 
additional genotype (sample no. 9 and 12) (Table 2), and 1 sample showed a different 
genotype (sample no. 13) (Table 2).
Concordance and discordance of hr-HPV
Table 2 shows a summary of the genotypes per sample set as well as the concordance of 
hr-HPV between the liquid-based and filter-based samples. Taking all 51 samples into 
account, all samples were concordant for hr-HPV detection, of which 9 (17.6%) were 
hr-HPV positive. In these 9 liquid-based stored self-samples, one or more hr-HPV types 
were detected; all samples (100%) also tested hr-HPV positive on the FTA cartridges.
Additionally, the overall agreement for hr-HPV positivity between FTA cartridge and 
liquid-based medium was 100% (kappa value 1.0, 95% C.I. 1.0;1.0).
Concordance and discordance of lr-HPV
One or more lr-HPV types were detected in 7 of the liquid-based stored self-obtained 
samples (13.7%) versus 7 on the FTA cartridges (Table 2). However, not all samples 
showed similar types, resulting in only 5 concordant lr-HPV types. The overall agreement 
for lr-HPV positivity between FTA cartridge and liquid-based medium was 96.1% (kappa 
value 0.83, 95% C.I. 0.609;1.059).
DNA elution versus DNA extraction
In sample set 2, HPV DNA yielded from the self-obtained material on the FTA cartridge 
by DNA elution was again compared to DNA yielded from the FTA cartridge by extraction. 
The results showed an overall agreement of 100% (kappa value 1.0, 95% C.I. 1.0;1.0).
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Table 2.   HPV detection by SPF10 Line Blot 25 for corresponding genital self-obtained 
smears with liquid-based medium versus FTA cartridge (sample set 2)
Sample HPV detection using 
self-obtained samples 
(LBC)
HPV detection using self-obtained 
samples
(FTA cartridge)
HPV 
Accordance 
DNA 
extraction hr lr
DNA 
extraction
DNA 
elution hr lr hr lr
1
18, 51, 54, 
68
+ +
18, 51, 54, 
68
18, 51, 54, 
68
+ + c c
2 56 + - 56 56 + - c c
3 X - + X X - + c c
4 X - + X X - + c c
5 42, 51, 54 + + 42, 51, 54 42, 51, 54 + + c c
6 52 + - 52 52 + - c c
7 X - + X X - + c c
8 16 + - 16 16 + - c c
9 16, 45, 51 + -
11, 16, 45, 
51
11, 16, 45, 
51
+ + c d
10 68 + - 68 68 + - c c
11 31 + - 31 31 + - c c
12 39, 54 + + 39 39 + - c d
13 54 - + X X - + c c
14-51 N - - N N - - c c
LBC: liquid based cytology
hr: hr-HPV types were 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 59, and 68/73, probable hr-HPV: 53 and 66
lr: lr-HPV types were 6, 11, 34, 40, 42, 43, 44, 54, 55, 58, 70, 74, and X
c: concordant
d: discordant
N: HPV negative
-: negative
+: positive
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It has been shown that self-sampling methods are unsuitable for cytological analysis.9;13 
To complete the diagnosis for the individual hr-HPV positive patient, a subsequent 
 physician-obtained smear ought to be performed. Preferably, this is solely done in 
women who are persistently hr-HPV positive. Whether the self-sampling women are 
willing to have an additional cytology smear taken in case of hr-HPV persistence has not 
yet been studied.
Since cervico-vaginal self-sampling could be an easily accessible and user-friendly 
method, women not participating in the screening programme due to fear or other 
reasons might be interested to actually participate since this technique could be 
applicable to at-home self-sampling. Therefore, the introduction of cervico-vaginal 
self-sampling will probably increase the participation rate.9;10;13;18 Recently, Bais et al. 
showed that the active response to self-sampling in populations-based screening 
non-responders was significantly higher than the active response to an extra recall for 
conventional cytology.21
For HPV detection and genotyping, we used the HPV SPF10 Line Blot 25. This assay has 
previously shown high concordance with various other systems.26;28 This indicates the 
suitability of the FTA cartridge for various other HPV detection and genotyping systems 
like the Roche Amplicor and Linear Array assays. Preliminary studies indeed showed an 
excellent concordance (data not shown). However, further study may be needed to 
assess genital self-sampled FTA cartridges using other commercially available HPV 
detection tests with lower analytical sensitivity (e.g. Hybrid Capture II).  Additionally, 
since this was a pilot study and sample sizes were small, further research should be 
conducted. Furthermore, since not all samples were checked for specimen sufficiency 
(e.g. beta globin), future research should include a measure for sample sufficiency.
In conclusion, the results of HPV detection and genotyping on self-sampled 
cervico-vaginal samples using a Rovers® Viba-brush and the Whatman® indicating FTA® 
elute cartridge are highly representative for the cervical HPV status.
Furthermore and equally important, this study shows that elution of DNA from the 
Whatman® indicating FTA® elute cartridge, without the necessity of DNA extraction 
procedures, is a fast, cheap, and reliable method. The Whatman® Indicating FTA® Elute 
cartridge technique is a convenient medium for collection, as the colour of the FTA 
cartridge changes after application of the self-sampled material, confirming proper use. 
Additionally, the FTA cartridges can be stored at ambient temperatures for months, and 
since the method is non-hazardous, the samples are allowed to be sent by regular mail. 
This suggests that this method might be applicable to at-home self-sampling in 
 population-based screening non-responders, as well as for the introduction of primary 
However, despite differences in self-sampling methods, many previous studies have 
used liquid-based sample storage and transport media. Use of these solutions may 
result in a delay or inability to implement at-home self-sampling of population-based 
screening non-responders because of a number of reasons. For example, one reason is 
the high cost due to legislations for these potentially hazardous liquid-based techniques, 
which require difficult and therefore expensive logistics. An alternative for the transport 
of potentially hazardous solutions could be storage on filter papers, i.e., FTA cartridges. 
These FTA cartridges, for example, are less prone to contamination and are therefore 
easy to handle. For instance, filters have been used for decades in the postnatal screening 
of certain congenital disorders and diseases. The air-dried samples showed stability at 
room temperature for months, up to years.29 Furthermore, at-home collection for HIV 
testing on filter papers has been considered feasible and acceptable in a high-risk cohort. 
Additionally, also viral load and genotypic-resistance assessments in applied whole 
blood and plasma of HIV-positive patients appear to be possible.22;23
To compare the transport media used in this study, it would be ideal if all conditions across 
the groups were equal. However, as we are particularly interested in whether results of HPV 
detection in cervico-vaginal self-obtained samples are comparable to the results of HPV 
detection in physician-taken cervical smears, the “golden standard”, despite or precisely 
because the conditions differ, we think it is important to compare the self-sampling 
method with the “regular” physician-taken smear as a proof of principle. This study shows 
a high level of overall agreement of HPV detection and genotyping between physician-
obtained cervical smears which are applied to a liquid-based medium and self-obtained 
cervico-vaginal samples that are subsequently applied to an FTA cartridge. Additionally, all 
hr-HPV positive physician-obtained smears were hr-HPV positive in the cervico-vaginal 
self-samples as well. Besides the reliability of the FTA cartridge regarding hr-HPV testing, its 
unique properties make it easy to handle. For instance, the air dried FTA cartridges showed 
stability at room temperature for months. Furthermore, the uncertainty about performing 
the self-sampling procedure properly will be overcome since the indicating FTA cartridge 
has an indicating dye which changes upon application of the sample. Furthermore, the 
contamination risk is reduced as the virus is denaturised upon application, making it 
biohazard free and safe for transport by mail. This allows cervical or self-obtained genital 
samples to be added to this FTA cartridge and sent to designated central laboratories for 
analysis. Even more important, by using the FTA cartridge, processing costs will be low as 
DNA is eluted by a simple method using only water and heat, without requiring expensive 
DNA extraction. Besides the use in existing screening programmes, usage of the FTA 
cartridge could simplify the introduction of organised HPV-based cervical screening 
programmes in developing countries as well.
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The identification of the central aetiological role of high-risk (hr) HPV in cervical 
carcinogenesis has led to the development of prophylactic vaccines against the two 
most prevalent hr-HPV genotypes, HPV 16 and HPV 18.1-5 As HPV transmission mainly 
occurs sexually, the best results of prophylactic vaccination will be achieved by 
vaccinating girls before they become genitally infected i.e. sexually active. Given the lag 
time between age of vaccination and age at development of cervical cancer, the effect 
of vaccination on cervical cancer rates will take several decades after the introduction of 
the vaccine. In order to decrease cervical cancer incidence without a 15 to 20 years lag 
time, vaccination of older already sexually active women is under consideration in many 
countries. In the group up to 30 years of age, little is known about epidemiology of HPV 
infections. The studies in this thesis mainly focus on the HPV epidemiology among 
unscreened women aged 18 to 29 years in the pre-vaccine era. Additionally, the studies 
provide insight in factors influencing HPV infection as well as vaccine acceptance. 
HPV and sexual behaviour
Being sexually active itself has been described as the main risk for exposure to HPV. 
Besides being sexually active, we also explored several aspects of sexual behaviour like 
number of sexual partners and condom use. Several studies questioned whether 
condom use reduces transmission of HPV.6;7 Unfortunately, results are too inconsistent to 
produce actual estimates. This may partly be due to different populations studied, as 
well as differences in study design. In chapter two and three we show that the use of 
contraceptive methods like condoms was influenced by type of relationship and 
therefore was not independently related to HPV prevalence or incidence. Furthermore, 
studies raised young age at first intercourse and corresponding cervical immaturity as 
an influencing factor of susceptibility of infection and consequent development of 
abnormalities.8;9 In our population, age at first intercourse was not associated with HPV 
infection, as it was influenced by time interval between age at first intercourse and 
current age as well as by lifetime number of partners. Both lifetime number of partners 
and type of relationship were related to prevalence, incidence as well as clearance of 
infection. It was striking that aspects of present as well as past sexual behaviour were 
independent factors influencing current presence of HPV. These results suggest that 
some infections detected were newly acquired whereas others were acquired in the 
past and remained latent below detection level for a long time and may be considered 
as randomly detected latent infections.
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in time between HPV infection and the development of cervical cancer, the impact of 
(universal) vaccination on cervical cancer rates will take several decades after vaccine 
introduction. Taken the above into account, the Cervical Screening Programme (CSP) 
must be continued after the introduction of vaccination. However, along with routine 
vaccination, screening guidelines may need adaptation in order to retain efficient and 
cost-effective prevention measures.
HPV and cervical screening in the (post-) vaccination era
In the (post-) vaccination era, HPV 16 and HPV 18 infection will be prevented which will 
lead to a subsequent decrease in incidence of cervical cancer and its precursors. In the 
present screening setting 2-5% of the smears contain abnormalities, with an overall 
sensitivity for CIN2+ of 53.0% (48.6-57.4%).16 However, sensitivity varies enormously 
between studies reviewing screening.16-18 The reduction in prevalence of abnormal 
cytology may lead to smears not being read as attentively and thoroughly as before 
given the expectation that abnormalities will be rare. This would result in more 
false-negative diagnoses with consequent loss in sensitivity.19 Additionally, the decrease 
in prevalence of abnormalities would  also lead to a decrease in positive predictive value 
of cervical cytology, the parameter that indicates how correct a positive result would be 
in triggering management.19 This may lead to unnecessary medical interventions and 
patient stress. Therefore, the CSP will need transformation and new screening tools will 
be necessary to meet the new post-vaccination screening requirements. 
Given the strong etiologic link between hr-HPV infection and cervical cancer an 
alternative for cytology-based cervical cancer screening may be hr-HPV testing.20 Unlike 
cytology, HPV tests are objective and highly reproducible. HPV testing is based on highly 
standardized and validated systems which do not suffer from the pitfalls that typically 
affect the performance of cervical cytology. For detecting high-grade lesions or cancer, 
HPV testing has a 20 to 40% greater sensitivity, but about 5 to 10% lower specificity than 
cervical cytology.16;21 This lower specificity may be explained by the detection of transient 
HPV infections instead of detecting exclusively persistent infections. Studies have shown 
that this somewhat lower specificity may be compensated by using cervical cytology for 
triage testing. Other potential triage tests, like methylation detection assays, are being 
studied. HPV genotyping can also be used as a triage test in HPV positive women, as it 
allows detection of HPV type specific persistence and is therefore important in individual 
patient management. Because the risk of cervical abnormalities in the five year period 
following a HPV negative test is much lower than the risk predicted by normal cytology, 
the screening interval may be extended.
HPV epidemiology and vaccination
Equally important, besides providing insight into HPV dynamics in the pre-vaccine era, 
the studies in this thesis provide baseline data to allow future research on shifts in HPV 
epidemiology due to HPV vaccination. With HPV mass vaccination, HPV epidemiology 
may change gradually by progressive reduction in HPV 16 and HPV 18 infections, as well 
as a possible decrease in non-vaccine types HPV 45 and HPV 31, induced by cross- 
protection.4;10 Theoretically, it is possible that these vacated niches may be filled by other 
genotypes, leading to (as yet unproven) type replacement.11 This may raise concerns 
about the potential of other oncogenic HPV types to replace the position of HPV 16 and 
HPV 18 as the main initiator of cervical cancer development. As a result of extensive 
vaccination, it may be possible that new HPV 16 or 18 subtypes or intra-type variants 
develop, influencing vaccination efficacy. Monitoring these changes on a population 
level may prove crucial in assessing the effect of mass vaccination on HPV epidemiology 
as well as the success of vaccination as primary prevention strategy.
For HPV vaccination to be successfully incorporated into the fight against cervical cancer, 
widespread vaccine coverage is crucial. Presently, vaccination programmes have started 
in many countries around the world, primarily targeting 9 to 16 year old girls.12-14 At the 
verge of European vaccine licensure in 2006, we conducted a study among parents of 10 
to 12 year old children to determine their acceptance of HPV vaccination.15 This study 
showed an 88% acceptance among parents, with the remark that they requested 
additional information about HPV and HPV vaccination. When the vaccine was 
implemented into the funded Dutch national vaccination programme early 2009, the 
coverage of catch-up vaccination among girls aged 13 to 16 years reached only 50%. 
This relatively low coverage was attributed to the age of the catch-up group and even 
more important to negative media attention and a lack of appropriate information. In 
the United Kingdom vaccine coverage for the first dose among girls aged 12-13 years 
was 70.6%.12 Again, the main reason for parents’ refusal of vaccination was insufficient 
information about the vaccine and its long term safety. These findings support the need 
of educational campaigns to reach a high vaccine coverage.
Although the vaccines have shown cross-protection for other genotypes than originally 
invented for, protection does not include all hr-HPV genotypes. As the current vaccines 
only protect against up to 70 to 80% of cervical cancer, the need for additional protection 
remains a challenge. Therefore, future HPV vaccination needs to focus on the development 
of a new generation of preventive vaccines that are capable of protecting against 
additional types and subsequently protect against most cervical cancers. Given the lag 
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collection procedure than a cervical smear. With regard to hr-HPV detection, self 
sampling has repetitively been proven to be as reliable as physician-taken samples.24;26 
However, standardization of self-sampling procedures may lead to better comparability 
across studies. HPV testing on self-sampled materials might be a promising opportunity 
for future screening. Using HPV genotyping assays instead of HPV detection assays will 
enable the possibility of monitoring shifts in the natural history of HPV. 
HPV vaccination in combination with continued cervical screening will eventually lead 
to a major reduction in cervical cancer deaths and cervical precancerous lesions. Studies 
performed in the pre-vaccine era contribute to the understanding of risk factors 
associated with HPV infections and provide a basis for research on possible future shifts 
in HPV epidemiology due to mass vaccination. In time, CSPs will need modification to 
maximize synergy with primary prevention. The challenge remains to link data from 
screening to data from immunisation allowing epidemiological surveillance of vaccinated 
populations.
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Summary
Chapter 1
Genital infection with the Human Papillomavirus (HPV) is one of the most common 
sexually transmitted diseases among young sexually active women. Studying aspects of 
sexual behaviour may inform us about the risk of exposure to HPV and the effect on the 
course of infection. Fortunately, most HPV infections are transient.
The HPV genotypes that are able to infect the genital epithelium have been classified 
low-risk or high-risk (hr) according to their oncogenic potential. A persistent infection with 
a hr-HPV type is a risk factor for the development of cervical abnormalities. As hr-HPV 
genotypes 16 and 18 together account for the majority of cervical carcinomas and its 
precursors, prophylactic vaccines against these two hr-HPV types have been developed. 
Worldwide mass vaccination with HPV vaccines will most certainly change HPV 
epidemiology. To provide a basis for understanding possible future shifts in genotypes, as 
well as to provide insight in the HPV epidemiology of a target group for vaccination, 
baseline data should be gathered before vaccination takes place. Additionally, in order to 
correlate risk factors associated with HPV infection in the pre- and the post-vaccine era, 
data regarding sexual behaviour are needed. In chapter 1, aspects of HPV mediated 
carcinogenesis, HPV detection methods, and sampling methods are addressed as well.
Chapter 2
Infection with HPV is a necessary event in the multi-step process of cervical carcinogenesis. 
Little is known about the natural history of HPV infection among young unscreened 
adults. As prophylactic vaccines have been developed to prevent specifically HPV 16 
and 18 infections, shifts in prevalence in the post-vaccination era may be expected. 
Chapter 2 describes a cross-sectional study among 2065 unscreened women aged 18 to 
29 years. Women returned a self-collected cervico-vaginal specimen and filled out a 
questionnaire. All HPV DNA-positive samples were genotyped using the SPF10 LiPA HPV 
genotyping assay. HPV point prevalence was 19% and hr-HPV point prevalence was 
11.8%. In the majority of the infections it concerned an infection with a single HPV type. 
HPV vaccine types 16 (2.8%) and 18 (1.4%) were found concomitantly in only 3 (0.1%) 
women. HPV prevalence increased till 22 years of age, afterwards a plateau phase was 
reached. Factors independently associated with HPV prevalence were mainly related to 
sexual behaviour. Number of lifetime sexual partners was the most powerful predictor 
of HPV positivity followed by type of relationship. Combination of these results with the 
relative low prevalence of HPV 16 and/or 18 may be promising for expanding the future 
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had heard of HPV and 14% was aware of the causal relationship of HPV and cervical 
cancer. Knowledge of HPV and cervical cancer, religion, age, educational level, and 
marital status did not show any significant relation with HPV vaccine acceptance. Among 
these parents HPV vaccine acceptance seems to be dependent on vaccine acceptance 
in general, even more than on knowledge of HPV and its causal relationship with cervical 
cancer. However, parents requested more information about cervical cancer, HPV, and 
HPV vaccination, before the HPV vaccine is introduced into the vaccination programme.
Chapter 5
In order to decrease cervical cancer without a 15 to 20 years lag time, catch-up vaccination 
is necessary. The main target group for catch-up vaccination consists of women aged 15 
to 25 years. In addition to chapter 4, this chapter describes knowledge of HPV, vaccine 
acceptability as well as influencing factors among 600 male and female participants 
aged 18 to 25 years recruited and surveyed at two university departments and one 
non-university technical college. The majority of the participants had heard of cervical 
cancer but only a minority could correctly identify risk factors. Female participants had 
significantly more knowledge of cervical cancer.  Only a minority of the participants had 
ever heard of HPV. Despite this lack of knowledge, a small majority would accept catch-up 
HPV vaccination. Women and younger participants had a significantly higher acceptance 
rate. Educational level and knowledge of HPV and cervical cancer were not significantly 
related to vaccine acceptance. However, this may be influenced by the relatively high 
educational level of the participants as well as the fact that the general knowledge level 
of HPV was very low. The exact factors that do influence vaccine acceptance in this age 
group, in both men and women, remain to be eluded. To reach a high vaccine coverage 
in this group, an educational campaign is needed that not only covers knowledge of 
HPV and cervical cancer, but also beliefs and behaviours associated with vaccine 
acceptance.
Chapter 6
Efficacy of HPV vaccines has been proven in women who are HPV 16 and/or 18 negative 
at time of vaccination. The benefit of HPV vaccination of sexually naïve women is likely 
to be higher than that of older already sexually active women. The individual decision of 
these women to get vaccinated will be balanced between personal benefit and costs. 
This study is based on the results of a large prospective epidemiologic study performed 
among 2065 unscreened women aged 18-29 years. Finally, data were used from 1322 
women aged 18-25 years who reported to be sexually active in past or present time. HPV 
target group for catch-up vaccination. These results provide a basis for research on 
possible future shifts in HPV genotype prevalence.
Chapter 3
The natural course of an HPV infection in healthy unscreened young women may be 
influenced by viral, host, and environmental factors. In addition to Chapter 2, this part of 
the prospective epidemiologic study analyses the results of HPV incidence and clearance 
in 1812 women aged 18-29 years, of whom 1729 were sexually active during follow-up. 
Women provided three consecutive cervico-vaginal self-samples with a 6 month interval 
and filled out accompanying questionnaires. During the 12 month follow up hr-HPV 
incidence in sexually active women was 6.3%. HPV 16 was the most commonly acquired 
hr-HPV type. The risk of hr-HPV acquisition increased with being single, change in current 
type of relationship, as well as change in number of sexual partners 3 months prior to 
sampling, and sexual age at study entry. Hr-HPV clearance was significantly associated 
with currently being in a relationship as well as total number of sexual partners (lifetime). 
Hr-HPV incidence as well as clearance were related to past and present sexual behaviour. 
These results suggest that some infections were newly acquired whereas others were 
acquired in the past and remained latent below detection level for some time and may 
be considered as randomly detected latent infections. As HPV infections are very 
common, it is difficult to discriminate separate risk factors for HPV dynamics. Our results 
indicate that sexual behaviour itself, i.e. being sexually active, is the most important 
determinant.
Chapter 4
Before introduction of an HPV vaccine, it is important to consider whether the public is 
aware of the causal relationship between HPV infections and cervical cancer and whether 
they would be willing to accept vaccination. This chapter describes the results of the 
cross-sectional survey performed  before the front-page news about the HPV vaccine 
appeared in the newspapers. To determine whether parents would accept HPV 
vaccination for their children and which variables may influence their decision, 356 
parents of children aged 10 to 12 years were interviewed. HPV vaccination would be 
accepted by 88% of the parents, preferably at the age of 10 to12 years. Parents of children 
who received all the vaccinations of the National Vaccination Programme were 
significantly more likely to accept HPV vaccination. Parents who were not willing to 
vaccinate their children were more likely to think that the child should be involved in 
deciding whether to be vaccinated against HPV or not. Less than a third of all parents 
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temperatures. Therefore, this method may contribute to a new way of cervical cancer 
screening.
Chapter 8
In this section we consider our results and speculate about vaccine uptake and the effects 
of HPV vaccination on HPV epidemiology and the current screening programmes.
detection was performed on self-collected cervico-vaginal specimens and a 
questionnaire regarding sexual activity was completed. Multivariate logistic regression 
with backward variable deletion was used to estimate the probability of HPV infection. 
The model predicting the optimal probability of being HPV 16 and/or 18 positive was 
based on the combination of age, number and gender of sexual partners, condom use, 
and frequency of sexual contact in past 6 months. A nomogram including significant 
predictors calculates the probability of being HPV 16 and/or 18 infected. This risk 
assessment tool may be helpful in counselling individual women in outpatient settings. 
It provides an estimation of the probability of being infected with HPV 16 and/or 18 and 
therefore provides insight into the personal situation. Furthermore, it may provide a 
guideline to discriminate between sexually active individuals eligible for direct 
vaccination and sexually active individuals who may benefit from prior HPV-testing.
Chapter 7
HPV testing in cervical cancer screening has a beneficial effect in patient management 
and may increase the success rate of population-based screening programmes. 
Regarding HPV testing, cervico-vaginal self-samples have been proven to be as reliable 
as physician-taken samples. The introduction of cervico-vaginal self-sampling might 
increase the participation rate of screening programmes and may therefore potentially 
reduce cancer incidence. In chapter 7 we assess the reliability of HPV detection and 
genotyping in self-sampled genital smears applied to an indicating FTA elute cartridge 
(FTA cartridge). All samples were analysed by the SPF10 LiPA HPV genotyping assay. The 
study group consisted of 96 women, divided in two sample sets. In set 1, women 
obtained a cervico-vaginal self-sample which was applied to an FTA cartridge. In 
addition, a  cervical smear (liquid-based) was taken by a trained physician. In set 2, 
women obtained a cervico-vaginal self-sample at home which was applied to an FTA 
cartridge and to a liquid-based medium. DNA was obtained from the FTA cartridges by 
simple elution as well as extraction. In sample set 1 overall agreement between self- and 
physician-obtained samples was 93.3%, in favour of the self-samples. In sample set 2, 
overall agreement for hr-HPV presence between FTA cartridge and liquid-based medium 
was 100%. In both sample sets overall agreement for hr-HPV presence between DNA 
elution and DNA extraction was 100%. This shows that HPV detection and genotyping in 
self-obtained cervico-vaginal samples applied to an FTA cartridge is highly reliable. 
It shows a high level of overall agreement with HPV detection and genotyping in 
 physician-obtained cervical smears and liquid-based self-samples. DNA can be obtained 
by simple elution and is therefore easy, cheap, and fast. Furthermore, as the FTA cartridge 
is non-hazardous it is a convenient medium for collection and safe transport at ambient 
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Samenvatting
Hoofdstuk 1
Een genitale infectie met het Humaan Papillomavirus (HPV) is een van de meest 
voorkomende seksueel overdraagbare aandoeningen onder seksueel actieve jonge 
vrouwen. Het in kaart brengen van seksueel gedrag kan inzicht bieden in het risico van 
blootstelling aan HPV en het effect op het verloop van de infectie. Gelukkig zijn de 
meeste HPV infecties van voorbijgaande aard. 
De HPV genotypen die het genitale gebied kunnen infecteren zijn op basis van hun 
oncogene potentie ingedeeld in hoog en laag risico typen. Een persistente infectie met 
een hoog risico HPV type (hr-HPV) is een risicofactor voor de ontwikkeling van afwijkingen 
aan de cervix (baarmoederhals). Hr-HPV type 16 en 18 zijn samen verantwoordelijk voor 
de meerderheid van de gevallen van baarmoederhalskanker en de voorstadia ervan. 
Daarom zijn er tegen deze typen profylactische vaccins ontwikkeld. Wereldwijde 
vaccinatie met het HPV vaccin zal een verandering tot gevolg hebben in het voorkomen 
van HPV. Om een basis te vormen voor toekomstig onderzoek naar verschuivingen in 
het vóórkomen van HPV genotypen zullen er data verzameld moeten worden voordat 
vaccinatie plaats gaat vinden. Deze gegevens zullen ook inzicht bieden in het voorkomen 
van HPV in een mogelijke doelgroep voor vaccinatie en de mogelijkheid bieden om in 
het pre- en postvaccinatie tijdperk risicofactoren met HPV te correleren. In hoofdstuk 1 
komen tevens aspecten van de rol van HPV in de carcinogenese alsmede HPV detectie-
methoden en manier van monsterafname aan de orde.
Hoofdstuk 2
Infectie met HPV is een voorwaarde voor het ontstaan van  baarmoederhalskanker. 
Er is weinig bekend over het natuurlijk verloop van HPV infecties bij ongescreende 
jongvolwassenen. Aangezien er profylactische vaccins ontwikkeld zijn om specifiek 
infectie met HPV 16 en 18 te voorkomen, kan er in het postvaccinatie tijdperk een 
verschuiving in het voorkomen van HPV worden verwacht. Hoofdstuk 2 beschrijft een 
cross-sectionele studie onder 2065 ongescreende vrouwen van18 tot en met 29 jaar. De 
vrouwen vulden een vragenlijst in en namen zelf een cervico-vaginaal monster (zelfsample) 
af en stuurden dit tezamen terug. Alle HPV DNA-positieve monsters werden gegenotypeerd 
met behulp van de SPF10 LiPA HPV genotyperingstest. De HPV prevalentie bedroeg 19%. 
De hr-HPV prevalentie was 11.8% en HPV 16 en HPV 18 werden bij respectievelijk 2.8% en 
1.4% van de vrouwen aangetoond. In de meerderheid van de infecties betrof het een 
infectie met een enkel HPV type. Bij slechts  3 vrouwen (0.1%) werden de HPV vaccin types 
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baarmoederhals. Het is ook van belang te weten of men bereid is zich te laten vaccineren 
dan wel of ouders bereid zouden zijn hun kinderen te laten vaccineren en welke factoren 
hun keuze zouden beïnvloeden. Dit hoofdstuk beschrijft de resultaten van een cross-
sectioneel onderzoek dat verricht is voordat het nieuws over het HPV vaccin in oktober 
2005 de voorpagina’s van de kranten haalde. Telefonisch werden 356 ouders van 
kinderen tussen de 10 en de 12 jaar geïnterviewd. Van de ouders zou 88% de HPV 
vaccinatie accepteren, met een voorkeur voor vaccinatie op de leeftijd van 10 tot 12 jaar. 
Ouders van kinderen die reeds alle aanbevolen vaccinaties van het nationale vaccinatie 
programma hadden gekregen, waren significant vaker bereid hun kinderen tegen HPV 
te laten vaccineren. Ouders die niet bereid waren om hun kinderen te laten vaccineren 
waren significant vaker van mening dat het kind betrokken moest worden bij deze keuze.
Minder dan één derde van alle ouders had ooit gehoord van HPV en slechts 14% was 
zich bewust van de relatie met baarmoederhalskanker. Kennis van HPV en baarmoeder-
halskanker, religie, leeftijd, opleidingsniveau, en burgerlijke staat waren niet significant 
van invloed op de vaccinatiebereidheid. Onder de geïnterviewde ouders bleek de 
 vaccinatiebereidheid afhankelijk te zijn van vaccinatiebereidheid in het algemeen, en 
niet zo zeer van kennis van HPV en baarmoederhalskanker. De ouders gaven evenwel 
aan, dat zij graag meer informatie zouden ontvangen over baarmoederhalskanker, HPV 
en HPV vaccinatie voordat het vaccin geïntroduceerd zou worden in het vaccinatie 
programma.
Hoofdstuk 5
Om de incidentie van baarmoederhalskanker te verlagen zonder een vertraging van 15 
tot 20 jaar zal catch-up vaccinatie noodzakelijk zijn. De doelgroep van catch-up vaccinatie 
zal voornamelijk bestaan uit vrouwen van 17 tot en met 25 jaar. In aanvulling op 
hoofdstuk 4, beschrijft dit hoofdstuk de kennis van HPV, vaccinatiebereidheid en factoren 
die hiervan op invloed zijn in een groep van 600 mannen en vrouwen van 18 tot en met 
25  jaar. De deelnemers werden geïnterviewd op twee universitaire faculteiten en op 
één technische beroepsopleiding. De meerderheid van de deelnemers had ooit gehoord 
van baarmoederhalskanker, maar slechts een minderheid kon correct de risicofactoren 
benoemen. Vrouwelijke deelnemers hadden significant meer kennis van baarmoeder-
halskanker. Zeer weinig deelnemers hadden ooit gehoord van HPV. Ondanks dit gebrek 
aan kennis zou een kleine meerderheid bereid zijn zich te laten vaccineren tegen HPV. 
Vrouwelijke en jongere deelnemers waren significant vaker bereid zich te laten 
vaccineren. Opleidingsniveau en kennis van HPV en baarmoederhalskanker waren niet 
significant geassocieerd met vaccinatiebereidheid. Deze uitkomst zou echter beïnvloed 
kunnen zijn door het relatief hoge opleidingsniveau alsmede de geringe kennis over 
16 en 18 tegelijkertijd aangetroffen. De HPV prevalentie nam toe tot de leeftijd van 22 jaar 
waarna een plateaufase werd bereikt. De factoren die onafhankelijk van invloed waren op 
de HPV prevalentie waren met name gerelateerd aan seksueel gedrag. Het totale aantal 
seksuele partners hing het sterkst samen met het aanwezig zijn van HPV; dit werd gevolgd 
door het type relatie. Deze resultaten, samen met de relatief lage prevalentie van HPV 16 
en 18 zou veelbelovend kunnen zijn voor het uitbreiden van de toekomstige doelgroep 
voor catch-up vaccinatie. Verder vormen deze resultaten een basis voor onderzoek naar 
mogelijke toekomstige verschuivingen in HPV epidemiologie.
Hoofdstuk 3
Het natuurlijk verloop van een HPV infectie in gezonde ongescreende jonge vrouwen 
kan beïnvloed worden door virale, gastheer / vrouw en omgevingsfactoren. In aanvulling 
op hoofdstuk 2, worden in dit hoofdstuk de resultaten van HPV incidentie en klaring 
geanalyseerd van de 1812 vrouwen die deelnemen aan het prospectieve deel van de 
studie. Van deze vrouwen waren er 1729 seksueel actief tijdens de follow-up van de 
studie. De deelneemsters vulden een vragenlijst in en namen bij het begin van de studie 
een zelfsample af gevolgd door twee opeenvolgende zelfsamples met een interval van 
zes maanden. Tijdens de 12 maanden follow-up bedroeg de hr-HPV incidentie onder de 
seksueel actieve vrouwen 6.3%. Het hr-HPV type dat het meest werd opgelopen was 
HPV 16. Het risico om hr-HPV op te lopen werd groter wanneer iemand “single” was, 
wanneer er sprake was van een verandering in het type relatie of in het aantal seksuele 
partners in de 3 maanden voor het afnemen van het monster, alsmede een toename in 
het aantal jaar van seksuele activiteit bij het starten van de studie. Het klaren van hr-HPV 
werd geassocieerd met het hebben van een relatie alsmede met het totale aantal 
seksuele partners. Zowel hr-HPV incidentie als hr-HPV klaring waren gerelateerd aan 
zowel huidig seksueel gedrag als seksueel gedrag in het verleden. Deze resultaten 
suggereren dat sommige aangetoonde infecties nieuw opgelopen infecties waren 
terwijl andere infecties reeds in het verleden waren opgelopen en enige tijd onder de 
detectiegrens aanwezig zijn gebleven en nu toevallig zijn opgepikt door de test. 
Aangezien HPV infecties veel voorkomen, is het moeilijk om specifieke risicofactoren 
aan te wijzen. Onze resultaten laten zien dat het seksueel actief zijn zelf de meest 
belangrijke factor is.
Hoofdstuk 4
Voordat een HPV vaccin geïntroduceerd wordt, is het van belang te weten of de populatie 
zich bewust is van de relatie tussen HPV en het ontstaan van afwijkingen aan de 
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betrouwbaar zijn als cervicale monsters die zijn afgenomen door een arts. De introductie 
van cervico-vaginale zelfsampling zou de opkomst van het bevolkingsonderzoek 
kunnen verhogen en op deze manier kunnen bijdragen aan het voorkómen van baar-
moederhalskanker. In hoofdstuk 7 wordt de betrouwbaarheid in kaart gebracht van HPV 
detectie en genotypering in cervico-vaginale zelfsamples die aangebracht zijn op een 
“indicating FTA elute cartridge” (FTA cartridge). Alle monsters werden op HPV getest met 
de SPF10 LiPA HPV genotyperingstest. De onderzoeksgroep bestond uit 96 vrouwen die 
konden worden opgedeeld in twee groepen. In groep 1 namen vrouwen een zelfsample 
die zij op een FTA cartridge aanbrachten. Verder werd er door een arts een cervicale 
uitstrijk (opgeslagen in een vloeistof medium) afgenomen. In groep 2 namen vrouwen 
een zelfsample die zij op een FTA cartridge aanbrachten alsmede in een vloeistof 
medium uitschudden. Het DNA werd van de FTA cartridge gehaald door middel van 
eenvoudige elutie alsmede extractie. In groep 1 was de overeenkomst tussen het zelf- 
en arts-verkregen monster 93.3%, in het voordeel van de zelfsamples. In groep 2 was de 
overeenkomst tussen de  FTA cartridge en het vloeistof medium ten aanzien van de 
aanwezigheid van hr-HPV 100%. In beide groepen was de overeenkomst tussen DNA 
elutie en DNA extractie ten aanzien van de aanwezigheid van hr-HPV 100%. Deze 
resultaten laten zien dat HPV detectie en genotypering van cervico-vaginale zelfsamples 
die aangebracht zijn op een FTA cartridge zeer betrouwbaar is. Het toont een hoge 
overeenkomst met HPV detectie en genotypering in arts-verkregen monsters en in 
vloeistof medium opgeslagen zelfsamples.  Het DNA kan verkregen worden door middel 
van eenvoudige elutie, wat makkelijk, goedkoop en snel is. De FTA cartridge is een 
praktisch medium om materiaal op te verzamelen en te versturen omdat het geen 
gevaarlijke stoffen bevat en het aangebrachte materiaal niet meer infectieus is en stabiel 
blijft bij wisselende temperaturen. Daarom zou deze methode onderdeel uit kunnen 
maken van een nieuwe manier van baarmoederhalskankerscreening.
Hoofdstuk 8
In dit deel worden de resultaten besproken en in perspectief geplaatst van de huidige 
ontwikkelingen. Verder wordt er gediscussieerd over de mogelijke effecten van HPV 
vaccinatie op HPV epidemiologie en de huidige screeningsprogramma’s.
HPV. De exacte factoren die in deze groep mannen en vrouwen van invloed zijn op de 
vaccinatiebereidheid blijven onduidelijk. Om met de catch-up vaccinatie een hoge 
dekkingsgraad te bereiken, zal er een campagne nodig zijn die niet alleen voorlichting 
geeft over HPV en baarmoederhalskanker maar die ook in gaat op gedrag en 
overtuigingen met betrekking tot vaccinatiebereidheid.
Hoofdstuk 6
De effectiviteit van de HPV vaccins is aangetoond bij vrouwen die op het moment van 
vaccineren HPV 16 en/of 18 negatief waren. Het voordeel van vaccinatie zal groter zijn 
voor vrouwen die nog niet seksueel actief zijn, dan voor (oudere) vrouwen die al wel 
seksueel actief zijn en dus blootgesteld zijn aan HPV. De individuele beslissing van deze 
seksueel actieve vrouwen om zich te laten vaccineren, zal een afweging zijn tussen 
kosten verbonden aan vaccinatie en baat bij vaccinatie. Dit hoofdstuk beschrijft een 
model dat de schatting weergeeft van de kans om HPV 16 en/of 18 positief te zijn. Deze 
studie is gebaseerd op de uitkomsten van de prospectieve studie onder 2065 
ongescreende vrouwen van 18 tot 29 jaar zoals beschreven in hoofdstuk 2 en 3. 
Uiteindelijk zijn de resultaten gebruikt van 1322 seksueel actieve vrouwen die tussen de 
18 en de 25 jaar oud waren. De deelneemsters vulden een vragenlijst in en namen een 
zelfsample af. De monsters werden op HPV getest. Door middel van “multivariate logistic 
regression analysis with backward variable deletion” werd de waarschijnlijkheid van het 
aanwezig zijn van een HPV infectie geschat. Het model dat de optimale schatting van 
de aanwezigheid van HPV 16 en/of 18 weergeeft, werd gebaseerd op de combinatie van 
leeftijd, aantal en geslacht van seksuele partners, condoomgebruik en coïtusfrequentie 
in de afgelopen 6 maanden. Een nomogram gebaseerd op bovengenoemde factoren 
berekent de kans op de aanwezigheid van HPV 16 en/of 18. Dit model kan van pas komen 
in het begeleiden van individuele vrouwen bij hun keuze om zich wel of niet te laten 
vaccineren. Het model geeft een schatting van de waarschijnlijkheid om geïnfecteerd te 
zijn met HPV 16 en/of 18 en geeft op deze manier inzicht in de persoonlijke situatie. 
Verder biedt het de  mogelijkheid om een verschil te kunnen maken tussen seksueel 
actieve vrouwen die direct gevaccineerd kunnen worden en seksueel actieve vrouwen 
die baat zouden hebben bij testen op HPV voorafgaand aan vaccinatie.
Hoofdstuk 7
Het testen op hr-HPV in het bevolkingsonderzoek is van voordeel in de patiënt-
beleidsvoering en kan zo het succespercentage van het bevolkingsonderzoek vergroten. 
Ten aanzien van het testen op HPV is bewezen dat cervico-vaginale zelfsamples  net zo 
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Dankwoord
Bij deze wil ik iedereen bedanken die heeft bijgedragen aan het tot stand komen van dit 
proefschrift. 
Beste Leon, dank voor de begeleiding van de afgelopen tijd. Je wist altijd net even dat 
beetje extra te motiveren en nieuwe ideeën te lanceren. Dank voor de leerzame jaren.
Beste Willem, als ik dr. Melchers bleef zeggen, moest ik in Praag aan een tafeltje apart 
zitten, gelukkig was dat niet nodig. Dank voor het razendsnel stukken van commentaar 
voorzien en al je ideeën, maar vooral ook de gezellige congressen, je verhalen en je 
interesse.
Beste Ruud, naast copromotor zijn, was je ook erg betrokken. Vele besprekingen over 
uiteraard de studie, maar met name over “het leven” maakten het promoveren een 
mooie tijd! Samen namen we uiteindelijk de “midden-bocht”, dank voor je persoonlijke 
 begeleiding!
Beste Petra, als ik jou toch niet had gehad…dan was ik hier niet eens aan begonnen! Dank!!
Mede auteurs: Jan Hendriks, Nel Roeleveld en Marloes Gerrits, hartelijk dank voor jullie 
bijdragen.
MMB-lab, beste Judith, Annelies en Onno, dank voor jullie eindeloze geduld en tomeloze 
inzet bij de duizenden monsters die altijd gisteren klaar moesten zijn. 
Beste Wim Quint, dank voor het bepalen van alle monsters die o.a. in zakjes werden 
 aangeleverd, ik heb ervan geleerd! Ook dank voor het gezellige congres in Praag, ik heb 
de kunst toen goed af kunnen kijken.
Beste Wim Abma, “access”, je legde het me uit, we dachten na over de database/queries/
etc, en het werkte! 10.000 monsters en vragenlijsten gingen (bijna) automatisch de deur 
uit, daar kan geen agenda tegen op!!
Beste student-stagiaires, Annette, Fanny, Marieke, Daphne-Sophie, Dion, Neeltje, Marloes 
en Moniek, dank voor al jullie enthousiasme en jullie inzet. Annette, zonder jouw inzet 
van het hele eerste jaar was het nooit zo gestroomlijnd gelopen, dank hiervoor!
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Lieve zussen & co, dank voor jullie plezier en gezelligheid van alle jaren, voor jullie 
 interesse in het onderzoek en het feit dat ik op de meest rare momenten op mocht 
 bellen om een of ander woord te checken… Lieve Lies en Peter, dank voor jullie hulp bij 
het reviseren!
Lieve papa en mama, wat zijn jullie toch altijd trots op ons en wat is dat fijn! Jullie  hebben 
altijd met alles achter me gestaan en me gestimuleerd door te gaan, ook toen ik ’t  Stichtse 
heb verlaten. Julie zijn echt geweldig en ik ben dankbaar dat ik zulke lieve ouders heb.  
Lieve Stefke, al jaren supervriendinnen. Jij naar Venlo en ik naar Nijmegen, dat kwam mooi 
uit! Dank voor je “zen-momenten” in de Limburgse lucht en je nuchtere  commentaar op 
zaken... Geweldig dat jij mijn paranimf bent!
Lieve Wiet, wat hebben we een lol samen, gelukkig vinden “wij” het zelf altijd erg  geslaagd! 
Dat jij mijn paranimf zou zijn, was vanzelfprekend maar is toch ook heel bijzonder.
Beste Nel, even brainstormen met jou en de monsters van de poli stroomden binnen. 
Dank voor je hulp en de gezellige borrelmomenten met o.a.Tommy.
Kantoortuin: teveel om op te noemen… dank voor de leuke onderzoekersweekenden, 
de etentjes en alle gezellige koffie momenten met “publicatie-taart”.
Dennis, mijn helpdesk, één wanhopige blik vanachter mijn compu-scherm vandaan was 
genoeg… Dat ik later deze taak over kon nemen, blijft een wonder!
Irene, als overbuurvrouw erg gezellig en jij weet gewoon altijd alles, als  nieuwkomer in 
de tuin en in Nijmegen was dat erg praktisch ;-)
Angèle, BP zat toch op t Valkhof? Jij wist me op zaterdag naar de Houtstraat te leiden, 
met succes! Dank voor de fijne start die je me bood in de tuin.
Channa, inclusiekanon van het eerste uur. Het was best moeilijk de studie uit handen 
te geven, maar de follow-up van de studie is je toevertrouwd. Dank voor de gezellige 
congressen in Nice en Malmö en uiteraard alle “overleg” momenten.
Eva en Anne, de nieuwe overburen, een knipoog en een terrasje op zijn tijd maakte de 
afgelopen jaren erg geslaagd! 
Anneke, door jou leerde ik mijn nieuwe Nijmeegse collegae snel en goed kennen. 
Dank voor je gezelligheid!
Lieve AIOS collegae, dank voor jullie gezelligheid, de hulp bij de eerste stapjes in 
 Nijmegen, onderzoeksland en die in de kliniek. Met jullie is het altijd gezellig.
Lieve Ralph, Marieke en Jolieneke, de eerste opvang in het Nijmeegse verliep soepel, 
waarvoor veel dank!
Lieve ladies van de Jc en uit Amersfoort, ondanks dat jullie in het begin geen idee 
 hadden van wat ik nou eigenlijk deed de hele dag, waren jullie altijd erg geïnteresseerd 
en behulpzaam! Dank voor jullie gezelligheid en sorry voor het tijdelijk afhaken, we halen 
het zeker in !!
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De levensloop van Charlotte Lenselink tussen 1978 en 2009
Als tienjarig meisje in 1988, wist Charlotte al wat ze wilde worden: arts. Geen speld  tussen 
te krijgen. Ze kwam op het idee nadat ze een tv-programma had gezien over Artsen  zonder 
Grenzen. Dit werk leek haar fantastisch. Dat ze het echt meende, is wel gebleken.
Het stedelijk gymnasium in Amersfoort doorliep de jongste van het gezin Lenselink 
glansrijk, terwijl ze ondertussen aan steile wand klimmen deed, roeide, paardreed en 
veelvuldig de stad inging met vriendinnen. In één keer werd ze in 1996 ingeloot voor 
Geneeskunde in Utrecht. Voortvarend als altijd, stortte ze zich in het studenten- en 
 verenigingsleven. Maar ook de studie werd serieus aangepakt, wat resulteerde in een 
propedeuse een jaar later en een doctoraal in 2001.
Welke richting ze vervolgens op zou gaan wist ze toen nog niet. Alhoewel haar weten-
schappelijke stage in 2001 met betrekking tot retinopathie van de prematuur in het 
Wilhelmina Ziekenhuis in Utrecht, zeer goed bevallen was. Toen ze in 2003 in Tilburg het 
keuze co-schap Gynaecologie & Obstetrie volgde, viel de zaak op zijn plaats. Dit was het 
vakgebied waarin deze inmiddels arts, verder wilde.
Na een korte stop in Tilburg ging ze in 2004 in het Rijnstate Ziekenhuis te Arnhem als 
 ANIOS aan de slag. Dit werk maakte Charlotte gelukkig. Om serieus door te kunnen in de 
gynaecologie besloot zij onderzoek te gaan doen. Het UMC St Radboud in  Nijmegen bood 
hier de mogelijkheid voor. Professor Massuger, dr. Bekkers en dr. Melchers  begeleidden 
haar tussen 2006 en 2009, wat resulteerde in dit proefschrift.
Sinds oktober 2009 is Charlotte werkzaam als AIOS gynaecologie in het Catharina Zieken-
huis te Eindhoven. Ondertussen geniet ze van het leven in Nijmegen, haar  vrienden en 
familie en haar weg naar de volgende mijlpaal.
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